




Full Group Care Formulary



A large, stylized, three-dimensional geometric shape composed of various colored facets (teal, light blue, grey, white) serves as the background for the text. The shape has sharp, angular edges and is positioned centrally below the main title.

September 2021



Alameda Alliance for Health

Group Care FORMULARY

Last updated

September 1, 2021

The **Drug Formulary** is a complete list of covered and preferred outpatient prescription drugs for members. The Alliance reviews the list at least four times a year (formulary updates can be found on the Alliance website) and makes updates as needed. This printable list may not reflect the latest updates. Members can search the current list online at www.alamedaalliance.org or simply call the Alliance Customer Service Department (number listed below) to confirm if a drug is covered. The formulary is subject to change and all previous versions of the formulary are no longer in effect. This printable formulary can also be found on our website: <https://alamedaalliance.org/members/pharmacy-and-medication-benefits/medication-formulary/>

Members please call Member Services at (877) 932-2738. Open Monday to Friday from 8am – 5pm PST (Pacific Standard Time).

HOW TO USE THE DRUG FORMULARY

To find a drug on the list, search first for what the drug will treat. All drugs are then listed by their generic and brand names in their therapeutic category, class and in alphabetical order. Any drug not found in this Formulary by looking up the therapeutic category and class, brand or generic names then list is a Non-Formulary drug. If a generic equivalent for a brand name drug is not available or is not covered, the drug will not be separately listed by its generic name. This Drug Formulary applies only to outpatient drugs prescribed to members. It does not apply to drugs used in inpatient settings.

DEFINITIONS

ENROLLEE

An enrollee is a person enrolled in a health plan who is entitled to receive services from the plan. All references to enrollees in this formulary template shall also include subscribers as defined in this section below.

PRESCRIPTION

A prescription is an oral, written or electronic order by a prescribing provider for a specific enrollee (and requires prescription under applicable law) that contains the name of the prescription drug, the quantity, the route of administration, directions for use, the date of issue, the name and contact information of the prescribing provider, the signature of the prescribing provider if the prescription is in writing, and if requested by the enrollee, the medical condition or purpose for which the drug is being prescribed. Other requirements may apply depending on the drug requested. Please note that the presence of a prescription drug on the formulary does not guarantee the enrollee will be prescribed that prescription drug by his or her prescribing provider for a particular medication condition.

PREScription DRUG

A prescription drug is a drug that is prescribed by the enrollee's prescribing provider and requires a prescription under applicable law.

PREScribing PROVIDER

A prescribing provider is a health care provider authorized to write a prescription to treat a medical condition for a health plan enrollee.

SUBSCRIBER

A subscriber is the person who is responsible for payment to the plan or whose employment or other status, except for family dependency, is the basis for eligibility for membership in the plan.

CO-INSURANCE

Co-insurance is a percentage of the cost of a covered health care benefit that an enrollee pays after the enrollee has paid the deductible, if a deductible applies to the health care benefit, such as the prescription drug benefit.

OUT-OF-POCKET COST

Out-of-pocket costs are copayments, coinsurance, and the applicable deductible, plus all costs for health care services that are not covered by the health plan.

COPAYMENT

A copayment is a fixed dollar amount that an enrollee pays for a covered health care benefit after the enrollee has paid the deductible, if a deductible applies to the health care benefit, such as the prescription drug benefit.

DEDUCTIBLE

A deductible is the amount an enrollee pays for covered health care benefits before the enrollee's health plan begins payment for all or part of the cost of the health care benefit

under the terms of the policy.

DRUG TIER

A drug tier is a group of prescription drugs that correspond to a specified cost sharing tier in the health plan's prescription drug coverage. The tier in which a prescription drug is placed determines the enrollee's portion of the cost of the drug.

EXCEPTION REQUEST

An exception request is a request for coverage of a prescription drug. If an enrollee, his or her designee, or prescribing health care provider submits an exception request for coverage of a prescription drug, the health plan must cover the prescription drug when the drug is determined to be medically necessary to treat the enrollee's condition.

PRIOR AUTHORIZATION

Health plan's requirement that the enrollee or the enrollee's prescribing provider obtain the health plan's authorization for a prescription drug before the health plan will cover the drug. The health plan shall grant a prior authorization when it is medically necessary for the enrollee to obtain the drug.

EXIGENT CIRCUMSTANCES

An exigent circumstance is when an enrollee is suffering from a health condition that may seriously jeopardize the enrollee's life, health or ability to regain maximum function, or when an enrollee is undergoing a current course of treatment using a non-formulary drug.

GENERIC DRUG

The same drug as its brand name equivalent in dosage, safety, strength, how it is taken, quality, performance and intended use. A generic drug is listed in bold and italicized lowercase letters.

INTRAVENOUS SOLUTIONS OF UNLISTED ANTIBIOTICS ml

Restricted to dispensing within 10 days following inpatient discharge from an acute care hospital, when I.V. therapy with the same antibiotic was started before discharge. There is a maximum of a 10 day supply per dispensing within the 10-day period.

Note: Non-compounded products must be billed using the product's NDC number.

Compounded solutions must be billed as a compound claim. See the Compound Drug Pharmacy Claim Form {30-4} Completion section for more information.

INTRAVENOUS SOLUTIONS OF OTHER UNLISTED DRUGS ml

Restricted to dispensing within 10 days following inpatient discharge from an acute care hospital, when I.V. therapy with the same drug was started before discharge. There is a maximum of a 10 day supply per dispensing within the 10-day period

Note: Non-compounded products must be billed using the product's NDC number.

Compounded solutions must be billed as a compound claim. See the Compound Drug Pharmacy Claim Form {30-4} Completion section for more information.

EXCEPTION REQUEST

An exception request is a request for coverage of a prescription drug. If an enrollee, his or her designee, or prescribing health care provider submits an exception request for coverage of a prescription drug, the health plan must cover the prescription drug when the drug is determined to be medically necessary to treat the enrollee's condition.

Drug Coverage Requirements or Limits

A health plan may request an omission, deviation or substitution of the stated definitions to the Director for review and approval. There are some processes and limits that may apply to drugs in the formulary. Some are marked with a code on the list. The explanation for code is below:

| Code | Meaning | Definition |
|------|---------------------|--|
| QL | Quantity Limit | Coverage may be limited to specific quantities per prescription and/or time period |
| ST | Step Therapy | Coverage may depend on previous use of another drug |
| PA | Prior Authorization | Requires specific request process |

Quantity Limits: For certain drugs, the Alliance has a limit on the number of pills that will be covered. In general, a 30-day supply is covered. However, if a member requires a drug in excess of the limit, a doctor can submit a Prior Authorization Form.

Step Therapy: In some cases, the Alliance requires members to first try certain drugs to treat a medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat a medical condition, we may not cover Drug B unless the member tries Drug A first. If Drug A does not work for the member, we will then cover Drug B. Doctors can request an exception by submitting a Prior Authorization Form.

Generic Substitutions: The Alliance has a mandatory generic program. This program promotes the use of **generic drugs** over brand when medically appropriate. A doctor may write a prescription for a brand name drug and not a generic due to medical need. In these cases the doctor must submit a Prior Authorization Form.

Brand Name Drugs: A BRAND NAME DRUG is a drug that is marketed under a proprietary, trademark protected name.

Prior Authorization Process: To prescribe drugs that are not in our Drug Formulary or that exceed the plan quantity limits, a doctor can submit a Prior Authorization Form. The Alliance reviews these requests and asks for more details

if needed. We will inform the doctor of our decision within 24 hours to 72 hours for all requests.

Therapeutic Interchange: The Alliance may, with a doctor's approval, change the drug that the doctor prescribed to a drug on the formulary that is the same in effectiveness and safety.

NON-FORMULARY MEDICATIONS

A non-formulary drug is a drug not listed on the health plan's formulary. These medications are reserved for members who have used (or cannot/should not use) up to three formulary alternatives that are used to treat the documented diagnosis OR meet off-label criteria OR has tried and failed or is unable to use separate components (or therapeutic equivalents) of a combination medication or is unable to use a consolidated dose form. Each request can be reviewed via a prior authorization request within 24 to 72 hours from the time received. Non-formulary drugs will also be covered when determined to be medically necessary (e.g. once reviewed with a prior authorization request). The enrollee may file a grievance or complaint for a denial of coverage, along with information on appeal rights and procedures.

Authorization and Billing Instructions

Providers can supply in-office injectable drugs to Alliance members by purchasing directly from suppliers/manufacturers (commonly known as buy and bill) or Diplomat Specialty Pharmacy (Diplomat). The authorization and billing processes differ based on the method of obtaining the drug and the member's delegate:

| Method of Procurement | Delegate | Requires Authorization | Where to Submit Authorization | Whom to Bill |
|-----------------------------------|---------------------------------|---|---------------------------------|---|
| Diplomat (Pharmacy Benefit) | All | Yes | PerformRx | Not necessary (Pharmacy bills Alliance directly) |
| Buy and Bill (Medical Benefit) | Alliance | Refer to list below for Alliance delegate or check with member's delegate | Alliance | Alliance |
| | Children First Medical Group | | Children First Medical Group | |
| | Community Health Center Network | | Community Health Center Network | |
| | | | Hill Physician Medical Group | |

Please use the corresponding authorization form for the type of request:

Medical Benefit: Alliance Authorization Request form

Pharmacy Benefit :

- PerformRx Medication Request Form (for Medi-Cal and Alliance GroupCare)*
- Request for Medicare Prescription Drug Coverage Determination (Medicare)*

Filling your Prescription at a Network Pharmacy

In most cases, you can fill prescriptions at any network retail pharmacy, except for prescriptions for a specialty drug. To find a network retail pharmacy, you can look in the Alliance Provider Directory, visit our website (www.alamedaalliance.org), or call Member Services at 510-747-4567 or toll-free 1-877-932-2738 (CRS/TTY 711 or 1-800-735-2929) from Monday to Friday, 8 a.m. to 5 p.m.

Process for Obtaining Specialty Drugs from Diplomat

Diplomat is the Alliance's specialty pharmacy for Alliance Medi-Cal and Alliance Group Care members. Retail pharmacies may not dispense these drugs for Medi-Cal or Alliance Group Care members. Specialty drug orders for Alliance CompleteCare members can be filled by Diplomat or any other Alliance contracted pharmacy.

Refer to the attached list of available drugs from Diplomat.

Certain drugs are only available from specific distributors and not Diplomat. The clinic can purchase these drugs directly from the distributors and bill the Alliance or have the distributor bill the Alliance. These drugs, along with the name and contact of the alternate distributors, are listed on the Limited Distribution Drug List.

Prior authorization is required for new specialty drug orders and for renewals (usually annually). The same review process is used for specialty drug orders as is used for other retail drugs that require prior authorization.

Authorization process for Diplomat Drugs:

- ② Fax the appropriate pharmacy request form to PerformRX (see above)
- Requests are processed (and notification of the decision sent to your office and Diplomat) within 72 hours for urgent requests or 14 days for routine requests.
- ② Upon PerformRx approval, **Diplomat** will call your office to obtain the prescription and dispense the drug by mail.

Contacts for Additional Information:

- ② Call Diplomat toll-free at **1-855-347-4783** for:
 - A complete list of specialty drugs provided by Diplomat
 - Questions related to dispensing of the drugs
- ② Call PerformRx toll-free at **1-855-508-1713** for questions related to prior authorizations
- ② Call Alliance Pharmacy Services at **510-747-4541** for questions related to specialty drugs from Diplomat

Alameda IHSS Formulary

| | |
|--|------------|
| Informational Section | 2 |
| Antihistamine Drugs - Drugs For Allergy | 1 |
| Anti-Infective Agents - Drugs For Infections | 3 |
| Antineoplastic Agents - Drugs For Cancer | 19 |
| Antitoxins,Immune Glob,Toxoids,Vaccines - Drugs For The Immune System | 27 |
| Autonomic Drugs - Drugs For The Nervous System..... | 32 |
| Blood Formation, Coagulation, Thrombosis - Drugs For The Blood | 40 |
| Cardiovascular Drugs - Drugs For The Heart..... | 46 |
| Central Nervous System Agents - Drugs For The Nervous System..... | 71 |
| Devices - Medical Supplies And Durable Medical Equipment..... | 94 |
| Diagnostic Agents..... | 101 |
| Electrolytic, Caloric, And Water Balance..... | 102 |
| Enzymes | 107 |
| Eye, Ear, Nose And Throat (Eent) Preps..... | 107 |
| Gastrointestinal Drugs..... | 117 |
| Gastrointestinal Drugs - Drugs For The Stomach..... | 117 |
| Gold Compounds | 124 |
| Heavy Metal Antagonists - Drugs To Reduce Iron | 124 |
| Hormones And Synthetic Substitutes - Hormones..... | 125 |
| Miscellaneous Therapeutic Agents | 145 |
| Nonhormonal Contraceptives - Drugs For Women..... | 168 |
| Oxytocics - Drugs For Women | 169 |
| Respiratory Tract Agents - Drugs For The Lungs | 169 |
| Skin And Mucous Membrane Agents - Drugs For The Skin | 184 |
| Smooth Muscle Relaxants - Drugs To Relax Muscles | 195 |
| Vitamins | 196 |

Informational Section

| | | Coverage Requirements and Limits | | | |
|---|------------------|---|---|--|--|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies | | |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | | | |
| Antihistamine Drugs - Drugs For Allergy | | | | | |
| Ethanolamine Derivatives - Drugs For Allergy | | | | | |
| <i>clemastine oral tablet 2.68 mg</i> | T2 | | | | |
| <i>diphenhydramine hcl oral capsule 50 mg</i> | T2 | | | | |
| SLEEP AID (DOXYLAMINE) ORAL TABLET 25 MG <i>(doxylamine succinate)</i> | T2 | | | | |
| First Gen. Antihist. Derivatives, Misc. - Drugs For Allergy | | | | | |
| <i>cyproheptadine oral syrup 2 mg/5 ml</i> | T2 | | | | |
| <i>cyproheptadine oral tablet 4 mg</i> | T2 | | | | |
| First Generation Antihistamines - Drugs For Allergy | | | | | |
| <i>clemastine oral tablet 2.68 mg</i> | T2 | | | | |
| <i>cyproheptadine oral syrup 2 mg/5 ml</i> | T2 | | | | |
| <i>cyproheptadine oral tablet 4 mg</i> | T2 | | | | |
| <i>diphenhydramine hcl oral capsule 50 mg</i> | T2 | | | | |
| SLEEP AID (DOXYLAMINE) ORAL TABLET 25 MG <i>(doxylamine succinate)</i> | T2 | | | | |
| Phenothiazine Derivatives - Drugs For Allergy | | | | | |
| <i>promethazine hcl</i> (Phenadoz Rectal Suppository 12.5 Mg, 25 Mg) | T2 | | | | |
| <i>promethazine oral syrup 6.25 mg/5 ml</i> | T2 | | | | |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | T2 | | | | |
| <i>phenylephrine hcl/promethazine hcl</i> (Promethazine Vc Oral Syrup 6.25-5 Mg/5 MI) | T2 | | | | |
| <i>promethazine/phenylephrine hcl/codeine</i> (Promethazine Vc-Codeine Oral Syrup 6.25-5-10 Mg/5 MI) | T2 | AL (Min 12 Years) | | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>promethazine-dm oral syrup 6.25-15 mg/5 ml</i> | T2 | QL (240 ML per 30 days); AL (Min 4 Years) |
| <i>promethazine-phenyleph-codeine oral syrup 6.25-5-10 mg/5 ml</i> | T2 | AL (Min 12 Years) |
| <i>promethazine hcl</i> (Promethegan Rectal Suppository 50 Mg) | T2 | |
| Piperazine Derivatives - Drugs For Allergy | | |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> | T2 | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | T2 | |
| <i>hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>meclizine oral tablet 12.5 mg, 25 mg</i> | T2 | |
| Propylamine Derivatives - Drugs For Allergy | | |
| <i>APRODINE ORAL TABLET 2.5-60 MG (triprolidine hcl/pseudoephedrine hcl)</i> | T2 | |
| <i>WAL-PHED ORAL TABLET 4-60 MG (chlorpheniramine maleate/pseudoephedrine hcl)</i> | T2 | |
| Second Generation Antihistamines - Drugs For Allergy | | |
| <i>ALL DAY ALLERGY (CETIRIZINE) ORAL TABLET 10 MG (cetirizine hcl)</i> | T2 | |
| <i>ALLERGY RELIEF (LORATADINE) ORAL TABLET,DISINTEGRATING 10 MG (loratadine)</i> | T2 | |
| <i>cetirizine oral solution 1 mg/ml</i> | T2 | |
| <i>cetirizine oral tablet 5 mg</i> | T2 | |
| <i>cetirizine-pseudoephedrine oral tablet extended release 12 hr 5-120 mg</i> | T2 | |
| <i>desloratadine oral tablet 5 mg</i> | T2 | |
| <i>fexofenadine oral suspension 30 mg/5 ml</i> | T2 | |
| <i>fexofenadine oral tablet 180 mg, 60 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>fexofenadine-pseudoephedrine oral tablet extended release 12 hr 60-120 mg</i> | T2 | ST |
| <i>levocetirizine oral solution 2.5 mg/5 ml</i> | T2 | |
| <i>levocetirizine oral tablet 5 mg</i> | T2 | |
| <i>loratadine oral tablet 10 mg</i> | T2 | |
| LORATADINE-D ORAL TABLET EXTENDED RELEASE 12 HR 5-120 MG (<i>loratadine/pseudoephedrine sulfate</i>) | T2 | |
| <i>loratadine-pseudoephedrine oral tablet extended release 24 hr 10-240 mg</i> | T2 | |
| WAL-FEX D 24 HOUR ORAL TABLET EXTENDED RELEASE 24 HR 180-240 MG (<i>fexofenadine hcl/pseudoephedrine hcl</i>) | T2 | ST |
| WAL-ITIN ORAL SOLUTION 5 MG/5 ML (<i>loratadine</i>) | T2 | QL (300 ML per 30 days) |
| Anti-Infective Agents - Drugs For Infections | | |
| 1St Generation Cephalosporin Antibiotics - Antibiotics | | |
| <i>cefazolin injection recon soln 1 gram</i> | T2 | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | T2 | |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | T2 | |
| <i>cephalexin oral tablet 250 mg, 500 mg</i> | T2 | |
| 2Nd Generation Cephalosporin Antibiotics - Antibiotics | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | T2 | |
| <i>cefaclor oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml</i> | T2 | |
| <i>cefuroxime axetil oral tablet 500 mg</i> | T2 | |
| 3Rd Generation Cephalosporin Antibiotics - Antibiotics | | |
| <i>cefdinir oral capsule 300 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | T2 | |
| SUPRAX ORAL SUSPENSION FOR RECONSTITUTION 200 MG/5 ML (<i>cefixime</i>) | T3 | |
| Adamantane Antivirals - Drugs For Viral Infections | | |
| <i>amantadine hcl oral capsule 100 mg</i> | T2 | |
| <i>amantadine hcl oral tablet 100 mg</i> | T2 | |
| Allylamine Antifungals - Drugs For Fungus | | |
| <i>terbinafine hcl oral tablet 250 mg</i> | T2 | QL (30 Qty per 30 days) |
| Amebicides - Drugs For The Mouth And Throat | | |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | T2 | |
| Aminoglycoside Antibiotics - Antibiotics | | |
| ARIKAYCE INHALATION SUSPENSION FOR NEBULIZATION 590 MG/8.4 ML (<i>amikacin sulfate liposomal with nebulizer accessories</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>neomycin oral tablet 500 mg</i> | T2 | QL (10 EA per 1 fill) |
| TOBI PODHALER INHALATION CAPSULE 28 MG (<i>tobramycin</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE 28 MG (<i>tobramycin</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>tobramycin with nebulizer inhalation solution for nebulization 300 mg/5 ml</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Aminopenicillin Antibiotics - Antibiotics | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | T2 | |
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | T2 | |
| <i>amoxicillin oral tablet 875 mg</i> | T2 | |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | T2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml</i> | T2 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i> | T2 | |
| <i>amoxicillin-pot clavulanate oral tablet, chewable 200-28.5 mg, 400-57 mg</i> | T2 | |
| <i>ampicillin oral capsule 250 mg, 500 mg</i> | T2 | |
| AUGMENTIN ORAL SUSPENSION FOR RECONSTITUTION 125-31.25 MG/5 ML (<i>amoxicillin/potassium clavulanate</i>) | T3 | |
| <i>lansoprazole/amoxicillin trihydrate/clarithromycin</i> (Prevpac Oral Combo Pack 500-500-30 Mg) | T3 | PA |
| Anthelmintics - Drugs For Parasites | | |
| <i>ivermectin oral tablet 3 mg</i> | T2 | QL (30 EA per 365 days) |
| PIN-X ORAL SUSPENSION 50 MG/ML (<i>pyrantel pamoate</i>) | T2 | |
| PIN-X ORAL TABLET,CHEWABLE 250 MG (<i>pyrantel pamoate</i>) | T3 | |
| Antifungals, Miscellaneous - Drugs For Fungus | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | T2 | AL (Max 12 Years) |
| <i>griseofulvin microsize oral tablet 500 mg</i> | T2 | ST |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | T2 | ST |
| SSKI ORAL SOLUTION 1 GRAM/ML (<i>potassium iodide</i>) | T2 | |
| Antimalarials - Drugs For The Mouth And Throat | | |
| <i>atovaquone-proguanil oral tablet 250-100 mg, 62.5-25 mg</i> | T2 | PA |
| <i>chloroquine phosphate oral tablet 250 mg</i> | T2 | |
| <i>chloroquine phosphate oral tablet 500 mg</i> | T2 | |
| <i>hydroxychloroquine oral tablet 200 mg</i> | T2 | |
| <i>mefloquine oral tablet 250 mg</i> | T2 | |
| <i>primaquine oral tablet 26.3 mg</i> | T3 | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | T2 | |
| Antimycobacterials, Miscellaneous - Antibiotics | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | T2 | |
| Antiprotozoals, Miscellaneous - Drugs For The Mouth And Throat | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | T2 | |
| MEPRON ORAL SUSPENSION 750 MG/5 ML (<i>atovaquone</i>) | T3 | QL (300 ML per 30 days); AL (Min 21 Years) |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | T2 | |
| Antituberculosis Agents - Antibiotics | | |
| <i>ciprofloxacin hcl oral tablet 100 mg</i> | T2 | QL (60 per per 30 days) |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | T2 | |
| <i>cycloserine oral capsule 250 mg</i> | T2 | ST |
| <i>ethambutol oral tablet 100 mg, 400 mg</i> | T2 | |
| <i>isoniazid oral solution 50 mg/5 ml</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | T2 | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | T2 | |
| <i>moxifloxacin oral tablet 400 mg</i> | T2 | ST |
| PASER ORAL GRANULES DR FOR SUSP IN PACKET 4 GRAM (<i>aminosalicylic acid</i>) | T3 | ST |
| <i>pretomanid oral tablet 200 mg</i> | T3 | PA |
| PRIFTIN ORAL TABLET 150 MG (<i>rifapentine</i>) | T3 | QL (24 EA per 28 days) |
| <i>pyrazinamide oral tablet 500 mg</i> | T2 | |
| <i>rifabutin oral capsule 150 mg</i> | T2 | PA |
| RIFAMATE ORAL CAPSULE 300-150 MG (<i>rifampin/isoniazid</i>) | T3 | |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | T2 | |
| RIFATER ORAL TABLET 50-120-300 MG (<i>rifampin/isoniazid/pyrazinamide</i>) | T3 | |
| SIRTURO ORAL TABLET 100 MG (<i>bedaquiline fumarate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SIRTURO ORAL TABLET 20 MG (<i>bedaquiline fumarate</i>) | T3 | PA |
| TRECATOR ORAL TABLET 250 MG (<i>ethionamide</i>) | T3 | ST |
| Azole Antifungals - Drugs For Fungus | | |
| <i>fluconazole oral suspension for reconstitution 10 mg/ml, 40 mg/ml</i> | T2 | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | T2 | |
| <i>itraconazole oral capsule 100 mg</i> | T2 | PA |
| <i>ketoconazole oral tablet 200 mg</i> | T2 | |
| SPORANOX ORAL SOLUTION 10 MG/ML (<i>itraconazole</i>) | T3 | |
| <i>voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml)</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|--|--|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | T2 | PA |
| Erythromycin Antibiotics - Antibiotics | | |
| <i>erythromycin ethylsuccinate</i> (E.E.S. 400 Oral Tablet 400 Mg) | T2 | |
| <i>erythromycin stearate</i> (Erythrocin (As Stearate) Oral Tablet 250 Mg) | T2 | |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml, 400 mg/5 ml</i> | T2 | |
| <i>erythromycin oral capsule,delayed release(dr/ec) 250 mg</i> | T2 | |
| <i>erythromycin oral tablet 250 mg, 500 mg</i> | T2 | |
| <i>erythromycin oral tablet,delayed release (dr/ec) 250 mg, 333 mg, 500 mg</i> | T2 | |
| Glycopeptide Antibiotics - Antibiotics | | |
| <i>FIRVANQ ORAL RECON SOLN 25 MG/ML (vancomycin hcl)</i> | T3 | QL (200 ML per 28 days) |
| <i>FIRVANQ ORAL RECON SOLN 50 MG/ML (vancomycin hcl)</i> | T3 | QL (400 ML per 28 days) |
| <i>vancomycin oral capsule 125 mg</i> | T2 | QL (40 EA per 28 days) |
| <i>vancomycin oral capsule 250 mg</i> | T2 | QL (80 EA per 28 days) |
| Hcv Polymerase Inhibitor Antivirals - Drugs For Viral Infections | | |
| <i>HARVONI ORAL TABLET 45-200 MG (ledipasvir/sofosbuvir)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>ledipasvir-sofosbuvir 90-400 mg 90-400 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | |
|--|---|---|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| SOVALDI ORAL TABLET 200 MG (<i>sofosbuvir</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Hcv Protease Inhibitor Antivirals - Drugs For Viral Infections | | |
| MAVYRET ORAL TABLET 100-40 MG (<i>glecaprevir/pibrentasvir</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ZEPATIER ORAL TABLET 50-100 MG (<i>elbasvir/grazoprevir</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Hcv Replication Complex Inhibitors - Drugs For Viral Infections | | |
| HARVONI ORAL TABLET 45-200 MG (<i>ledipasvir/sofosbuvir</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>ledipasvir-sofosbuvir 90-400 mg 90-400 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| MAVYRET ORAL TABLET 100-40 MG (<i>glecaprevir/pibrentasvir</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> | | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ZEPATIER ORAL TABLET 50-100 MG (elbasvir/grazoprevir) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Hiv Entry And Fusion Inhibitors - Drugs For Viral Infections | | | |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG (enfuvirtide) | | T3 | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG (fostemsavir tromethamine) | | T3 | |
| SELZENTRY ORAL SOLUTION 20 MG/ML (maraviroc) | | T3 | |
| SELZENTRY ORAL TABLET 150 MG, 25 MG, 300 MG, 75 MG (maraviroc) | | T3 | |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33 ML (150 MG/ML) (ibalizumab-uiyk) | | T3 | |
| Hiv Integrase Inhibitor Antiretrovirals - Drugs For Viral Infections | | | |
| BIKTARVY ORAL TABLET 50-200-25 MG (bictegravir sodium/emtricitabine/tenofovir alafenamide fumar) | | T3 | |
| CABENUVA INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE 400 MG/2 ML- 600 MG/2 ML, 600 MG/3 ML- 900 MG/3 ML (cabotegravir/rilpivirine) | | T3 | |
| DOVATO ORAL TABLET 50-300 MG (dolutegravir sodium/lamivudine) | | T3 | |
| GENVOYA ORAL TABLET 150-150-200-10 MG (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) | | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| ISENTRESS HD ORAL TABLET 600 MG (<i>raltegravir potassium</i>) | T3 | |
| ISENTRESS ORAL POWDER IN PACKET 100 MG (<i>raltegravir potassium</i>) | T3 | |
| ISENTRESS ORAL TABLET 400 MG (<i>raltegravir potassium</i>) | T3 | |
| ISENTRESS ORAL TABLET, CHEWABLE 100 MG, 25 MG (<i>raltegravir potassium</i>) | T3 | |
| JULUCA ORAL TABLET 50-25 MG (<i>dolutegravir sodium/rilpivirine hcl</i>) | T3 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG (<i>elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil</i>) | T3 | |
| TIVICAY ORAL TABLET 10 MG, 25 MG, 50 MG (<i>dolutegravir sodium</i>) | T3 | |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG (<i>dolutegravir sodium</i>) | T3 | |
| TRIUMEQ ORAL TABLET 600-50-300 MG (<i>abacavir sulfate/dolutegravir sodium/lamivudine</i>) | T3 | |
| Hiv Nonnucleoside Rev. Transcrip. Inhib. - Drugs For Viral Infections | | |
| COMPLERA ORAL TABLET 200-25-300 MG (<i>emtricitabine/rilpivirine hcl/tenofovir disoproxil fumarate</i>) | T3 | |
| DELSTRIGO ORAL TABLET 100-300-300 MG (<i>doravirine/lamivudine/tenofovir disoproxil fumarate</i>) | T3 | |
| EDURANT ORAL TABLET 25 MG (<i>rilpivirine hcl</i>) | T3 | |
| <i>efavirenz oral capsule 200 mg, 50 mg</i> | T2 | |
| <i>efavirenz oral tablet 600 mg</i> | T2 | |
| <i>efavirenz-emtricitabin-tenofov oral tablet 600-200-300 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|-----------|----------------------------------|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| <i>efavirenz-lamivu-tenofovir disop oral tablet 400-300-300 mg, 600-300-300 mg</i> | T2 | | |
| <i>etravirine oral tablet 100 mg, 200 mg</i> | T2 | | |
| INTELENCE ORAL TABLET 25 MG (<i>etravirine</i>) | T3 | | |
| JULUCA ORAL TABLET 50-25 MG (<i>dolutegravir sodium/rilpivirine hcl</i>) | T3 | | |
| <i>nevirapine oral suspension 50 mg/5 ml</i> | T2 | | |
| <i>nevirapine oral tablet 200 mg</i> | T2 | | |
| <i>nevirapine oral tablet extended release 24 hr 100 mg, 400 mg</i> | T2 | | |
| ODEFSEY ORAL TABLET 200-25-25 MG (<i>emtricitabine/rilpivirine hcl/tenofovir alafenamide fumarate</i>) | T3 | | |
| PIFELTRO ORAL TABLET 100 MG (<i>doravirine</i>) | T3 | | |
| RESCRIPTOR ORAL TABLET 200 MG (<i>delavirdine mesylate</i>) | T3 | | |
| RESCRIPTOR ORAL TABLET, DISPERSIBLE 100 MG (<i>delavirdine mesylate</i>) | T3 | | |
| Hiv Nucleoside, Nucleotide Rt Inhibitors - Drugs For Viral Infections | | | |
| <i>abacavir oral solution 20 mg/ml</i> | T2 | | |
| <i>abacavir oral tablet 300 mg</i> | T2 | | |
| <i>abacavir-lamivudine oral tablet 600-300 mg</i> | T2 | | |
| <i>abacavir-lamivudine-zidovudine oral tablet 300-150-300 mg</i> | T2 | | |
| BIKTARVY ORAL TABLET 50-200-25 MG (<i>bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate</i>) | T3 | | |
| CIMDUO ORAL TABLET 300-300 MG (<i>lamivudine/tenofovir disoproxil fumarate</i>) | T3 | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| COMPLERA ORAL TABLET 200-25-300 MG <i>(emtricitabine/rilpivirine hcl/tenofovir disoproxil fumarate)</i> | T3 | |
| DELSTRIGO ORAL TABLET 100-300-300 MG <i>(doravirine/lamivudine/tenofovir disoproxil fumarate)</i> | T3 | |
| DESCOVY ORAL TABLET 200-25 MG <i>(emtricitabine/tenofovir alafenamide fumarate)</i> | T3 | |
| <i>didanosine oral capsule,delayed release(dr/ec) 125 mg, 200 mg, 250 mg, 400 mg</i> | T2 | |
| DOVATO ORAL TABLET 50-300 MG (<i>dolutegravir sodium/lamivudine</i>) | T3 | |
| <i>efavirenz-emtricitabin-tenofov oral tablet 600-200-300 mg</i> | T2 | |
| <i>efavirenz-lamivu-tenofov disop oral tablet 400-300-300 mg, 600-300-300 mg</i> | T2 | |
| <i>emtricitabine oral capsule 200 mg</i> | T2 | |
| <i>emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg, 200-300 mg</i> | T2 | |
| EMTRIVA ORAL SOLUTION 10 MG/ML (<i>emtricitabine</i>) | T3 | |
| EPIVIR HBV ORAL SOLUTION 25 MG/5 ML (5 MG/ML) <i>(lamivudine)</i> | T3 | PA |
| GENVOYA ORAL TABLET 150-150-200-10 MG <i>(elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)</i> | T3 | |
| <i>lamivudine oral solution 10 mg/ml</i> | T2 | |
| <i>lamivudine oral tablet 100 mg</i> | T2 | PA |
| <i>lamivudine oral tablet 150 mg, 300 mg</i> | T2 | |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| ODEFSEY ORAL TABLET 200-25-25 MG <i>(emtricitabine/rilpivirine hcl/tenofovir alafenamide fumarate)</i> | | T3 | |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML <i>(zidovudine)</i> | | T3 | |
| <i>stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg</i> | | T2 | |
| <i>stavudine oral recon soln 1 mg/ml</i> | | T2 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG <i>(elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil)</i> | | T3 | |
| SYMTUZA ORAL TABLET 800-150-200-10 MG (<i>darunavir eth/cobicistat/emtricitabine/tenofovir alafenamide</i>) | | T3 | |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | | T2 | |
| TRIUMEQ ORAL TABLET 600-50-300 MG (<i>abacavir sulfate/dolutegravir sodium/lamivudine</i>) | | T3 | |
| VIDEX 2 GRAM PEDIATRIC ORAL RECON SOLN 10 MG/ML (FINAL) (<i>didanosine</i>) | | T3 | |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG <i>(tenofovir disoproxil fumarate)</i> | | T3 | PA |
| <i>zidovudine oral capsule 100 mg</i> | | T2 | |
| <i>zidovudine oral syrup 10 mg/ml</i> | | T2 | |
| <i>zidovudine oral tablet 300 mg</i> | | T2 | |
| Hiv Protease Inhibitor Antiretrovirals - Drugs For Viral Infections | | | |
| APTIVUS (WITH VITAMIN E) ORAL SOLUTION 100 MG/ML (<i>tipranavir/vitamin e tpgs</i>) | | T3 | |
| APTIVUS ORAL CAPSULE 250 MG (<i>tipranavir</i>) | | T3 | |
| <i>atazanavir oral capsule 150 mg, 200 mg</i> | | T2 | |
| CRIXIVAN ORAL CAPSULE 200 MG, 400 MG (<i>indinavir sulfate</i>) | | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| EVOTAZ ORAL TABLET 300-150 MG (<i>atazanavir sulfate/cobicistat</i>) | | T3 | |
| INVIRASE ORAL CAPSULE 200 MG (<i>saquinavir mesylate</i>) | | T3 | |
| INVIRASE ORAL TABLET 500 MG (<i>saquinavir mesylate</i>) | | T3 | |
| KALETRA ORAL SOLUTION 400-100 MG/5 ML (<i>lopinavir/ritonavir</i>) | | T3 | |
| LEXIVA ORAL SUSPENSION 50 MG/ML (<i>fosamprenavir calcium</i>) | | T3 | |
| LEXIVA ORAL TABLET 700 MG (<i>fosamprenavir calcium</i>) | | T3 | |
| <i>lopinavir-ritonavir oral tablet 100-25 mg, 200-50 mg</i> | | T2 | |
| NORVIR ORAL CAPSULE 100 MG (<i>ritonavir</i>) | | T3 | |
| NORVIR ORAL POWDER IN PACKET 100 MG (<i>ritonavir</i>) | | T3 | |
| NORVIR ORAL SOLUTION 80 MG/ML (<i>ritonavir</i>) | | T3 | |
| PREZCOBIX ORAL TABLET 800-150 MG-MG (<i>darunavir ethanolate/cobicistat</i>) | | T3 | |
| PREZISTA ORAL SUSPENSION 100 MG/ML (<i>darunavir ethanolate</i>) | | T3 | |
| PREZISTA ORAL TABLET 150 MG, 75 MG, 800 MG (<i>darunavir ethanolate</i>) | | T3 | |
| PREZISTA ORAL TABLET 600 MG (<i>darunavir ethanolate</i>) | | T3 | QL (60 Qty per 30 days) |
| REYATAZ ORAL POWDER IN PACKET 50 MG (<i>atazanavir sulfate</i>) | | T3 | |
| <i>ritonavir oral tablet 100 mg</i> | | T2 | |
| SYMTUZA ORAL TABLET 800-150-200-10 MG (<i>darunavir eth/cobicistat/emtricitabine/tenofovir alafenamide</i>) | | T3 | |
| VIRACEPT ORAL TABLET 250 MG, 625 MG (<i>nelfinavir mesylate</i>) | | T3 | |
| Lincomycin Antibiotics - Antibiotics | | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg</i> | T2 | |
| <i>clindamycin palmitate hcl oral recon soln 75 mg/5 ml</i> | T2 | AL (Max 12 Years) |
| Monobactam Antibiotics - Antibiotics | | |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML (<i>aztreonam lysine</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Natural Penicillin Antibiotics - Antibiotics | | |
| <i>penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml</i> | T2 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | T2 | |
| Neuraminidase Inhibitor Antivirals - Drugs For Viral Infections | | |
| <i>oseltamivir oral capsule 30 mg</i> | T2 | QL (28 EA per 30 days) |
| <i>oseltamivir oral capsule 45 mg</i> | T2 | QL (16 EA per 30 days) |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> | T2 | QL (120 ML per 30 days) |
| RELENZA DISKHALER INHALATION BLISTER WITH DEVICE 5 MG/ACTUATION (<i>zanamivir</i>) | T3 | |
| <i>oseltamivir phosphate</i> (Tamiflu Oral Capsule 75 Mg) | T3 | QL (14 EA per 30 days) |
| Nucleoside And Nucleotide Antivirals - Drugs For Viral Infections | | |
| <i>acyclovir oral capsule 200 mg</i> | T2 | |
| <i>acyclovir oral suspension 200 mg/5 ml</i> | T2 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | T2 | |
| <i>adefovir oral tablet 10 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| BARACLUDE ORAL SOLUTION 0.05 MG/ML (<i>entecavir</i>) | T3 | PA |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | T2 | |
| <i>ganciclovir sodium intravenous recon soln 500 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>ribavirin oral tablet 200 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SYMTUZA ORAL TABLET 800-150-200-10 MG (<i>darunavir eth/cobicistat/emtricitabine/tenofovir alafenamide</i>) | T3 | |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i> | T2 | |
| <i>valganciclovir oral recon soln 50 mg/ml</i> | T2 | QL (60 ML per 30 days); AL (Min 21 Years) |
| <i>valganciclovir oral tablet 450 mg</i> | T2 | QL (60 Qty per 30 days); AL (Min 21 Years) |
| VEMLIDY ORAL TABLET 25 MG (<i>tenofovir alafenamide</i>) | T3 | PA |
| Other Macrolide Antibiotics - Antibiotics | | |
| <i>azithromycin oral packet 1 gram</i> | T2 | |
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | T2 | |
| <i>azithromycin oral tablet 250 mg, 500 mg, 600 mg</i> | T2 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | T2 | |
| <i>lansoprazole/amoxicillin trihydrate/clarithromycin</i> (Prevpac Oral Combo Pack 500-500-30 Mg) | T3 | PA |
| Oxazolidinone Antibiotics - Antibiotics | | |
| <i>linezolid oral suspension for reconstitution 100 mg/5 ml</i> | Tier 1 | ST |
| <i>linezolid oral tablet 600 mg</i> | T2 | ST |
| Penicillinase-Resistant Penicillins - Antibiotics | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i> | T2 | |
| Polyene Antifungals - Drugs For Fungus | | |
| <i>nystatin oral suspension 100,000 unit/ml</i> | T2 | |
| <i>nystatin oral tablet 500,000 unit</i> | T2 | |
| Quinolone Antibiotics - Antibiotics | | |
| <i>ciprofloxacin hcl oral tablet 100 mg</i> | T2 | QL (60 per per 30 days) |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | T2 | |
| <i>moxifloxacin oral tablet 400 mg</i> | T2 | ST |
| <i>ofloxacin oral tablet 300 mg</i> | T2 | |
| Rifamycin Antibiotics - Antibiotics | | |
| AEMCOLO ORAL TABLET,DELAYED RELEASE (DR/EC) 194 MG (<i>rifamycin sodium</i>) | T3 | PA |
| PRIFTIN ORAL TABLET 150 MG (<i>rifapentine</i>) | T3 | QL (24 EA per 28 days) |
| <i>rifabutin oral capsule 150 mg</i> | T2 | PA |
| RIFAMATE ORAL CAPSULE 300-150 MG (<i>rifampin/isoniazid</i>) | T3 | |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | T2 | |
| RIFATER ORAL TABLET 50-120-300 MG (<i>rifampin/isoniazid/pyrazinamide</i>) | T3 | |
| XIFAXAN ORAL TABLET 200 MG, 550 MG (<i>rifaximin</i>) | T3 | ST |
| Sulfonamide Antibiotics (Systemic) - Antibiotics | | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i> | T2 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | T2 | |
| <i>sulfasalazine oral tablet 500 mg</i> | T2 | |
| <i>sulfasalazine oral tablet,delayed release (dr/ec) 500 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| Tetracycline Antibiotics - Antibiotics | | |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | T2 | QL (180 days per 365 days) |
| <i>doxycycline monohydrate oral tablet 100 mg</i> | T2 | QL (180 days per 365 days) |
| <i>minocycline oral capsule 100 mg</i> | T2 | ST |
| <i>tetracycline oral capsule 250 mg, 500 mg</i> | T2 | QL (180 days per 365 days) |
| Urinary Anti-Infectives - Drugs For The Urinary System | | |
| <i>methenamine mandelate oral tablet 0.5 g, 1 gram</i> | T2 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>nitrofurantoin monohyd/m-cryst oral capsule 100 mg</i> | T2 | |
| <i>nitrofurantoin oral suspension 25 mg/5 ml</i> | T2 | |
| PRIMSOL ORAL SOLUTION 50 MG/5 ML (<i>trimethoprim</i>) | T3 | |
| <i>trimethoprim oral tablet 100 mg</i> | T2 | |
| Antineoplastic Agents - Drugs For Cancer | | |
| Antineoplastic Agents - Drugs For Cancer | | |
| <i>abiraterone oral tablet 250 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>abiraterone oral tablet 500 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG (<i>everolimus</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| AFINITOR ORAL TABLET 10 MG (everolimus) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>anastrozole oral tablet 1 mg</i> | T2 | |
| <i>bexarotene oral capsule 75 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>bicalutamide oral tablet 50 mg</i> | T2 | |
| BOSULIF ORAL TABLET 100 MG, 500 MG (bosutinib) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>capecitabine oral tablet 150 mg, 500 mg</i> | T2 | PA ; AL (Min 21 Years) |
| CAPRELSA ORAL TABLET 100 MG, 300 MG (vandetanib) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) |
| <i>diclofenac sodium topical gel 3 %</i> | T2 | PA |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG (hydroxyurea) | T3 | |
| EMCYT ORAL CAPSULE 140 MG (estramustine phosphate sodium) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>erlotinib oral tablet 100 mg, 150 mg, 25 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| ERWINAZE INJECTION RECON SOLN 10,000 UNIT (<i>asparaginase (erwinia chrysanthemi)</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>etoposide oral capsule 50 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>everolimus (antineoplastic) oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>exemestane oral tablet 25 mg</i> | T2 | |
| <i>fluorouracil topical cream 5 %</i> | T2 | |
| <i>fluorouracil topical solution 2 %, 5 %</i> | T2 | |
| <i>flutamide oral capsule 125 mg</i> | T2 | |
| HEXALEN ORAL CAPSULE 50 MG (<i>altretamine</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.); AL (Min 21 Years) |
| HYCAMTIN ORAL CAPSULE 0.25 MG, 1 MG (<i>topotecan hcl</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>hydroxyurea oral capsule 500 mg</i> | T2 | AL (Min 21 Years) |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG (<i>ponatinib hcl</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|---|--|---|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>imatinib oral tablet 100 mg, 400 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) | |
| KYPROLIS INTRAVENOUS RECON SOLN 60 MG (<i>carfilzomib</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| <i>lapatinib oral tablet 250 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.); AL (Min 21 Years) | |
| <i>letrozole oral tablet 2.5 mg</i> | T2 | | |
| LEUKERAN ORAL TABLET 2 MG (<i>chlorambucil</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) | |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG, 22.5 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 7.5 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| LUPRON DEPOT-PED INTRAMUSCULAR KIT 11.25 MG, 15 MG, 7.5 MG (PED) (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| LYSODREN ORAL TABLET 500 MG (<i>mitotane</i>) | T3 | |
| MATULANE ORAL CAPSULE 50 MG (<i>procarbazine hcl</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml)</i> | T2 | |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | T2 | |
| <i>melphalan hcl intravenous recon soln 50 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|---|---|
| | | AL = Age Limit Applies | PA = PA Applies |
| | | QL = Quantity Limit | SP = Specialty Product |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>melphalan oral tablet 2 mg</i> | | T2 | AL (Min 21 Years) |
| <i>mercaptopurine oral tablet 50 mg</i> | | T2 | |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | | T2 | |
| MYLERAN ORAL TABLET 2 MG (<i>busulfan</i>) | | T3 | |
| NEXAVAR ORAL TABLET 200 MG (<i>sorafenib tosylate</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) |
| NILANDRON ORAL TABLET 150 MG (<i>nilutamide</i>) | | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| OTREXUP (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.4 ML, 15 MG/0.4 ML, 20 MG/0.4 ML, 25 MG/0.4 ML (<i>methotrexate/pf</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| OTREXUP (PF) SUBCUTANEOUS AUTO-INJECTOR 12.5 MG/0.4 ML, 17.5 MG/0.4 ML, 22.5 MG/0.4 ML (<i>methotrexate/pf</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML (<i>methotrexate/pf</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| REVLIMID ORAL CAPSULE 10 MG, 15 MG, 25 MG, 5 MG (<i>lenalidomide</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) |
| REVLIMID ORAL CAPSULE 2.5 MG, 20 MG (<i>lenalidomide</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 22 Years) |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML (<i>tamoxifen citrate</i>) | T3 | |
| SPRYCEL ORAL TABLET 100 MG (<i>dasatinib</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.); AL (Min 21 Years) |
| SPRYCEL ORAL TABLET 140 MG, 20 MG, 50 MG, 70 MG, 80 MG (<i>dasatinib</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SUTENT ORAL CAPSULE 12.5 MG, 25 MG, 50 MG (<i>sunitinib malate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| SUTENT ORAL CAPSULE 37.5 MG (<i>sunitinib malate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| TABLOID ORAL TABLET 40 MG (<i>thioguanine</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | T2 | |
| TARGRETIN TOPICAL GEL 1 % (<i>bexarotene</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| TASIGNA ORAL CAPSULE 150 MG (<i>nilotinib hcl</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 20 Years) |
| TASIGNA ORAL CAPSULE 200 MG (<i>nilotinib hcl</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>temozolomide oral capsule 100 mg, 140 mg, 180 mg, 20 mg, 250 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.); AL (Min 21 Years) |
| <i>temozolomide oral capsule 5 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>toremifene oral tablet 60 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.); AL (Min 21 Years) |
| <i>tretinooin (antineoplastic) oral capsule 10 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.); AL (Max 21 Years) |
| VOTRIENT ORAL TABLET 200 MG (<i>pazopanib hcl</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG (<i>crizotinib</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ZOLINZA ORAL CAPSULE 100 MG (<i>vorinostat</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Antitoxins,Immune Glob,Toxoids,Vaccines - Drugs For The Immune System | | |
| Toxoids - Vaccines | | |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML (<i>diphtheria,pertussis(acellular),tetanus vaccine/pf</i>) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG-LF/0.5ML (<i>diphtheria,pertussis(acellular),tetanus vaccine</i>) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5-8-5 LF-MCG-LF/0.5ML (diphtheria,pertussis(acellular),tetanus vaccine) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF UNIT/0.5 ML (tetanus and diphtheria toxoids, adult) | T2 | QL (0.5 EA per 1 fill); AL (Min 19 Years) |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML (tetanus and diphtheria toxoids, adsorbed, adult/pf) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML (tetanus and diphtheria toxoids, adsorbed, adult/pf) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| Vaccines - Vaccines | | |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML (haemophilus b conjugate vaccine(tetanus toxoid conjugate)/pf) | T3 | QL (0.5 EA per 1 fill); AL (Min 19 Years) |
| AFLURIA QD 2020-21(3YR UP)(PF) INTRAMUSCULAR SYRINGE 60 MCG (15 MCG X 4)/0.5 ML (influenza virus vaccine quadrivalent 2020-21 (36 mos up)/pf) | T3 | AL (Min 36 Months and Max 64 Years) |
| AFLURIA QD 2020-21(6-35MO)(PF) INTRAMUSCULAR SYRINGE 30 MCG (7.5 MCG X 4)/0.25 ML (influenza virus vaccine quadrival 2020-21 (6 mos-35 mos)/pf) | T3 | AL (Min 6 Months and Max 35 Months) |
| AFLURIA QUAD 2020-2021(6MO UP) INTRAMUSCULAR SUSPENSION 60 MCG (15 MCG X 4)/0.5 ML (influenza virus vaccine quadrivalent 2020-21 (6 mos and up)) | T3 | AL (Min 3 Years and Max 64 Years) |
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML (meningococcal group b vaccine, 4-component) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| CERVARIX VACCINE (PF) INTRAMUSCULAR SYRINGE 20-20 MCG/0.5 ML (human papillomavirus vaccine, bivalent/pf) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML (hepatitis b virus vaccine recombinant/pf) | T3 | QL (1 ML per 1 fill); AL (Min 19 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML (<i>hepatitis b virus vaccine recombinant/pf</i>) | T3 | QL (1 ML per 1 fill); AL (Min 19 Years) |
| FLUAD 2020-2021 (65 YR UP)(PF) INTRAMUSCULAR SYRINGE 45 MCG (15 MCG X 3)/0.5 ML (<i>influenza vaccine tvs 2020-21 (65 yr up)/adjuvant mf59c.1/pf</i>) | T3 | AL (Min 65 Years) |
| FLUAD QUAD 2020-21(65Y UP)(PF) INTRAMUSCULAR SYRINGE 60 MCG (15 MCG X 4)/0.5 ML (<i>influenza vaccine quadrivalent 2020-21 (65 yr up)/mf59c.1/pf</i>) | T3 | AL (Min 65 Years) |
| FLUARIX QUAD 2020-2021 (PF) INTRAMUSCULAR SYRINGE 60 MCG (15 MCG X 4)/0.5 ML (<i>influenza virus vaccine quadrival 2020-2021(6 mos and up)/pf</i>) | T3 | AL (Min 3 Years and Max 64 Years) |
| FLUBLOK QUAD 2020-2021 (PF) INTRAMUSCULAR SYRINGE 180 MCG (45 MCG X 4)/0.5 ML (<i>influenza virus vaccine qv 2020-21(18 yrs and older)rcmb/pf</i>) | T3 | AL (Min 18 Years and Max 64 Years) |
| FLUCELVAX QUAD 2020-2021 (PF) INTRAMUSCULAR SYRINGE 60 MCG (15 MCG X 4)/0.5 ML (<i>flu vaccine quad 2020-2021(4 years and older)cell derived/pf</i>) | T3 | AL (Min 4 Years and Max 64 Years) |
| FLUCELVAX QUAD 2020-2021 INTRAMUSCULAR SUSPENSION 60 MCG (15 MCG X 4)/0.5 ML (<i>flu vaccine quadriv 2020-2021(4 years and older)cell derived</i>) | T3 | AL (Min 4 Years and Max 64 Years) |
| FLULAVAL QUAD 2020-2021 (PF) INTRAMUSCULAR SYRINGE 60 MCG (15 MCG X 4)/0.5 ML (<i>influenza virus vaccine quadrival 2020-2021(6 mos and up)/pf</i>) | T3 | AL (Min 3 Years and Max 64 Years) |
| FLUMIST QUAD 2020-2021 NASAL NASAL SPRAY SYRINGE 10EXP6.5-7.5 FF UNIT/0.2 ML (<i>influenza vaccine quadrivalent live 2020-2021 (2 yrs-49 yrs)</i>) | T3 | AL (Min 2 Years and Max 49 Years) |
| FLUZONE HIGHDOSE QUAD 20-21 PF INTRAMUSCULAR SYRINGE 240 MCG/0.7 ML (<i>influenza virus vaccine quadrival split 2020-21(65 yr up)/pf</i>) | T3 | AL (Min 65 Years) |
| FLUZONE QUAD 2020-2021 (PF) INTRAMUSCULAR SUSPENSION 60 MCG (15 MCG X 4)/0.5 ML (<i>influenza virus vaccine quadrival 2020-2021(6 mos and up)/pf</i>) | T3 | AL (Min 3 Years and Max 64 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| FLUZONE QUAD 2020-2021 (PF) INTRAMUSCULAR SYRINGE 60 MCG (15 MCG X 4)/0.5 ML (<i>influenza virus vaccine quadrivalent 2020-2021 (6 mos and up)/pf</i>) | T3 | AL (Min 3 Years and Max 64 Years) |
| FLUZONE QUAD 2020-2021 INTRAMUSCULAR SUSPENSION 60 MCG (15 MCG X 4)/0.5 ML (<i>influenza virus vaccine quadrivalent 2020-21 (6 mos and up)</i>) | T3 | AL (Min 3 Years and Max 64 Years) |
| GARDASIL (PF) INTRAMUSCULAR SUSPENSION 20-40-40-20 MCG/0.5 ML (<i>human papillomavirus vaccine, quadrivalent/pf</i>) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| GARDASIL (PF) INTRAMUSCULAR SYRINGE 20-40-40-20 MCG/0.5 ML (<i>human papillomavirus vaccine, quadrivalent/pf</i>) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML (<i>human papillomavirus vaccine, 9-valent/pf</i>) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML (<i>human papillomavirus vaccine, 9-valent/pf</i>) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| HAVRIX (PF) INTRAMUSCULAR SUSPENSION 1,440 ELISA UNIT/ML (<i>hepatitis a virus vaccine/pf</i>) | T3 | QL (1 ML per 1 fill); AL (Min 19 Years) |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML (<i>hepatitis a virus vaccine/pf</i>) | T3 | QL (1 ML per 1 fill); AL (Min 19 Years) |
| HEPLISAV-B (PF) INTRAMUSCULAR SOLUTION 20 MCG/0.5 ML (<i>hepatitis b vaccine recombinant/vaccine adjuvant cpg 1018/pf</i>) | T3 | QL (1 EA per 1 FILL); AL (Min 19 Years) |
| HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML (<i>hepatitis b vaccine recombinant/vaccine adjuvant cpg 1018/pf</i>) | T3 | QL (1 EA per 1 fill) |
| IMOVAZ RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT (<i>rabies vaccine, human diploid cell/pf</i>) | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|-----------|---|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| JANSEN COVID-19 VACCINE (EUA) INTRAMUSCULAR SUSPENSION 0.5 ML (covid-19 vac, ad26.cov2.s (janssen)/pf) | T3 | | |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION 4 MCG/0.5 ML (meningococcal vaccine a,c,y,w-135,diphtheria toxoid conj/pf) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) | |
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML (meningococcal vaccine a,c,y and w-135,conj tetanus toxoid/pf) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) | |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML (meningococcal vaccine a,c,y,w-135,diphtheria toxoid conj/pf) | T3 | QL (0.5 EA per 1 fill); AL (Min 19 Years) | |
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML (measles, mumps, and rubella vaccine live/pf) | T3 | QL (0.5 EA per 1 fill); AL (Min 19 Years) | |
| MODERNA COVID-19 VACCINE (EUA) INTRAMUSCULAR SUSPENSION 100 MCG/0.5 ML (covid-19 vaccine, mrna, cx-024414, Inp-s (moderna)/pf) | T3 | | |
| PFIZER COVID-19 VACCINE (EUA) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 30 MCG/0.3 ML (covid-19 vaccine, mrna, bnt162b2, Inp-s (pfizer)/pf) | T3 | | |
| PNEUMOVAX-23 INJECTION SOLUTION 25 MCG/0.5 ML (pneumococcal 23-valent polysaccharide vaccine) | T3 | QL (1 EA per 1 fill); AL (Min 19 Years) | |
| PNEUMOVAX-23 INJECTION SYRINGE 25 MCG/0.5 ML (pneumococcal 23-valent polysaccharide vaccine) | T3 | QL (1 EA per 1 Fill); AL (Min 19 Years) | |
| PREVNAR 13 (PF) INTRAMUSCULAR SYRINGE 0.5 ML (pneumococcal 13-valent conjugate vaccine (diphtheria CRM)/pf) | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) | |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT (rabies vaccine, purified chicken embryo cell (pcec)/pf) | T3 | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|---|--|---|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML (hepatitis b virus vaccine recombinant/pf) | | T3 | QL (1 ML per 1 fill); AL (Min 19 Years) |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML (hepatitis b virus vaccine recombinant/pf) | | T3 | QL (1 ML per 1 fill); AL (Min 19 Years) |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 50 MCG/0.5 ML (varicella-zoster virus glycoprotein e,rec/as01b adjuvant/pf) | | T3 | QL (1 EA per 1 fill); AL (Min 50 Years) |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML (neisseria meningitidis group b, lipidated fgbp recombinant) | | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| TWINRIX (PF) INTRAMUSCULAR SUSPENSION 720 ELISA UNIT- 20 MCG/ML (hepatitis a virus and hepatitis b virus vaccine/pf) | | T3 | QL (1 ML per 1 fill); AL (Min 19 Years) |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML (hepatitis a virus and hepatitis b virus vaccine/pf) | | T3 | QL (1 ML per 1 fill); AL (Min 19 Years) |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML, 50 UNIT/ML (hepatitis a virus vaccine/pf) | | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML, 50 UNIT/ML (hepatitis a virus vaccine/pf) | | T3 | QL (0.5 ML per 1 fill); AL (Min 19 Years) |
| VIVOTIF ORAL CAPSULE,DELAYED RELEASE(DR/EC) 2 BILLION UNIT (typhoid vacc,live,attenuated) | | T3 | QL (4 EA per 1 Fill); AL (Min 6 Years) |
| ZOSTAVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 19,400 UNIT/0.65 ML (zoster vaccine live/pf) | | T3 | PA ; QL (0.65 EA per 1 fill); AL (Min 19 Years) |
| Autonomic Drugs - Drugs For The Nervous System | | | |
| Alpha- And Beta-Adrenergic Agonists - Drugs For Heart And Lungs | | | |
| APRODINE ORAL TABLET 2.5-60 MG (triprolidine hcl/pseudoephedrine hcl) | T2 | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| cetirizine-pseudoephedrine oral tablet extended release 12 hr 5-120 mg | | T2 | |
| epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml | | T2 | |
| fexofenadine-pseudoephedrine oral tablet extended release 12 hr 60-120 mg | | T2 | ST |
| LORATADINE-D ORAL TABLET EXTENDED RELEASE 12 HR 5-120 MG (loratadine/pseudoephedrine sulfate) | | T2 | |
| loratadine-pseudoephedrine oral tablet extended release 24 hr 10-240 mg | | T2 | |
| SYMJEPI INJECTION SYRINGE 0.15 MG/0.3 ML, 0.3 MG/0.3 ML (epinephrine) | | T3 | |
| WAL-FEX D 24 HOUR ORAL TABLET EXTENDED RELEASE 24 HR 180-240 MG (fexofenadine hcl/pseudoephedrine hcl) | | T2 | ST |
| WAL-PHED ORAL TABLET 4-60 MG (chlorpheniramine maleate/pseudoephedrine hcl) | | T2 | |
| Alpha-Adrenergic Agonists - Drugs For Heart And Lungs | | | |
| clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg | | T2 | |
| clonidine transdermal patch weekly 0.1 mg/24 hr, 0.2 mg/24 hr, 0.3 mg/24 hr | | T2 | ST ; QL (4 Qty per 30 days) |
| methyldopa oral tablet 250 mg, 500 mg | | T2 | |
| methyldopa-hydrochlorothiazide oral tablet 250-15 mg, 250-25 mg | | T2 | |
| midodrine oral tablet 10 mg, 2.5 mg, 5 mg | | T2 | QL (90 Qty per 30 days) |
| phenylephrine hcl/promethazine hcl (Promethazine Vc Oral Syrup 6.25-5 Mg/5 MI) | | T2 | |
| promethazine/phenylephrine hcl/codeine (Promethazine Vc-Codeine Oral Syrup 6.25-5-10 Mg/5 MI) | | T2 | AL (Min 12 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>promethazine-phenyleph-codeine oral syrup 6.25-5-10 mg/5 ml</i> | T2 | AL (Min 12 Years) |
| Antimuscarinics/Antispasmodics - Drugs For Parkinson | | |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION (<i>ipratropium bromide</i>) | T3 | |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION (<i>ipratropium bromide/albuterol sulfate</i>) | T3 | |
| CUVPOSA ORAL SOLUTION 1 MG/5 ML (0.2 MG/ML) (<i>glycopyrrolate</i>) | T3 | QL (20 ML per 1 day) |
| <i>dicyclomine oral capsule 10 mg</i> | T2 | |
| <i>dicyclomine oral tablet 20 mg</i> | T2 | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml</i> | T2 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | T2 | |
| <i>glycopyrrolate oral tablet 1 mg</i> | T2 | QL (120 Qty per 30 days) |
| <i>glycopyrrolate oral tablet 2 mg</i> | T2 | QL (120 Qty per 30 days) |
| <i>hydrocodone-homatropine oral syrup 5-1.5 mg/5 ml</i> | T2 | QL (240 ML per 30 days); AL (Min 6 Years) |
| <i>hyoscyamine sulfate oral drops 0.125 mg/ml</i> | T2 | |
| <i>hyoscyamine sulfate oral elixir 0.125 mg/5 ml</i> | T2 | |
| <i>hyoscyamine sulfate oral tablet 0.125 mg</i> | T2 | |
| <i>hyoscyamine sulfate oral tablet extended release 12 hr 0.375 mg</i> | T2 | |
| <i>hyoscyamine sulfate oral tablet,disintegrating 0.125 mg</i> | T2 | |
| <i>hyoscyamine sulfate sublingual tablet 0.125 mg</i> | T2 | |
| INCRUSE ELLIPTA INHALATION BLISTER WITH DEVICE 62.5 MCG/ACTUATION (<i>umeclidinium bromide</i>) | T3 | QL (30 EA per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | T2 | |
| <i>propantheline oral tablet 15 mg</i> | T2 | |
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION (<i>tiotropium bromide</i>) | T3 | QL (4 GM per 30 days) |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION (<i>tiotropium bromide/olodaterol hcl</i>) | T3 | QL (4 GM per 30 days) |
| Antiparkinsonian Agents - Drugs For Parkinson | | |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | |
| <i>trihexyphenidyl oral elixir 0.4 mg/ml</i> | T2 | |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | T2 | |
| Autonomic Drugs, Miscellaneous - Drugs For The Nervous System | | |
| CHANTIX CONTINUING MONTH BOX ORAL TABLET 1 MG (<i>varenicline tartrate</i>) | T3 | QL (60 EA per 30 days) |
| CHANTIX ORAL TABLET 0.5 MG, 1 MG (<i>varenicline tartrate</i>) | T3 | QL (60 EA per 30 days) |
| CHANTIX STARTING MONTH BOX ORAL TABLETS,DOSE PACK 0.5 MG (11)- 1 MG (42) (<i>varenicline tartrate</i>) | T3 | QL (60 EA per 30 days) |
| NICODERM CQ TRANSDERMAL PATCH 24 HOUR 14 MG/24 HR, 21 MG/24 HR, 7 MG/24 HR (<i>nicotine</i>) | T3 | QL (84 Qty per 365 days) |
| <i>nicotine (polacrilex) buccal gum 2 mg, 4 mg</i> | T2 | QL (360 Qty per 30 days) |
| <i>nicotine (polacrilex) buccal lozenge 2 mg, 4 mg</i> | T2 | QL (360 EA per 30 days) |
| <i>nicotine transdermal patch 24 hour 14 mg/24 hr, 21 mg/24 hr, 7 mg/24 hr</i> | T2 | QL (84 Qty per 365 days) |
| NICOTROL INHALATION CARTRIDGE 10 MG (<i>nicotine</i>) | T3 | QL (504 EA per 30 days) |
| NICOTROL NS NASAL SPRAY,NON-AEROSOL 10 MG/ML (<i>nicotine</i>) | T3 | QL (120 ML per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| Centrally Acting Skeletal Muscle Relaxnt - Drugs For Relaxing Muscles | | |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | T2 | |
| <i>tizanidine oral capsule 2 mg, 4 mg, 6 mg</i> | T2 | QL (120 Qty per 30 days) |
| <i>tizanidine oral tablet 2 mg, 4 mg</i> | T2 | QL (120 Qty per 30 days) |
| Gaba-Derivative Skeletal Muscle Relaxant - Drugs For Relaxing Muscles | | |
| <i>baclofen oral tablet 10 mg, 20 mg</i> | T2 | |
| Non-Sel. Beta-Adrenergic Blocking Agents - Drugs For The Heart | | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | T2 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | T2 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>propranolol oral capsule,extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> | T2 | ST ; QL (30 Qty per 30 days) |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | T2 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | T2 | |
| <i>propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg</i> | T2 | |
| <i>sotalol hcl</i> (Sotalol Af Oral Tablet 120 Mg, 160 Mg, 80 Mg) | T2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | T2 | QL (60 Qty per 30 days) |
| Non-Sel.Alpha-1-Adrenergic Blocking Agts - Drugs For The Heart | | |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | T2 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | T2 | |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | T2 | |
| Non-Sel.Alpha-Adrenergic Blocking Agents - Drugs For The Heart | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>ergotamine tartrate/caffeine</i> (Cafergot Oral Tablet 1-100 Mg) | T3 | |
| ERGOMAR SUBLINGUAL TABLET 2 MG (<i>ergotamine tartrate</i>) | T3 | |
| MIGERGOT RECTAL SUPPOSITORY 2-100 MG (<i>ergotamine tartrate/caffeine</i>) | T2 | |
| Non-Selective Beta-Adrenergic Agonists - Drugs For Heart And Lungs | | |
| ISUPREL INJECTION SOLUTION 0.2 MG/ML (<i>isoproterenol hcl</i>) | T3 | |
| Parasympathomimetic (Cholinergic Agents) - Drugs For Bladder Incontinence | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | T2 | |
| BLOXIVERZ INTRAVENOUS SOLUTION 0.5 MG/ML, 1 MG/ML (<i>neostigmine methylsulfate</i>) | T3 | PA |
| <i>donepezil oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>donepezil oral tablet,disintegrating 10 mg, 5 mg</i> | T2 | |
| <i>galantamine oral capsule,ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i> | T2 | PA |
| <i>galantamine oral solution 4 mg/ml</i> | T2 | PA |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i> | T2 | PA |
| <i>physostigmine salicylate injection solution 1 mg/ml</i> | T2 | PA |
| <i>pyridostigmine bromide oral syrup 60 mg/5 ml</i> | T2 | PA |
| <i>pyridostigmine bromide oral tablet 60 mg</i> | T2 | PA |
| <i>pyridostigmine bromide oral tablet extended release 180 mg</i> | T2 | PA |
| REGONOL INJECTION SOLUTION 5 MG/ML (<i>pyridostigmine bromide</i>) | T3 | PA |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|-----------|----------------------------------|--|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | | Drug Tier | |
| | | NF = Non-Formulary | |
| | | T2 = Formulary Generic Drugs | |
| | | T3 = Formulary Brand Drugs | |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour</i> | T2 | PA | |
| Selective Alpha-1-Adrenergic Block.Agent - Drugs For The Heart | | | |
| <i>alfuzosin oral tablet extended release 24 hr 10 mg</i> | T2 | | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | T2 | | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | T2 | | |
| <i>tamsulosin oral capsule 0.4 mg</i> | T2 | | |
| Selective Beta-2-Adrenergic Agonists - Drugs For Heart And Lungs | | | |
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION (<i>fluticasone propionate/salmeterol xinafoate</i>) | T3 | PA | |
| <i>albuterol hfa 90 mcg inhaler 90 mcg/actuation</i> | T2 | QL (2 INH per 30 days) | |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 5 mg/ml</i> | T2 | | |
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i> | T2 | | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | T2 | | |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE (<i>fluticasone furoate/vilanterol trifénatate</i>) | T3 | PA | |
| <i>budesonide-formoterol inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | T2 | PA | |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION (<i>ipratropium bromide/albuterol sulfate</i>) | T3 | | |
| DULERA INHALATION HFA AEROSOL INHALER 100-5 MCG/ACTUATION, 200-5 MCG/ACTUATION, 50-5 MCG/ACTUATION (<i>mometasone furoate/formoterol fumarate</i>) | T3 | PA ; AL (Max 12 Years) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>fluticasone propion-salmeterol inhalation aerosol powdr breath activated 113-14 mcg/actuation, 232-14 mcg/actuation, 55-14 mcg/actuation</i> | T2 | QL (1 EA per 30 days) |
| <i>fluticasone propion-salmeterol inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | T2 | |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | T2 | |
| <i>levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml</i> | T2 | ST |
| <i>levalbuterol tartrate inhalation hfa aerosol inhaler 45 mcg/actuation</i> | T2 | ST |
| <i>metaproterenol oral syrup 10 mg/5 ml</i> | T2 | |
| <i>metaproterenol oral tablet 10 mg, 20 mg</i> | T2 | |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE (<i>salmeterol xinafoate</i>) | T3 | |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION (<i>tiotropium bromide/olodaterol hcl</i>) | T3 | QL (4 GM per 30 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i> | T2 | |
| <i>fluticasone propionate/salmeterol xinafoate</i> (Wixela Inhub Inhalation Blister With Device 100-50 Mcg/Dose, 250-50 Mcg/Dose, 500-50 Mcg/Dose) | T2 | |
| Selective Beta-Adrenergic Blocking Agent - Drugs For The Heart | | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | T2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | T2 | |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>metoprolol tartrate oral tablet 100 mg, 50 mg</i> | T2 | |
| <i>metoprolol tartrate oral tablet 25 mg</i> | T2 | |
| Skeletal Muscle Relaxants, Miscellaneous - Drugs For Relaxing Muscles | | |
| XEOMIN INTRAMUSCULAR RECON SOLN 100 UNIT, 200 UNIT, 50 UNIT (<i>incobotulinumtoxina</i>) | T3 | PA |
| Blood Formation, Coagulation, Thrombosis - Drugs For The Blood | | |
| Blood Form.,Coag,Thrombosis Agents Misc. - Drugs To Prevent Bleeding | | |
| OXBRYTA ORAL TABLET 500 MG (<i>voxeletor</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Coumarin Derivatives - Drugs To Prevent Blood Clots | | |
| <i>warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | T2 | |
| Direct Factor Xa Inhibitors - Drugs To Prevent Blood Clots | | |
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS) (<i>apixaban</i>) | T3 | QL (74 EA per 30 days) |
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG (<i>apixaban</i>) | T3 | QL (60 EA per 30 days) |
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)- 20 MG (9) (<i>rivaroxaban</i>) | T3 | QL (51 EA per 30 days) |
| XARELTO ORAL TABLET 10 MG, 20 MG (<i>rivaroxaban</i>) | T3 | QL (30 EA per 30 days) |
| XARELTO ORAL TABLET 15 MG, 2.5 MG (<i>rivaroxaban</i>) | T3 | QL (60 EA per 30 days) |
| Direct Thrombin Inhibitors - Drugs To Prevent Blood Clots | | |
| PRADAXA ORAL CAPSULE 110 MG, 150 MG, 75 MG (<i>dabigatran etexilate mesylate</i>) | T3 | QL (60 EA per 30 days) |
| Hematopoietic Agents - Drugs For Anemia | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|-----------|---|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| ARANESP (IN POLYSORBATE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML (<i>darbepoetin alfa in polysorbate 80</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| ARANESP (IN POLYSORBATE) INJECTION SOLUTION 150 MCG/0.75 ML, 300 MCG/ML (<i>darbepoetin alfa in polysorbate 80</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| ARANESP (IN POLYSORBATE) INJECTION SYRINGE 10 MCG/0.4 ML, 100 MCG/0.5 ML, 150 MCG/0.3 ML, 40 MCG/0.4 ML, 500 MCG/ML, 60 MCG/0.3 ML (<i>darbepoetin alfa in polysorbate 80</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| ARANESP (IN POLYSORBATE) INJECTION SYRINGE 200 MCG/0.4 ML, 25 MCG/0.42 ML, 300 MCG/0.6 ML (<i>darbepoetin alfa in polysorbate 80</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| DOPTELET (10 TAB PACK) ORAL TABLET 20 MG (<i>avatrombopag maleate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| EPOGEN INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML (<i>epoetin alfa</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| FULPHILA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML (<i>pegfilgrastim-jmdb</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| LEUKINE INJECTION RECON SOLN 250 MCG (<i>sargramostim</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|------------------|--|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies | |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| MOZOBIL SUBCUTANEOUS SOLUTION 24 MG/1.2 ML (20 MG/ML) (<i>plerixafor</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| MULPLETA ORAL TABLET 3 MG (<i>lusutrombopag</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML (<i>filgrastim-aafi</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| NIVESTYM SUBCUTANEOUS SYRINGE 480 MCG/0.8 ML (<i>filgrastim-aafi</i>) | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| NPLATE SUBCUTANEOUS RECON SOLN 125 MCG (<i>romiplostim</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| NPLATE SUBCUTANEOUS RECON SOLN 250 MCG, 500 MCG (<i>romiplostim</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML (<i>epoetin alfa</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG (<i>eltrombopag olamine</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML (<i>epoetin alfa-epbx</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| UDENYCA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML (<i>pegfilgrastim-cbqv</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ZARXIO INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML (<i>filgrastim-sndz</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Hemorrheologic Agents - Drugs For Blood Flow | | |
| <i>pentoxifylline oral tablet extended release 400 mg</i> | T2 | |
| Hemostatics - Drugs To Prevent Bleeding | | |
| DDAVP NASAL SOLUTION 0.1 MG/ML (REFRIGERATE) (<i>desmopressin acetate</i>) | T3 | |
| <i>desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml)</i> | T2 | |
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg</i> | T2 | |
| <i>tranexamic acid oral tablet 650 mg</i> | T2 | PA ; QL (30 EA per 30 days) |
| Heparins - Drugs To Prevent Blood Clots | | |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 150 mg/ml</i> | T2 | QL (20 ML per 1 fill) |
| <i>enoxaparin subcutaneous syringe 120 mg/0.8 ml, 80 mg/0.8 ml</i> | T2 | QL (16 ML per 1 fill) |
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml</i> | T2 | QL (6 ML per 1 fill) |
| <i>enoxaparin subcutaneous syringe 40 mg/0.4 ml</i> | T2 | QL (8 ML per 1 fill) |
| <i>enoxaparin subcutaneous syringe 60 mg/0.6 ml</i> | T2 | QL (12 ML per 1 fill) |
| <i>heparin (porcine) injection solution 5,000 unit/ml</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | |
|--|--|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| HEPARIN LOCK FLUSH INTRAVENOUS SYRINGE 10 UNIT/ML (<i>heparin sodium,porcine</i>) | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Iron Preparations - Vitamins And Minerals | | |
| CERTA PLUS ORAL TABLET 18-0.4-250 MG-MG-MCG (<i>folic acid/multivit with iron, minerals/lutein</i>) | T2 | |
| <i>ferrous gluconate oral tablet 324 mg (37.5 mg iron)</i> | T2 | |
| INFED INJECTION SOLUTION 50 MG/ML (<i>iron dextran complex</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| MULTI-VIT WITH FLUORIDE-IRON ORAL DROPS 0.25MG FLUORIDE -10 MG IRON/ML (<i>pediatric multivitamin no.45/sodium fluoride/ferrous sulfate</i>) | T2 | AL (Max 5 Years) |
| MYNATAL ORAL CAPSULE 65 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| MYNATAL-Z ORAL TABLET 65 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| O-CAL FA ORAL TABLET 66 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATABS FA ORAL TABLET 29-1 MG (<i>prenatal vits with calcium no.78/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATABS RX ORAL TABLET 29 MG IRON- 1 MG (<i>prenatal vitamin with calcium no.76/iron,carbonyl/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATAL 19 ORAL TABLET,CHEWABLE 29 MG IRON- 1 MG (<i>prenatal vits with calcium no.115/iron fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|-----------|----------------------------------|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| PRENATAL LOW IRON ORAL TABLET 27 MG IRON- 1 MG (<i>prenatal vits with calcium no.74/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| PRENATAL MULTIVITAMINS ORAL TABLET 28 MG IRON- 800 MCG (<i>prenatal vits with calcium 95/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| PRENATAL PLUS ORAL TABLET 29 MG IRON- 1 MG (<i>prenatal vits with calcium no.72/iron,carbonyl/folic acid</i>) | T2 | AL (Max 50 Years) | |
| PRENATAL VITAMIN PLUS LOW IRON ORAL TABLET 27 MG IRON- 1 MG (<i>prenatal vits with calcium no.72/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| PRENATAL VITAMIN WITH MINERALS ORAL TABLET 28 MG IRON- 800 MCG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| SE-NATAL 19 CHEWABLE ORAL TABLET,CHEWABLE 29 MG IRON- 1 MG (<i>prenatal vits with calcium 118/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| TRICARE ORAL TABLET 27 MG IRON- 1 MG (<i>prenatal vits with calcium 103/ferrous fumarate/folic acid</i>) | T3 | AL (Max 50 Years) | |
| TRINATE ORAL TABLET 28 MG IRON- 1 MG (<i>prenatal vits with calcium no.73/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| TRI-VIT WITH FLUORIDE AND IRON ORAL DROPS 0.25-10 MG/ML (<i>fluoride/iron/vitamins a,c, and d</i>) | T2 | AL (Max 5 Years) | |
| TRUST NATAL DHA ORAL COMBO PACK 29-1-250-200 MG (<i>prenatal vitamin no.52/iron/folic acid/omega-3/dha</i>) | T2 | AL (Max 50 Years) | |
| VINATE M ORAL TABLET 27 MG IRON-1 MG (<i>prenatal vits with calcium 136/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| VINATE ONE ORAL TABLET 60 MG IRON-1 MG (<i>prenatal vitamin 27 with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| Platelet-Aggregation Inhibitors - Drugs To Prevent Blood Clots | | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | T2 | QL (60 EA per 30 days); AL (Min 21 Years) |
| BRILINTA ORAL TABLET 60 MG, 90 MG (<i>ticagrelor</i>) | T3 | PA |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>clopidogrel oral tablet 75 mg</i> | T2 | |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | T2 | |
| <i>prasugrel oral tablet 10 mg, 5 mg</i> | T2 | |
| Cardiovascular Drugs - Drugs For The Heart | | |
| Alpha-Adrenergic Blocking Agents - Drugs For High Blood Pressure | | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | T2 | |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | T2 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | T2 | |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | T2 | |
| Alpha-Adrenergic Blocking Agt.(Hypoten) - Drugs For High Blood Pressure & Angina | | |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | T2 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | T2 | |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | T2 | |
| Angiotensin II Receptor Antagon.(Hypotn) - Drugs For High Blood Pressure & Angina | | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | T2 | |
| <i>amlodipine-valsartan-hcthiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | T2 | PA |
| <i>candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | T2 | PA |
| EDARBI ORAL TABLET 40 MG, 80 MG (<i>azilsartan medoxomil</i>) | T3 | PA |
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG (<i>azilsartan medoxomil/chlorthalidone</i>) | T3 | PA |
| <i>eprosartan oral tablet 600 mg</i> | T2 | PA ; QL (30 Qty per 30 days) |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | T2 | |
| <i>olmesartan oral tablet 20 mg, 40 mg, 5 mg</i> | T2 | |
| <i>olmesartan-amlodipin-hcthiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | T2 | PA |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | T2 | |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | T2 | |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | T2 | PA |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | T2 | PA |
| <i>valsartan oral tablet 160 mg, 40 mg, 80 mg</i> | T2 | QL (60 EA per 30 days) |
| <i>valsartan oral tablet 320 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| Angiotensin II Receptor Antagonists - Drugs For The Heart | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|--|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | T2 | |
| <i>amlodipine-valsartan-hcthiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | T2 | PA |
| <i>candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | T2 | PA |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | T2 | PA |
| <i>EDARBI ORAL TABLET 40 MG, 80 MG (<i>azilsartan medoxomil</i>)</i> | T3 | PA |
| <i>EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG (<i>azilsartan medoxomil/chlorthalidone</i>)</i> | T3 | PA |
| <i>ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG (<i>sacubitril/valsartan</i>)</i> | T3 | QL (60 EA per 30 days) |
| <i>eprosartan oral tablet 600 mg</i> | T2 | PA ; QL (30 Qty per 30 days) |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | T2 | |
| <i>olmesartan oral tablet 20 mg, 40 mg, 5 mg</i> | T2 | |
| <i>olmesartan-amiodipin-hcthiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | T2 | PA |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | T2 | |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | T2 | |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|---|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | T2 | PA |
| <i>valsartan oral tablet 160 mg, 40 mg, 80 mg</i> | T2 | QL (60 EA per 30 days) |
| <i>valsartan oral tablet 320 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| Angiotensin-Convert. Enzyme Inhib(Hypotn) - Drugs For High Blood Pressure & Angina | | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | T2 | |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | T2 | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | T2 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | T2 | |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | T2 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | T2 | |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | T2 | |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | T2 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | T2 | |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | T2 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | T2 | |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | T2 | |
| Angiotensin-Converting Enzyme Inhibitors - Drugs For The Heart | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | | T2 | |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | | T2 | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | | T2 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | | T2 | |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | | T2 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | | T2 | |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | | T2 | |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | | T2 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | | T2 | |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | | T2 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | | T2 | |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | | T2 | QL (60 Qty per 30 days) |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | | T2 | |
| Antiarrhythmics, Miscellaneous - Drugs For Angina | | | |
| <i>digoxin oral solution 50 mcg/ml (0.05 mg/ml)</i> | | T3 | |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | | T2 | |
| Antilipemic Agents, Miscellaneous - Drugs For Cholesterol | | | |
| <i>FISH OIL ORAL CAPSULE 340-1,000 MG (<i>omega-3 fatty acids/fish oil</i>)</i> | | T2 | QL (160 Qty per 30 days) |
| <i>icosapent ethyl oral capsule 1 gram</i> | | T2 | PA |
| <i>NEXLETOL ORAL TABLET 180 MG (<i>bempedoic acid</i>)</i> | | T3 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|--|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| NEXLIZET ORAL TABLET 180-10 MG (<i>bempedoic acid/ezetimibe</i>) | T3 | PA |
| <i>niacin oral capsule, extended release 125 mg, 250 mg, 500 mg</i> | T2 | |
| <i>niacin oral tablet 100 mg, 50 mg, 500 mg</i> | T2 | |
| <i>niacin oral tablet 250 mg</i> | T2 | |
| <i>niacin oral tablet extended release 1,000 mg</i> | T2 | |
| <i>niacin oral tablet extended release 250 mg, 500 mg, 750 mg</i> | T2 | |
| <i>omega 3-dha-epa-fish oil oral capsule 1,000 mg (120 mg-180 mg)</i> | T2 | QL (160 Qty per 30 days) |
| <i>omega-3 acid ethyl esters oral capsule 1 gram</i> | T2 | PA |
| VASCEPA ORAL CAPSULE 0.5 GRAM (<i>icosapent ethyl</i>) | T3 | PA |
| Beta-Adrenergic Blocking Agents - Drugs For Abnormal Heart Rhythms | | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | T2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | T2 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | T2 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> | T2 | |
| <i>metoprolol tartrate oral tablet 100 mg, 50 mg</i> | T2 | |
| <i>metoprolol tartrate oral tablet 25 mg</i> | T2 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | T2 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>propranolol oral capsule,extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> | T2 | ST ; QL (30 Qty per 30 days) |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | T2 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | T2 | |
| <i>propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg</i> | T2 | |
| <i>sotalol hcl</i> (Sotalol Af Oral Tablet 120 Mg, 160 Mg, 80 Mg) | T2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | T2 | QL (60 Qty per 30 days) |
| Beta-Adrenergic Blocking Agt.(Hypoten) - Drugs For High Blood Pressure & Angina | | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | T2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | T2 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> | T2 | |
| <i>metoprolol tartrate oral tablet 100 mg, 50 mg</i> | T2 | |
| <i>metoprolol tartrate oral tablet 25 mg</i> | T2 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | T2 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>propranolol oral capsule,extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> | T2 | ST ; QL (30 Qty per 30 days) |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | T2 | |
| <i>propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg</i> | T2 | |
| <i>sotalol hcl</i> (Sotalol Af Oral Tablet 120 Mg, 160 Mg, 80 Mg) | T2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | T2 | QL (60 Qty per 30 days) |
| Bile Acid Sequestrants - Drugs For Cholesterol | | |
| <i>cholestyramine (with sugar) oral powder 4 gram</i> | T2 | |
| <i>cholestyramine/aspartame</i> (Cholestyramine Light Oral Powder 4 Gram) | T2 | |
| COLESTID FLAVORED ORAL PACKET 7.5 GRAM (<i>colestipol hcl</i>) | T3 | |
| Calcium-Channel Block.Agt,Misc(Hypoten) - Drugs For High Blood Pressure & Angina | | |
| <i>diltiazem hcl oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 180 mg, 240 mg, 300 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg</i> | T2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | T2 | |
| <i>diltiazem hcl</i> (Matzim La Oral Tablet Extended Release 24 Hr 300 Mg) | T2 | PA |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 360 mg</i> | T2 | QL (30 Qty per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 240 mg</i> | | T2 | |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | | T2 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral tablet extended release 240 mg</i> | | T2 | |
| Calcium-Channel Blocking Agents - Drugs For High Blood Pressure & Angina | | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> | | T2 | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | | T2 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | | T2 | |
| <i>amlodipine-valsartan-hcthiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | | T2 | PA |
| <i>diltiazem hcl oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 180 mg, 240 mg, 300 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg</i> | | T2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | | T2 | |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | | T2 | |
| <i>diltiazem hcl (Matzim La Oral Tablet Extended Release 24 Hr 300 Mg)</i> | | T2 | PA |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | | T2 | |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | | T2 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg</i> | | T2 | QL (30 EA per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>nifedipine oral tablet extended release 24hr 60 mg</i> | T2 | QL (60 EA per 30 days) |
| <i>nifedipine oral tablet extended release 24hr 90 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>nifedipine oral tablet extended release 30 mg, 90 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>nifedipine oral tablet extended release 60 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>olmesartan-amlodipin-hctiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | T2 | PA |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | T2 | PA |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 360 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 240 mg</i> | T2 | |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | T2 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral tablet extended release 240 mg</i> | T2 | |
| Calcium-Channel Blocking Agents(Hypoten) - Drugs For High Blood Pressure & Angina | | |
| <i>diltiazem hcl oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 180 mg, 240 mg, 300 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg</i> | T2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>diltiazem hcl</i> (Matzim La Oral Tablet Extended Release 24 Hr 300 Mg) | | T2 | PA |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | | T2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 360 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 240 mg</i> | | T2 | |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | | T2 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral tablet extended release 240 mg</i> | | T2 | |
| Calcium-Channel Blocking Agents, Misc. - Drugs For High Blood Pressure & Angina | | | |
| <i>diltiazem hcl oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 180 mg, 240 mg, 300 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg</i> | | T2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | | T2 | |
| <i>diltiazem hcl</i> (Matzim La Oral Tablet Extended Release 24 Hr 300 Mg) | | T2 | PA |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | | T2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 360 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 240 mg</i> | | T2 | |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>verapamil oral tablet extended release 120 mg, 180 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral tablet extended release 240 mg</i> | T2 | |
| Carbonic Anhydrase Inhibitors(Hypoten) - Drugs For High Blood Pressure & Angina | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | T2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | T2 | |
| Cardiac Drugs, Miscellaneous - Drugs For Angina | | |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG (<i>ivabradine hcl</i>) | T3 | PA |
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg, 500 mg</i> | T2 | PA |
| Cardiotonic Agents - Drugs For Angina | | |
| <i>digoxin oral solution 50 mcg/ml (0.05 mg/ml)</i> | T3 | |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | T2 | |
| Central Alpha-Agonists - Drugs For High Blood Pressure & Angina | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | T2 | |
| <i>clonidine transdermal patch weekly 0.1 mg/24 hr, 0.2 mg/24 hr, 0.3 mg/24 hr</i> | T2 | ST ; QL (4 Qty per 30 days) |
| <i>guanfacine oral tablet 1 mg, 2 mg</i> | T2 | |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>methyldopa oral tablet 250 mg, 500 mg</i> | T2 | |
| <i>methyldopa-hydrochlorothiazide oral tablet 250-15 mg, 250-25 mg</i> | T2 | |
| Cholesterol Absorption Inhibitors - Drugs For Cholesterol | | |
| <i>ezetimibe oral tablet 10 mg</i> | T2 | ST |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| NEXLIZET ORAL TABLET 180-10 MG (<i>bempedoic acid/ezetimibe</i>) | | T3 | PA |
| Class Ia Antiarrhythmics - Drugs For Angina | | | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | | T2 | |
| Class Ib Antiarrhythmics - Drugs For Angina | | | |
| <i>phenytoin sodium extended</i> (Dilantin Extended Oral Capsule 100 Mg) | | T3 | |
| <i>phenytoin</i> (Dilantin Infatabs Oral Tablet, Chewable 50 Mg) | | T3 | |
| DILANTIN ORAL CAPSULE 30 MG (<i>phenytoin sodium extended</i>) | | T3 | |
| DILANTIN-125 ORAL SUSPENSION 125 MG/5 ML (<i>phenytoin</i>) | | T3 | |
| <i>mexiletine oral capsule 150 mg, 200 mg, 250 mg</i> | | T2 | |
| <i>phenytoin sodium extended</i> (Phenytek Oral Capsule 200 Mg, 300 Mg) | | T3 | |
| <i>phenytoin sodium intravenous solution 50 mg/ml</i> | | T2 | |
| <i>phenytoin sodium intravenous syringe 50 mg/ml</i> | | T2 | |
| Class Ic Antiarrhythmics - Drugs For Angina | | | |
| <i>flecainide oral tablet 100 mg, 150 mg, 50 mg</i> | | T2 | |
| <i>propafenone oral capsule, extended release 12 hr 225 mg, 325 mg, 425 mg</i> | | T2 | |
| <i>propafenone oral tablet 150 mg, 225 mg, 300 mg</i> | | T2 | |
| Class II Antiarrhythmics - Drugs For Angina | | | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | | T2 | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | | T2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | | T2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | | T2 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | | T2 | |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> | | T2 | |
| <i>metoprolol tartrate oral tablet 100 mg, 50 mg</i> | | T2 | |
| <i>metoprolol tartrate oral tablet 25 mg</i> | | T2 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | | T2 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | | T2 | |
| <i>propranolol oral capsule,extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> | | T2 | ST ; QL (30 Qty per 30 days) |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | | T2 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | | T2 | |
| <i>propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg</i> | | T2 | |
| <i>sotalol hcl</i> (Sotalol Af Oral Tablet 120 Mg, 160 Mg, 80 Mg) | | T2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | | T2 | QL (60 Qty per 30 days) |
| Class III Antiarrhythmics - Drugs For Angina | | | |
| <i>amiodarone oral tablet 200 mg</i> | | T2 | |
| <i>MULTAQ ORAL TABLET 400 MG (dronedarone hcl)</i> | | T3 | PA |
| <i>sotalol hcl</i> (Sotalol Af Oral Tablet 120 Mg, 160 Mg, 80 Mg) | | T2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | | T2 | QL (60 Qty per 30 days) |
| Class IV Antiarrhythmics - Drugs For Angina | | | |
| <i>diltiazem hcl oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 180 mg, 240 mg, 300 mg</i> | | T2 | QL (30 Qty per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg</i> | T2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | T2 | |
| <i>diltiazem hcl</i> (Matzim La Oral Tablet Extended Release 24 Hr 300 Mg) | T2 | PA |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 360 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 240 mg</i> | T2 | |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | T2 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral tablet extended release 240 mg</i> | T2 | |
| Dihydropyridines - Drugs For High Blood Pressure & Angina | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> | T2 | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | T2 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | T2 | |
| <i>amlodipine-valsartan-hcthiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | T2 | PA |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | T2 | |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | T2 | |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | T2 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg</i> | T2 | QL (30 EA per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>nifedipine oral tablet extended release 24hr 60 mg</i> | | T2 | QL (60 EA per 30 days) |
| <i>nifedipine oral tablet extended release 24hr 90 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>nifedipine oral tablet extended release 30 mg, 90 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>nifedipine oral tablet extended release 60 mg</i> | | T2 | QL (60 Qty per 30 days) |
| <i>olmesartan-amlodipin-hcthiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | | T2 | PA |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | | T2 | PA |
| Dihydropyridines (Antihypertensive) - Drugs For High Blood Pressure & Angina | | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> | | T2 | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | | T2 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | | T2 | |
| <i>amlodipine-valsartan-hcthiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | | T2 | PA |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | | T2 | |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | | T2 | |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | | T2 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg</i> | | T2 | QL (30 EA per 30 days) |
| <i>nifedipine oral tablet extended release 24hr 60 mg</i> | | T2 | QL (60 EA per 30 days) |
| <i>nifedipine oral tablet extended release 24hr 90 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>nifedipine oral tablet extended release 30 mg, 90 mg</i> | | T2 | QL (30 Qty per 30 days) |
| <i>nifedipine oral tablet extended release 60 mg</i> | | T2 | QL (60 Qty per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|---|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>olmesartan-amlodipin-hctiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | T2 | PA |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | T2 | PA |
| Direct Vasodilators - Drugs For High Blood Pressure & Angina | | |
| BIDIL ORAL TABLET 20-37.5 MG (<i>isosorbide dinitrate/hydralazine hcl</i>) | T3 | |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | T2 | |
| Diuretics, Miscellaneous (Hypotensive) - Drugs For High Blood Pressure & Angina | | |
| THEO-24 ORAL CAPSULE, EXTENDED RELEASE 24HR 100 MG, 200 MG, 300 MG, 400 MG (<i>theophylline anhydrous</i>) | T3 | |
| THEOCHRON ORAL TABLET EXTENDED RELEASE 12 HR 300 MG (<i>theophylline anhydrous</i>) | T2 | |
| <i>theophylline oral elixir 80 mg/15 ml</i> | T2 | |
| <i>theophylline oral tablet extended release 12 hr 450 mg</i> | T2 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | T2 | |
| Fibric Acid Derivatives - Drugs For Cholesterol | | |
| <i>fenofibrate micronized oral capsule 134 mg, 200 mg, 67 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>fenofibrate nanocrystallized oral tablet 145 mg, 48 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>gemfibrozil oral tablet 600 mg</i> | T2 | |
| Hmg-Coa Reductase Inhibitors - Drugs For Cholesterol | | |
| <i>atorvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | T2 | AL (Min 21 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | T2 | |
| <i>pravastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | T2 | |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | T2 | |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | T2 | |
| <i>simvastatin oral tablet 80 mg</i> | T2 | QL (30 EA per 30 days) |
| Hypotensive Agents, Miscellaneous - Drugs For High Blood Pressure & Angina | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> | T2 | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | T2 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | T2 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | T2 | |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | T2 | |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | T2 | |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | T2 | |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | T2 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>nifedipine oral tablet extended release 24hr 60 mg</i> | T2 | QL (60 EA per 30 days) |
| <i>nifedipine oral tablet extended release 24hr 90 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>nifedipine oral tablet extended release 30 mg, 90 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>nifedipine oral tablet extended release 60 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>propranolol oral capsule,extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> | T2 | ST ; QL (30 Qty per 30 days) |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | T2 | |
| <i>sotalol hcl</i> (Sotalol Af Oral Tablet 120 Mg, 160 Mg, 80 Mg) | T2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | T2 | |
| Loop Diuretics (Hypotensive Agents) - Drugs For High Blood Pressure & Angina | | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | ST |
| <i>furosemide oral solution 10 mg/ml</i> | T2 | PA |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | T2 | |
| <i>torsemide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | T2 | |
| Mineralocorticoid (Aldosterone) Antagnts - Drugs For The Heart | | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | T2 | |
| Mineralocorticoid(Aldoster.)Antag(Hypot) - Drugs For High Blood Pressure & Angina | | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | T2 | |
| Nitrates And Nitrites - Drugs For The Heart | | |
| <i>BIDIL ORAL TABLET 20-37.5 MG (isosorbide dinitrate/hydralazine hcl)</i> | T3 | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i> | T2 | |
| <i>isosorbide dinitrate oral tablet extended release 40 mg</i> | T2 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | T2 | |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i> | T2 | |
| <i>nitroglycerin</i> (Nitro-Bid Transdermal Ointment 2 %) | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>nitroglycerin oral capsule, extended release 2.5 mg, 6.5 mg, 9 mg</i> | T2 | |
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i> | T2 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | T2 | |

Pcsk9 Inhibitors - Drugs For Cholesterol

| | | |
|--|----|---|
| PRALUENT PEN SUBCUTANEOUS PEN INJECTOR 150 MG/ML, 75 MG/ML (<i>alirocumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| REPATHA PUSHTRONEX SUBCUTANEOUS WEARABLE INJECTOR 420 MG/3.5 ML (<i>evolocumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/ML (<i>evolocumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| REPATHA SYRINGE SUBCUTANEOUS SYRINGE 140 MG/ML (<i>evolocumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

Phosphodiesterase Type 5 Inhibitors - Drugs For The Heart

| | | |
|--|----|--|
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>sildenafil (pulm.hypertension) oral suspension for reconstitution 10 mg/ml</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); QL (90 EA per 30 days) |
| <i>tadalafil (pulm. hypertension) oral tablet 20 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

Potassium-Sparing Diuretics (Hypoten) - Drugs For High Blood Pressure & Angina

| | | |
|--|----|--|
| <i>amiloride oral tablet 5 mg</i> | T2 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | T2 | |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | T2 | |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | T2 | |

Renin Inhibitors - Drugs For The Heart

| | | |
|--|----|----|
| <i>aliskiren oral tablet 150 mg, 300 mg</i> | T2 | PA |
| TEKTURN HCT ORAL TABLET 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG (<i>aliskiren hemifumarate/hydrochlorothiazide</i>) | T3 | PA |

Renin-Angioten.-Aldost. Sys. Inhib, Misc - Drugs For The Heart

| | | |
|--|----|------------------------|
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG (<i>sacubitril/valsartan</i>) | T3 | QL (60 EA per 30 days) |
|--|----|------------------------|

Thiazide Diuretics(Hypotensive Agents) - Drugs For High Blood Pressure & Angina

| | | |
|--|----|----|
| <i>amlodipine-valsartan-hcthiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | T2 | PA |
|--|----|----|

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | T2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | T2 | |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | T2 | PA |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | T2 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | T2 | |
| <i>hydrochlorothiazide oral tablet 12.5 mg</i> | T2 | |
| <i>hydrochlorothiazide oral tablet 25 mg, 50 mg</i> | T2 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | T2 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | T2 | |
| <i>methyldopa-hydrochlorothiazide oral tablet 250-15 mg, 250-25 mg</i> | T2 | |
| <i>olmesartan-amldipin-hcthiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | T2 | PA |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | T2 | |
| <i>propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg</i> | T2 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | T2 | |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| TEKTURNA HCT ORAL TABLET 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG (<i>aliskiren hemifumarate/hydrochlorothiazide</i>) | T3 | PA |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | T2 | PA |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | T2 | |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | T2 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>valsartan-hydrochlorothiazide oral tablet 80-12.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| Thiazide-Like Diuretics(Hypotensive Agt) - Drugs For High Blood Pressure & Angina | | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | T2 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | T2 | |
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG (<i>azilsartan medoxomil/chlorthalidone</i>) | T3 | PA |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | T2 | |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | T2 | ST ; QL (30 Qty per 30 days) |
| Vasodilating Agents, Miscellaneous - Drugs For The Heart | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG (<i>riociguat</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | T2 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | T2 | |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | T2 | QL (60 EA per 30 days); AL (Min 21 Years) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>diltiazem hcl oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 180 mg, 240 mg, 300 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg</i> | T2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | T2 | |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | T2 | |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | T2 | |
| <i>diltiazem hcl</i> (Matzim La Oral Tablet Extended Release 24 Hr 300 Mg) | T2 | PA |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | T2 | |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | T2 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>nifedipine oral tablet extended release 24hr 60 mg</i> | T2 | QL (60 EA per 30 days) |
| <i>nifedipine oral tablet extended release 24hr 90 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>nifedipine oral tablet extended release 30 mg, 90 mg</i> | T2 | QL (30 Qty per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|-----------|---|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| <i>nifedipine oral tablet extended release 60 mg</i> | T2 | QL (60 Qty per 30 days) | |
| OPSUMIT ORAL TABLET 10 MG (<i>macitentan</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG (<i>treprostинil diolamine</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | T2 | PA | |
| TRACLEER ORAL TABLET FOR SUSPENSION 32 MG (<i>bosentan</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| <i>treprostинil sodium injection solution 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| TYVASO INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) (<i>treprostинil</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| TYVASO REFILL KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) (<i>treprostинil/nebulizer accessories</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| TYVASO STARTER KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (<i>treprostинil/nebulizer and accessories</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| UPTRAVI ORAL TABLET 1,000 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG (<i>selexipag</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| UPTRAVI ORAL TABLET 1,200 MCG, 1,400 MCG, 1,600 MCG (<i>selexipag</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)-800 MCG (60) (<i>selexipag</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| VENTAVIS INHALATION SOLUTION FOR NEBULIZATION 10 MCG/ML, 20 MCG/ML (<i>iloprost tromethamine</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 360 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 240 mg</i> | T2 | |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | T2 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>verapamil oral tablet extended release 240 mg</i> | T2 | |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG (<i>vericiguat</i>) | T3 | PA |
| Central Nervous System Agents - Drugs For The Nervous System | | |
| Adamantanes (Cns) - Drugs For Parkinson | | |
| <i>amantadine hcl oral capsule 100 mg</i> | T2 | |
| <i>amantadine hcl oral tablet 100 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|---|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| Amphetamine Derivatives - Drugs For The Nervous System | | |
| <i>phentermine oral capsule 15 mg, 30 mg</i> | T2 | PA |
| <i>phentermine oral tablet 37.5 mg</i> | T2 | PA |
| Amphetamines - Drugs For The Nervous System | | |
| <i>dextroamphetamine oral tablet 10 mg, 5 mg</i> | T2 | QL (120 EA per 30 days); AL (Min 3 Years and Max 18 Years) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 10 mg, 5 mg</i> | T2 | QL (60 Qty per 30 days); AL (Min 4 Years and Max 18 Years) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 15 mg</i> | T2 | QL (60 Qty per 30 days); AL (Min 4 Years and Max 18 Years) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 20 mg</i> | T2 | QL (30 Qty per 30 days); AL (Min 4 Years and Max 18 Years) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 25 mg, 30 mg</i> | T2 | QL (30 Qty per 30 days); AL (Min 4 Years and Max 18 Years) |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> | T2 | QL (60 EA per 30 days); AL (Min 3 Years and Max 18 Years) |
| VYVANSE ORAL CAPSULE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, 70 MG (<i>lisdexamfetamine dimesylate</i>) | T3 | PA |
| VYVANSE ORAL TABLET,CHEWABLE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG (<i>lisdexamfetamine dimesylate</i>) | T3 | PA |
| VYVANSE ORAL TABLET,CHEWABLE 60 MG (<i>lisdexamfetamine dimesylate</i>) | T3 | PA ; AL (Max 13 Years) |
| Analgesics And Antipyretics, Misc. - Drugs For Pain | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | T2 | QL (1350 ML per 30 days); AL (Min 12 Years) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg, 300-60 mg</i> | T2 | QL (90 Qty per 30 days); AL (Min 12 Years) |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg</i> | T2 | AL (Min 12 Years) |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> | T2 | |
| <i>oxycodone hcl/acetaminophen</i> (Endocet Oral Tablet 10-325 Mg) | T2 | QL (90 QTY per 30 days) |
| <i>gabapentin oral capsule 100 mg, 300 mg, 400 mg</i> | T2 | |
| <i>gabapentin oral solution 250 mg/5 ml</i> | T2 | |
| <i>gabapentin oral tablet 600 mg, 800 mg</i> | T2 | |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i> | T2 | QL (1350 ML per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | T2 | QL (90 QTY per 30 days) |
| <i>isometh-dichloral-acetaminophn oral capsule 65-100-325 mg</i> | T2 | |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | T2 | QL (90 QTY per 30 days) |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 75 mg</i> | T2 | ST ; QL (60 EA per 30 days) |
| <i>pregabalin oral capsule 50 mg</i> | T2 | ST ; QL (90 EA per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> | T2 | PA |
| <i>pregabalin oral tablet extended release 24 hr 165 mg, 330 mg, 82.5 mg</i> | T2 | PA |
| Anorexigenic Agents, Miscellaneous - Drugs For The Nervous System | | |
| QSYMIA ORAL CAPSULE, ER MULTIPHASE 24 HR 11.25-69 MG, 15-92 MG, 3.75-23 MG, 7.5-46 MG (<i>phentermine hcl/topiramate</i>) | T3 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|-----------|---|--|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| Anticholinergic Agents (Cns) - Drugs For Parkinson | | | |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | | |
| <i>trihexyphenidyl oral elixir 0.4 mg/ml</i> | T2 | | |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | T2 | | |
| Anticonvulsants, Miscellaneous - Drugs For Seizures | | | |
| <i>APTIOM ORAL TABLET 200 MG, 400 MG, 600 MG, 800 MG (eslicarbazepine acetate)</i> | T3 | PA | |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> | T2 | | |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> | T2 | | |
| <i>carbamazepine oral tablet 200 mg</i> | T2 | | |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> | T2 | PA | |
| <i>carbamazepine oral tablet, chewable 100 mg</i> | T2 | | |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> | T2 | | |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> | T2 | | |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> | T2 | | |
| <i>EPIDIOLEX ORAL SOLUTION 100 MG/ML (cannabidiol (cbd))</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| <i>gabapentin oral capsule 100 mg, 300 mg, 400 mg</i> | T2 | | |
| <i>gabapentin oral solution 250 mg/5 ml</i> | T2 | | |
| <i>gabapentin oral tablet 600 mg, 800 mg</i> | T2 | | |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | T2 | | |
| <i>lamotrigine oral tablet extended release 24hr 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | T2 | PA | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>lamotrigine oral tablet, chewable dispersible 25 mg</i> | T2 | |
| <i>lamotrigine oral tablet, chewable dispersible 5 mg</i> | T2 | QL (150 Qty per 30 days) |
| <i>levetiracetam in nacl (iso-os) intravenous piggyback 1,000 mg/100 ml, 1,500 mg/100 ml, 500 mg/100 ml</i> | T2 | |
| <i>levetiracetam intravenous solution 500 mg/5 ml</i> | T2 | |
| <i>levetiracetam oral solution 100 mg/ml</i> | T2 | QL (900 ML per 30 days) |
| <i>levetiracetam oral solution 500 mg/5 ml (5 ml)</i> | T2 | |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i> | T2 | |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i> | T2 | QL (120 Qty per 30 days) |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | T2 | |
| POTIGA ORAL TABLET 200 MG, 300 MG, 400 MG, 50 MG (<i>ezogabine</i>) | T3 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 75 mg</i> | T2 | ST ; QL (60 EA per 30 days) |
| <i>pregabalin oral capsule 50 mg</i> | T2 | ST ; QL (90 EA per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> | T2 | PA |
| <i>pregabalin oral tablet extended release 24 hr 165 mg, 330 mg, 82.5 mg</i> | T2 | PA |
| <i>rufinamide oral suspension 40 mg/ml</i> | T2 | PA |
| <i>rufinamide oral tablet 200 mg, 400 mg</i> | T2 | PA |
| SABRIL ORAL POWDER IN PACKET 500 MG (<i>vigabatrin</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | T2 | PA |
| <i>topiramate oral capsule, sprinkle 15 mg, 25 mg</i> | T2 | PA |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>valproate sodium intravenous solution 500 mg/5 ml (100 mg/ml)</i> | T2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | T2 | |
| <i>valproic acid oral capsule 250 mg</i> | T2 | |
| <i>vigabatrin oral tablet 500 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| VIMPAT ORAL SOLUTION 10 MG/ML (<i>lacosamide</i>) | T3 | PA |
| VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG (<i>lacosamide</i>) | T3 | PA |
| <i>zonisamide oral capsule 100 mg</i> | T2 | QL (180 Qty per 30 days) |
| <i>zonisamide oral capsule 25 mg, 50 mg</i> | T2 | |
| Antidepressants, Miscellaneous - Drugs For Depression & Psychosis | | |
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | T2 | |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | T2 | |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg, 300 mg</i> | T2 | |
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg</i> | T2 | |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg</i> | T2 | |
| <i>mirtazapine oral tablet 7.5 mg</i> | T2 | |
| <i>mirtazapine oral tablet,disintegrating 15 mg, 45 mg</i> | T2 | |
| <i>mirtazapine oral tablet,disintegrating 30 mg</i> | T2 | QL (30 EA per 30 days) |
| SPRAVATO NASAL SPRAY, NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3) (esketamine hcl) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| Antimanic Agents - Drugs For Personality Disorder | | |
| ABILITY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG (<i>aripiprazole</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> | T2 | |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> | T2 | |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> | T2 | |
| <i>carbamazepine oral tablet 200 mg</i> | T2 | |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> | T2 | PA |
| <i>carbamazepine oral tablet, chewable 100 mg</i> | T2 | |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> | T2 | |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> | T2 | |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> | T2 | |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | T2 | |
| <i>lamotrigine oral tablet, chewable dispersible 25 mg</i> | T2 | |
| <i>lamotrigine oral tablet, chewable dispersible 5 mg</i> | T2 | QL (150 Qty per 30 days) |
| <i>lithium carbonate oral capsule 150 mg, 600 mg</i> | T2 | |
| <i>lithium carbonate oral capsule 300 mg</i> | T2 | |
| <i>lithium carbonate oral tablet 300 mg</i> | T2 | |
| <i>lithium carbonate oral tablet extended release 300 mg, 450 mg</i> | T2 | |
| <i>lithium citrate oral solution 8 meq/5 ml</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | T2 | QL (60 Qty per 30 days) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 12.5 MG/2 ML (<i>risperidone microspheres</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 25 MG/2 ML, 37.5 MG/2 ML, 50 MG/2 ML (<i>risperidone microspheres</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>risperidone oral solution 1 mg/ml</i> | T2 | |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>risperidone oral tablet, disintegrating 0.25 mg</i> | T2 | |
| <i>risperidone oral tablet, disintegrating 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | T2 | |
| <i>valproate sodium intravenous solution 500 mg/5 ml (100 mg/ml)</i> | T2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | T2 | |
| <i>valproic acid oral capsule 250 mg</i> | T2 | |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | T2 | QL (60 Qty per 30 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG, 300 MG, 405 MG (<i>olanzapine pamoate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Antimigraine Agents, Miscellaneous - Migraine Treatment | | |
| <i>butalbital-acetaminophen-cafergot oral capsule 50-325-40-30 mg</i> | T2 | AL (Min 12 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> | T2 | |
| <i>ergotamine tartrate/caffeine</i> (Cafergot Oral Tablet 1-100 Mg) | T3 | |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> | T2 | |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> | T2 | |
| <i>divalproex oral tablet,delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> | T2 | |
| ERGOMAR SUBLINGUAL TABLET 2 MG (<i>ergotamine tartrate</i>) | T3 | |
| MIGERGOT RECTAL SUPPOSITORY 2-100 MG (<i>ergotamine tartrate/caffeine</i>) | T2 | |
| <i>propranolol oral capsule,extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> | T2 | ST ; QL (30 Qty per 30 days) |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | T2 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | T2 | |
| <i>valproate sodium intravenous solution 500 mg/5 ml (100 mg/ml)</i> | T2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | T2 | |
| <i>valproic acid oral capsule 250 mg</i> | T2 | |
| Antipsychotics, Miscellaneous - Drugs For Depression & Psychosis | | |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | T2 | |
| ORAP ORAL TABLET 1 MG, 2 MG (<i>pimozide</i>) | T3 | |
| Anxiolytics,Sedatives,And Hypnotics,Misc - Drugs For Anxiety & Sleep Disorder | | |
| <i>buspirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|-----------|--|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| EDLUAR SUBLINGUAL TABLET 10 MG, 5 MG (<i>zolpidem tartrate</i>) | T3 | PA | |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> | T2 | QL (30 EA per 30 days) | |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> | T2 | | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | T2 | | |
| <i>hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg</i> | T2 | | |
| INTERMEZZO SUBLINGUAL TABLET 1.75 MG, 3.5 MG (<i>zolpidem tartrate</i>) | T3 | PA | |
| <i>promethazine hcl</i> (Phenadoz Rectal Suppository 12.5 Mg, 25 Mg) | T2 | | |
| <i>promethazine oral syrup 6.25 mg/5 ml</i> | T2 | | |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | T2 | | |
| <i>promethazine hcl</i> (Promethegan Rectal Suppository 50 Mg) | T2 | | |
| <i>ramelteon oral tablet 8 mg</i> | T2 | PA | |
| SLEEP AID (DOXYLAMINE) ORAL TABLET 25 MG (<i>doxylamine succinate</i>) | T2 | | |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | T2 | QL (30 Qty per 30 days) | |
| <i>zolpidem oral tablet 10 mg, 5 mg</i> | T2 | QL (30 Qty per 30 days) | |
| <i>zolpidem oral tablet,ext release multiphase 12.5 mg, 6.25 mg</i> | T2 | PA | |
| ZOLPIMIST ORAL SPRAY, NON-AEROSOL 5 MG/SPRAY (0.1 ML) (<i>zolpidem tartrate</i>) | T3 | PA | |
| Atypical Antipsychotics - Drugs For Depression & Psychosis | | | |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 300 MG, 400 MG (<i>aripiprazole</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> | T2 | |
| <i>clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | T2 | |
| <i>INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML, 156 MG/ML, 234 MG/1.5 ML, 39 MG/0.25 ML, 78 MG/0.5 ML (<i>paliperidone palmitate</i>)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 12.5 MG/2 ML (<i>risperidone microspheres</i>)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 25 MG/2 ML, 37.5 MG/2 ML, 50 MG/2 ML (<i>risperidone microspheres</i>)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>risperidone oral solution 1 mg/ml</i> | T2 | |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>risperidone oral tablet, disintegrating 0.25 mg</i> | T2 | |
| <i>risperidone oral tablet, disintegrating 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | T2 | |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG, 300 MG, 405 MG (<i>olanzapine pamoate</i>)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|--|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| Barbiturates (Anticonvulsants) - Drugs For Seizures | | |
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | T2 | |
| <i>phenobarbital oral tablet 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg</i> | T2 | |
| <i>phenobarbital oral tablet 15 mg, 30 mg, 60 mg</i> | T2 | |
| <i>primidone oral tablet 250 mg, 50 mg</i> | T2 | |
| Barbiturates (Anxiolytic, Sedative/Hyp) - Drugs For Anxiety & Sleep Disorder | | |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg</i> | T2 | AL (Min 12 Years) |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> | T2 | |
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | T2 | |
| <i>phenobarbital oral tablet 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg</i> | T2 | |
| <i>phenobarbital oral tablet 15 mg, 30 mg, 60 mg</i> | T2 | |
| Benzodiazepines (Anticonvulsants) - Drugs For Seizures | | |
| <i>clonazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | QL (90 EA per 30 days) |
| <i>clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | T2 | QL (90 EA per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg</i> | T2 | QL (90 Qty per 30 days) |
| <i>diazepam oral tablet 5 mg</i> | T2 | QL (90 Qty per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 5-7.5-10 mg</i> | T2 | QL (2 Qty per 365 days) |
| <i>diazepam rectal kit 2.5 mg</i> | T2 | QL (2 Qty per 365 days) |
| <i>lorazepam injection solution 2 mg/ml</i> | T2 | |
| <i>lorazepam (Lorazepam Intensol Oral Concentrate 2 Mg/Ml)</i> | T2 | |
| <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | QL (120 EA per 30 days) |
| Benzodiazepines (Anxiolytic,Sedativ/Hyp) - Drugs For Anxiety & Sleep Disorder | | |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | T2 | QL (120 EA per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>clonazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | QL (90 EA per 30 days) |
| <i>clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | T2 | QL (90 EA per 30 days) |
| <i>diazepam oral tablet 10 mg, 5 mg</i> | T2 | QL (90 Qty per 30 days) |
| <i>diazepam oral tablet 2 mg</i> | T2 | QL (90 Qty per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg</i> | T2 | QL (2 Qty per 365 days) |
| <i>diazepam rectal kit 2.5 mg, 5-7.5-10 mg</i> | T2 | QL (2 Qty per 365 days) |
| <i>flurazepam oral capsule 15 mg, 30 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>lorazepam injection solution 2 mg/ml</i> | T2 | |
| <i>lorazepam</i> (Lorazepam Intensol Oral Concentrate 2 Mg/Ml) | T2 | |
| <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | QL (120 EA per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>temazepam oral capsule 22.5 mg, 7.5 mg</i> | T2 | PA |
| <i>triazolam oral tablet 0.125 mg, 0.25 mg</i> | T2 | QL (30 EA per 30 days) |
| Butyrophenones - Drugs For Depression & Psychosis | | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | T2 | |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | T2 | |
| Calcitonin Gene-Related Peptide Antag. - Migraine Treatment | | |
| <i>AIMOVIG AUTOINJECTOR (2 PACK) SUBCUTANEOUS AUTO-INJECTOR 70 MG/ML (erenumab-aooe)</i> | T3 | PA |
| <i>AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML (erenumab-aooe)</i> | T3 | PA |
| <i>AJOVY AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 225 MG/1.5 ML (fremanezumab-vfrm)</i> | T3 | PA |
| <i>AJOVY SYRINGE SUBCUTANEOUS SYRINGE 225 MG/1.5 ML (fremanezumab-vfrm)</i> | T3 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML (<i>galcanezumab-gnlm</i>) | T3 | PA |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3) (<i>galcanezumab-gnlm</i>) | T3 | PA |
| NURTEC ODT ORAL TABLET,DISINTEGRATING 75 MG (<i>rimegepant sulfate</i>) | T3 | PA |
| UBRELVY ORAL TABLET 100 MG, 50 MG (<i>ubrogepant</i>) | T3 | PA |
| Catechol-O-Methyltransferase(Comt)Inhib. - Drugs For Parkinson | | |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | T2 | ST |
| <i>entacapone oral tablet 200 mg</i> | T2 | ST |
| <i>tolcapone oral tablet 100 mg</i> | T2 | PA |
| Central Nervous System Agents, Misc. - Drugs For Attention Deficit Disorder | | |
| <i>acamprosate oral tablet,delayed release (dr/ec) 333 mg</i> | T2 | |
| <i>atomoxetine oral capsule 10 mg, 100 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>guanfacine oral tablet 1 mg, 2 mg</i> | T2 | |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>memantine oral capsule,sprinkle,er 24hr 14 mg, 21 mg, 28 mg, 7 mg</i> | T2 | ST |
| <i>memantine oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>memantine oral tablets,dose pack 5-10 mg</i> | T2 | |
| NAMENDA XR ORAL CAP,SPRINKLE,ER 24HR DOSE PACK 7-14-21-28 MG (<i>memantine hcl</i>) | T3 | PA |
| NUEDEXTA ORAL CAPSULE 20-10 MG (<i>dextromethorphan hbr/quinidine sulfate</i>) | T3 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 150 MG, 200 MG (<i>viloxazine hcl</i>) | T3 | PA |
| Cyclooxygenase-2 (Cox-2) Inhibitors - Drugs For Pain | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 50 mg</i> | T2 | QL (60 EA per 30 days) |
| <i>celecoxib oral capsule 400 mg</i> | T2 | QL (30 EA per 30 days) |
| Dopamine Precursors - Drugs For Parkinson | | |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | T2 | |
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i> | T2 | |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | T2 | ST |
| Ergot-Deriv. Dopamine Receptor Agonists - Drugs For Parkinson | | |
| <i>bromocriptine oral tablet 2.5 mg</i> | T2 | |
| <i>cabergoline oral tablet 0.5 mg</i> | T2 | AL (Min 21 Years) |
| Fibromyalgia Agents - Drugs For Nerve Pain | | |
| <i>duloxetine oral capsule,delayed release(dr/ec) 20 mg, 30 mg</i> | T2 | QL (60 EA per 30 days) |
| <i>duloxetine oral capsule,delayed release(dr/ec) 60 mg</i> | T2 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 75 mg</i> | T2 | ST ; QL (60 EA per 30 days) |
| <i>pregabalin oral capsule 50 mg</i> | T2 | ST ; QL (90 EA per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> | T2 | PA |
| <i>pregabalin oral tablet extended release 24 hr 165 mg, 330 mg, 82.5 mg</i> | T2 | PA |
| Hydantoins - Drugs For Seizures | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>phenytoin sodium extended</i> (Dilantin Extended Oral Capsule 100 Mg) | T3 | |
| <i>phenytoin</i> (Dilantin Infatabs Oral Tablet, Chewable 50 Mg) | T3 | |
| DILANTIN ORAL CAPSULE 30 MG (<i>phenytoin sodium extended</i>) | T3 | |
| DILANTIN-125 ORAL SUSPENSION 125 MG/5 ML (<i>phenytoin</i>) | T3 | |
| <i>fosphenytoin injection solution 100 mg pe/2 ml, 500 mg pe/10 ml</i> | T2 | |
| <i>phenytoin sodium extended</i> (Phenytek Oral Capsule 200 Mg, 300 Mg) | T3 | |
| <i>phenytoin sodium intravenous syringe 50 mg/ml</i> | T2 | |
| Monoamine Oxidase B Inhibitors - Drugs For Parkinson | | |
| <i>selegiline hcl oral capsule 5 mg</i> | T2 | |
| <i>selegiline hcl oral tablet 5 mg</i> | T2 | |
| Monoamine Oxidase Inhibitors - Drugs For Depression & Psychosis | | |
| <i>phenelzine oral tablet 15 mg</i> | T2 | |
| <i>selegiline hcl oral capsule 5 mg</i> | T2 | |
| <i>selegiline hcl oral tablet 5 mg</i> | T2 | |
| Nonergot-Deriv.Dopamine Receptor Agonist - Drugs For Parkinson | | |
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | T2 | |
| <i>ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | T2 | |
| Opiate Agonists - Drugs For Pain | | |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | T2 | QL (1350 ML per 30 days); AL (Min 12 Years) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg, 300-60 mg</i> | T2 | QL (90 Qty per 30 days); AL (Min 12 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|--|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg</i> | T2 | AL (Min 12 Years) |
| <i>codeine-guaifenesin oral liquid 10-100 mg/5 ml</i> | T2 | QL (480 ML per 30 days); AL (Min 6 Years) |
| <i>oxycodone hcl/acetaminophen</i> (Endocet Oral Tablet 10-325 Mg) | T2 | QL (90 QTY per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | T2 | PA |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i> | T2 | QL (1350 ML per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | T2 | QL (90 QTY per 30 days) |
| <i>hydrocodone-homatropine oral syrup 5-1.5 mg/5 ml</i> | T2 | QL (240 ML per 30 days); AL (Min 6 Years) |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i> | T2 | QL (90 QTY per 30 days) |
| <i>hydromorphone rectal suppository 3 mg</i> | T2 | QL (6 Qty per 30 days) |
| KADIAN ORAL CAPSULE,EXTEND.RELEASE PELLETS 200 MG (<i>morphine sulfate</i>) | T3 | PA |
| <i>methadone oral solution 10 mg/5 ml, 5 mg/5 ml</i> | T2 | PA |
| <i>methadone oral tablet 10 mg, 5 mg</i> | T2 | PA |
| <i>methadone oral tablet,soluble 40 mg</i> | T2 | PA |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i> | T2 | QL (90 ML per 30 days) |
| <i>morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)</i> | T2 | QL (450 ML per 30 days) |
| <i>morphine oral tablet 15 mg, 30 mg</i> | T2 | QL (90 QTY per 30 days) |
| <i>morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg</i> | T2 | PA ; QL (90 Qty per 30 days) |
| <i>oxycodone oral tablet,oral only,ext.rel.12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | T2 | QL (90 QTY per 30 days) |
| <i>oxycodone-aspirin oral tablet 4.8355-325 mg</i> | T2 | QL (120 EA per 30 days) |
| <i>promethazine/phenylephrine hcl/codeine</i> (Promethazine Vc-Codeine Oral Syrup 6.25-5-10 Mg/5 ML) | T2 | AL (Min 12 Years) |
| <i>promethazine-codeine oral syrup 6.25-10 mg/5 ml</i> | T2 | QL (240 ML per 30 days); AL (Min 12 Years) |
| <i>promethazine-phenyleph-codeine oral syrup 6.25-5-10 mg/5 ml</i> | T2 | AL (Min 12 Years) |
| <i>tramadol oral tablet 50 mg</i> | T2 | QL (120 Qty per 30 days); AL (Min 18 Years) |
| Opiate Antagonists - Drugs For Overdose Or Poisoning | | |
| <i>naloxone injection solution 0.4 mg/ml</i> | T3 | |
| <i>naloxone injection syringe 0.4 mg/ml, 1 mg/ml</i> | T3 | |
| <i>naltrexone oral tablet 50 mg</i> | T2 | |
| NARCAN NASAL SPRAY, NON-AEROSOL 4 MG/ACTUATION (<i>naloxone hcl</i>) | T3 | |
| Opiate Partial Agonists - Drugs For Pain | | |
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i> | T2 | PA |
| <i>buprenorphine-naloxone sublingual film 12-3 mg, 2-0.5 mg, 4-1 mg, 8-2 mg</i> | T2 | PA |
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i> | T2 | PA |
| <i>butorphanol nasal spray, non-aerosol 10 mg/ml</i> | T2 | PA |
| ZUBSOLV SUBLINGUAL TABLET 1.4-0.36 MG, 5.7-1.4 MG (<i>buprenorphine hcl/naloxone hcl</i>) | T3 | PA |
| Other Nonsteroidal Anti-Inflam. Agents - Drugs For Pain | | |
| <i>diclofenac epolamine transdermal patch 12 hour 1.3 %</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 25 mg, 50 mg, 75 mg</i> | | T2 | |
| <i>diclofenac sodium topical drops 1.5 %</i> | | T2 | PA |
| <i>diclofenac sodium topical gel 1 %</i> | | T2 | QL (200 GM per 25 days) |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | | T2 | |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | | T2 | |
| <i>ibuprofen oral suspension 100 mg/5 ml</i> | | T2 | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | | T2 | |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | | T2 | |
| <i>ketoprofen oral capsule 25 mg, 50 mg, 75 mg</i> | | T2 | |
| <i>ketorolac oral tablet 10 mg</i> | | T2 | QL (20 EA per 5 days) |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | | T2 | |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | | T2 | |
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | | T2 | |
| <i>PENNSAID TOPICAL SOLUTION IN METERED-DOSE PUMP 20 MG/GRAM /ACTUATION(2 %) (diclofenac sodium)</i> | | T3 | PA |
| <i>piroxicam oral capsule 10 mg, 20 mg</i> | | T2 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | | T2 | |
| Phenothiazines - Drugs For Depression & Psychosis | | | |
| <i>chlorpromazine oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | | T2 | |
| <i>prochlorperazine (Compro Rectal Suppository 25 Mg)</i> | | T2 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | | T2 | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i> | | T2 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | | T2 | |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|-----------|---|--|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg</i> | T2 | | |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | T2 | | |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | T2 | | |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | T2 | | |
| Respiratory And Cns Stimulants - Drugs For The Nervous System | | | |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg</i> | T2 | AL (Min 12 Years) | |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> | T2 | | |
| DAYTRANA TRANSDERMAL PATCH 24 HOUR 10 MG/9 HR, 15 MG/9 HR, 20 MG/9 HR, 30 MG/9 HR <i>(methylphenidate)</i> | T3 | PA | |
| <i>dexmethylphenidate oral tablet 10 mg, 2.5 mg, 5 mg</i> | T2 | QL (60 EA per 30 days); AL (Min 6 Years and Max 18 Years) | |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 10 mg, 20 mg, 30 mg</i> | T2 | AL (Min 6 Years and Max 18 Years) | |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 40 mg, 50 mg, 60 mg</i> | T2 | QL (30 EA per 30 days); AL (Min 6 Years and Max 18 Years) | |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 10 mg, 20 mg, 30 mg, 40 mg, 60 mg</i> | T2 | ST ; QL (30 EA per 30 days); AL (Min 6 Years and Max 18 Years) | |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> | T2 | QL (90 EA per 30 days); AL (Min 6 Years and Max 18 Years) | |
| <i>methylphenidate hcl oral tablet extended release 10 mg</i> | T2 | QL (90 EA per 30 days); AL (Min 6 Years and Max 18 Years) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>methylphenidate hcl oral tablet extended release 20 mg</i> | T2 | QL (90 Qty per 30 days); AL (Min 6 Years and Max 18 Years) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 27 mg, 54 mg</i> | T2 | ST ; QL (30 EA per 30 days); AL (Min 4 Years and Max 18 Years) |
| <i>methylphenidate hcl oral tablet extended release 24hr 36 mg</i> | T2 | ST ; QL (60 EA per 30 days); AL (Min 4 Years and Max 18 Years) |
| Salicylates - Drugs For Pain | | |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | T2 | QL (60 EA per 30 days); AL (Min 21 Years) |
| <i>choline,magnesium salicylate oral liquid 500 mg/5 ml</i> | T2 | |
| <i>oxycodone-aspirin oral tablet 4.8355-325 mg</i> | T2 | QL (120 EA per 30 days) |
| <i>salsalate oral tablet 500 mg, 750 mg</i> | T2 | |
| Sel.Serotonin,Norepi Reuptake Inhibitor - Drugs For Depression & Psychosis | | |
| <i>desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg</i> | T2 | PA |
| <i>duloxetine oral capsule,delayed release(dr/ec) 20 mg, 30 mg</i> | T2 | QL (60 EA per 30 days) |
| <i>duloxetine oral capsule,delayed release(dr/ec) 60 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG (<i>milnacipran hcl</i>)</i> | T3 | ST |
| <i>SAVELLA ORAL TABLETS,DOSE PACK 12.5 MG (5)-25 MG(8)-50 MG(42) (<i>milnacipran hcl</i>)</i> | T3 | ST |
| <i>venlafaxine oral capsule,extended release 24hr 150 mg, 37.5 mg, 75 mg</i> | T2 | |
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | T2 | |
| Selective Serotonin Agonists - Migraine Treatment | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i> | T2 | QL (9 EA per 30 days) |
| REYVOW ORAL TABLET 100 MG, 50 MG (<i>lasmiditan succinate</i>) | T3 | PA |
| <i>rizatriptan oral tablet 10 mg, 5 mg</i> | T2 | QL (12 EA per 30 days) |
| <i>rizatriptan oral tablet,disintegrating 10 mg, 5 mg</i> | T2 | QL (12 EA per 30 days) |
| <i>sumatriptan nasal spray,non-aerosol 20 mg/actuation, 5 mg/actuation</i> | T2 | ST ; QL (6 Qty per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | QL (18 Qty per 30 days) |
| <i>sumatriptan succinate subcutaneous cartridge 4 mg/0.5 ml, 6 mg/0.5 ml</i> | T2 | PA |
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml, 6 mg/0.5 ml</i> | T2 | PA |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i> | T2 | PA |
| <i>sumatriptan succinate subcutaneous syringe 6 mg/0.5 ml</i> | T2 | PA |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> | T2 | ST ; QL (6 EA per 30 days) |
| <i>zolmitriptan oral tablet,disintegrating 2.5 mg, 5 mg</i> | T2 | ST ; QL (6 EA per 30 days) |
| Selective-Serotonin Reuptake Inhibitors - Drugs For Depression & Psychosis | | |
| <i>citalopram oral solution 10 mg/5 ml</i> | T2 | |
| <i>citalopram oral tablet 10 mg, 20 mg</i> | T2 | |
| <i>citalopram oral tablet 40 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> | T2 | |
| <i>fluoxetine oral capsule 10 mg, 20 mg, 40 mg</i> | T2 | |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i> | T2 | |
| <i>fluoxetine oral tablet 10 mg</i> | T2 | |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| PAXIL ORAL SUSPENSION 10 MG/5 ML (<i>paroxetine hcl</i>) | T3 | AL (Max 5 Years) |
| <i>sertraline oral concentrate 20 mg/ml</i> | T2 | |
| <i>sertraline oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| Serotonin Modulators - Drugs For Depression & Psychosis | | |
| <i>trazodone oral tablet 100 mg, 150 mg, 50 mg</i> | T2 | |
| Succinimides - Drugs For Seizures | | |
| <i>ethosuximide oral capsule 250 mg</i> | T2 | |
| <i>ethosuximide oral solution 250 mg/5 ml</i> | T2 | |
| Thioxanthenes - Drugs For Depression & Psychosis | | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | T2 | |
| Tricyclics, Other Norepi-Ru Inhibitors - Drugs For Depression & Psychosis | | |
| <i>amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | T2 | |
| <i>clomipramine oral capsule 25 mg, 50 mg, 75 mg</i> | T2 | |
| <i>desipramine oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | T2 | |
| <i>doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | T2 | |
| <i>doxepin oral concentrate 10 mg/ml</i> | T2 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | T2 | |
| <i>nortriptyline oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> | T2 | |
| <i>nortriptyline oral solution 10 mg/5 ml</i> | T2 | |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg</i> | T2 | |
| Wakefulness-Promoting Agents - Drugs For The Nervous System | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | T2 | PA |
| <i>modafinil oral tablet 100 mg, 200 mg</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| Devices - Medical Supplies And Durable Medical Equipment | | |
| Devices - Medical Supplies And Durable Medical Equipment | | |
| ACCU-CHEK SOFTCLIX LANCETS (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| ADVOCATE LANCET 30 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| ADVOCATE SYRINGES SYRINGE 0.3 ML 30 GAUGE X 5/16" (syringe with needle,insulin,0.3 ml) | T3 | QL (200 QY per 30 DYs) |
| ADVOCATE SYRINGES SYRINGE 0.5 ML 30 GAUGE X 5/16" (syringe with needle,insulin,0.5 ml) | T3 | QL (200 QY per 30 DYs) |
| AEROCHAMBER PLUS FLOW-VU,M MSK SPACER (inhaler,assist device with medium mask) | T3 | QL (2 QY per 365 DYs) |
| AEROCHAMBER PLUS Z STAT LG MSK SPACER (inhaler,assist device with large mask) | T2 | QL (2 QY per 365 DYs) |
| AEROCHAMBER PLUS Z STAT MD MSK SPACER (inhaler,assist device with medium mask) | T2 | QL (2 QY per 365 DYs) |
| AEROCHAMBER PLUS Z STAT SM MSK SPACER (inhaler,assist device with small mask) | T2 | QL (2 QY per 365 DYs) |
| AEROCHAMBER PLUS Z STAT SPACER (inhaler, assist devices) | T2 | QL (2 QY per 365 DYs) |
| AEROCHAMBER Z-STAT PLUS-FLW SG SPACER (inhaler, assist devices) | T2 | QL (2 QY per 365 DYs) |
| AIR TUBE WITH AIR PLUGS (nebulizer accessories) | T3 | QL (1 Qty per 365 days) |
| AIRS ADULT AEROSOL MASK (nebulizer accessories) | T3 | QL (1 Qty per 365 days) |
| AIRS DISPOSABLE NEBULIZER (nebulizer) | T3 | QL (1 Qty per 365 days) |
| ASSURE HAEMOLANCE PLUS 25 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| ASSURE LANCE 28 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| BD AUTOSHIELD DUO PEN NEEDLE NEEDLE 30 GAUGE X 3/16" (pen needle, diabetic disposable, safety) | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| BD INSULIN SYRINGE (HALF UNIT) SYRINGE 0.3 ML 31 GAUGE X 5/16" (syringe with needle,insulin 0.3 ml (half unit mark)) | T3 | QL (200 QY per 30 DYs) |
| BD INSULIN SYRINGE MICRO-FINE SYRINGE 1 ML 28 GAUGE X 1/2" (syringe with needle,disposable,insulin 1 ml) | T3 | QL (200 QY per 30 DYs) |
| BD INSULIN SYRINGE MICRO-FINE SYRINGE 1/2 ML 28 GAUGE X 1/2" (syringe with needle,insulin,0.5 ml) | T3 | QL (200 QY per 30 DYs) |
| BD INSULIN SYRINGE SAFETY-LOK SYRINGE 1 ML 29 GAUGE X 1/2" (syringe with needle,disposable,insulin 1 ml) | T3 | QL (200 QY per 30 DYs) |
| BD INSULIN SYRINGE SYRINGE 1 ML 25 GAUGE X 5/8", 1 ML 25 X 1" (syringe with needle,disposable,insulin 1 ml) | T3 | QL (200 QY per 30 DYs) |
| BD INSULIN SYRINGE ULTRA-FINE SYRINGE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16" (syringe with needle,insulin,0.3 ml) | T3 | QL (200 QY per 30 DYs) |
| BD INSULIN SYRINGE ULTRA-FINE SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16" (syringe with needle,insulin,0.5 ml) | T3 | QL (200 QY per 30 DYs) |
| BD INSULIN SYRINGE ULTRA-FINE SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16" (syringe with needle,disposable,insulin 1 ml) | T3 | QL (200 QY per 30 DYs) |
| BD LO-DOSE MICRO-FINE IV SYRINGE 0.3 ML 28 GAUGE X 1/2" (syringe with needle,insulin,0.3 ml) | T3 | QL (200 QY per 30 DYs) |
| BD LO-DOSE MICRO-FINE IV SYRINGE 1/2 ML 28 GAUGE X 1/2" (syringe with needle,insulin,0.5 ml) | T3 | QL (200 QY per 30 DYs) |
| BD LUER-LOK SYRINGE SYRINGE 3 ML 21 GAUGE X 1 1/2" (syringe with needle,disposable, 3 ml) | T3 | QL (30 Qty per 30 days) |
| BD NANO 2 GEN PEN NDL 32GX4MM 32 GAUGE X 5/32" (pen needle, diabetic) | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|-----------|----------------------------------|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| BD SAFETYGLIDE INSULIN SYRINGE SYRINGE 1 ML 29 GAUGE X 1/2" (<i>syringe with needle, disposable, insulin 1 ml</i>) | T3 | QL (200 QY per 30 DYs) | |
| BD UF MICRO PEN NEEDLE 6MMX32G 32 GAUGE X 1/4" (<i>pen needle, diabetic</i>) | T3 | | |
| BD UF NANO PEN NEEDLE 4MMX32G 32 GAUGE X 5/32" (<i>pen needle, diabetic</i>) | T3 | | |
| BD UF SHORT PEN NEEDLE 8MMX31G 31 GAUGE X 5/16" (<i>pen needle, diabetic</i>) | T3 | | |
| BD ULTRA FINE LANCETS 33 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) | |
| BD ULTRA-FINE II LANCETS 30 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) | |
| BD ULTRA-FINE MINI PEN NEEDLE NEEDLE 31 GAUGE X 3/16" (<i>pen needle, diabetic</i>) | T3 | | |
| BD ULTRA-FINE ORIG PEN NEEDLE NEEDLE 29 GAUGE X 1/2" (<i>pen needle, diabetic</i>) | T3 | | |
| BUBBLES THE FISH PEDI MASK (<i>nebulizer accessories</i>) | T3 | QL (1 Qty per 365 days) | |
| COMP-AIR ELITE COMP NEB SYSTEM DEVICE (<i>nebulizer and compressor</i>) | T3 | QL (1 Qty per 365 days) | |
| COMP-AIR XLT COMPRESSOR NEB DEVICE (<i>nebulizer and compressor</i>) | T3 | QL (1 Qty per 365 days) | |
| DEVILBISS COMPACT COMPRESSOR DEVICE (<i>compressor, for nebulizer</i>) | T3 | QL (1 Qty per 365 days) | |
| DEVILBISS PULMO-AIDE COMPRESSR DEVICE (<i>compressor, for nebulizer</i>) | T3 | QL (1 Qty per 365 days) | |
| DEVILBISS TRAVELER COMPRESSOR DEVICE (<i>nebulizer and compressor</i>) | T3 | QL (1 Qty per 365 days) | |
| EASY COMFORT LANCETS 30 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) | |
| EASY TOUCH INSULIN SYRINGE SYRINGE 0.3 ML 31 GAUGE X 5/16" (<i>syringe with needle, insulin, 0.3 ml</i>) | T3 | QL (200 QY per 30 DYs) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies | |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| EASY TOUCH INSULIN SYRINGE SYRINGE 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" (syringe with needle,insulin,0.5 ml) | T3 | QL (200 QY per 30 DYs) | |
| EASY TOUCH INSULIN SYRINGE SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16" (syringe with needle,disposable,insulin 1 ml) | T3 | QL (200 QY per 30 DYs) | |
| EASY TOUCH TWIST LANCETS 30 GAUGE (lancets) | T3 | QL (200 QY per 30 DYs) | |
| EUFLEXXA INTRA-ARTICULAR SYRINGE 10 MG/ML(MW 2.4 -3.6 MILLION) (hyaluronate sodium) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| FEMCAP VAGINAL DEVICE 22 MM, 26 MM, 30 MM (cervical cap) | T3 | | |
| FINGERSTIX LANCETS (lancets) | T3 | QL (200 Qty per 30 days) | |
| FORACARE LANCETS 30 GAUGE (lancets) | T3 | QL (200 QY per 30 DYs) | |
| FREESTYLE FREEDOM LITE KIT (blood-glucose meter) | T3 | | |
| FREESTYLE INSULINX (blood-glucose meter) | T3 | | |
| FREESTYLE LANCETS 28 GAUGE (lancets) | T3 | QL (200 QY per 30 DYs) | |
| FREESTYLE LITE METER KIT (blood-glucose meter) | T3 | | |
| HEPARIN LOCK FLUSH INTRAVENOUS SYRINGE 10 UNIT/ML (heparin sodium,porcine) | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| INJECT EASE LANCETS 30 GAUGE (lancets) | T3 | QL (200 QY per 30 DYs) | |
| INNOSPIRE ELEGANCE DEVICE (nebulizer and compressor) | T3 | QL (1 Qty per 365 days) | |
| INNOSPIRE ESSENCE DEVICE (nebulizer and compressor) | T3 | QL (1 Qty per 365 days) | |
| INSULIN SYRINGE MICROFINE SYRINGE 1/2 ML 28 GAUGE X 1/2" (syringe with needle,insulin,0.5 ml) | T3 | QL (200 QY per 30 DYs) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| INSULIN SYRINGE SYRINGE 0.5 ML 29 GAUGE X 1/2" <i>(syringe with needle,insulin,0.5 ml)</i> | T3 | QL (200 QY per 30 DYs) |
| INSULIN SYRINGE ULTRAFINE SYRINGE 0.5 ML 29 GAUGE X 1/2" <i>(syringe with needle,insulin,0.5 ml)</i> | T3 | QL (200 QY per 30 DYs) |
| <i>insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 0.3 ml 29 gauge x 1/2", 0.3 ml 30, 0.3 ml 30 gauge x 5/16", 0.3 ml 31 gauge x 5/16", 0.5 ml 30 gauge x 1/2", 0.5 ml 30 gauge x 5/16", 0.5 ml 31 gauge x 5/16", 1 ml 28 gauge x 1/2", 1 ml 29 gauge x 1/2", 1 ml 29 gauge x 7/16", 1 ml 30 gauge x 5/16, 1 ml 30 gauge x 7/16", 1 ml 31 gauge x 5/16, 1/2 ml 29 , 1/2 ml 30 gauge</i> | T3 | QL (200 QY per 30 DYs) |
| <i>insulin syringe-needle u-100 syringe 1/2 ml 28 gauge x 1/2"</i> | T3 | QL (200 Qty per 30 days) |
| <i>insulin syringes (disposable) syringe 1 ml lancets 30 gauge, 33 gauge</i> | T3 | QL (200 Qty per 30 days) |
| LANCETS,THIN 23 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| LANCETS,ULTRA THIN 26 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| LC PLUS (<i>nebulizer</i>) | T3 | QL (1 Qty per 365 days) |
| LITE TOUCH LANCETS 30 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| MICROLET LANCET (<i>lancets</i>) | T3 | QL (200 Qty per 30 days) |
| MONOJECT INSULIN SYRINGE SYRINGE 0.5 ML 29 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" <i>(syringe with needle,insulin,0.5 ml)</i> | T3 | QL (200 QY per 30 DYs) |
| MONOJECT INSULIN SYRINGE SYRINGE 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" <i>(syringe with needle,disposable,insulin 1 ml)</i> | T3 | QL (200 QY per 30 DYs) |
| ONETOUCH DELICA LANCETS 30 GAUGE, 33 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| ONETOUCH ULTRASOFT LANCETS (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| PEAK AIR PEAK FLOW METER DEVICE (<i>peak flow meter</i>) | T3 | QL (1 Qty per 365 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| PERSONAL BEST FULL RANGE DEVICE (<i>peak flow meter</i>) | | T3 | QL (1 Qty per 365 days) |
| POCKET PEAK FLOW METER DEVICE (<i>peak flow meter</i>) | | T3 | QL (1 Qty per 365 days) |
| PRECISION XTRA MONITOR (<i>blood-glucose meter</i>) | | T3 | |
| PRODIGY TWIST TOP LANCET 28 GAUGE (<i>lancets</i>) | | T3 | QL (200 QY per 30 DYs) |
| PRONEB ULTRA II DEVICE (<i>nebulizer and compressor</i>) | | T3 | QL (1 Qty per 365 days) |
| PULMO-AIDE COMPRESSOR DEVICE (<i>compressor, for nebulizer</i>) | | T3 | QL (1 Qty per 365 days) |
| REUSABLE NEBULIZER KIT KIT (<i>nebulizer accessories</i>) | | T3 | QL (1 Qty per 365 days) |
| SAFETY SEAL LANCETS 28 GAUGE, 30 GAUGE (<i>lancets</i>) | | T3 | QL (200 QY per 30 DYs) |
| SAFETY-LET LANCETS 30 GAUGE (<i>lancets</i>) | | T3 | QL (200 QY per 30 DYs) |
| SAMI THE SEAL DEVICE (<i>nebulizer and compressor</i>) | | T3 | QL (1 Qty per 365 days) |
| <i>sodium chloride inhalation solution for nebulization 0.9 %</i> | | T2 | |
| SOFT TOUCH LANCETS (<i>lancets</i>) | | T3 | QL (200 QY per 30 DYs) |
| SUNRISE COMPRESSOR-NEBULIZER DEVICE (<i>compressor, for nebulizer</i>) | | T3 | QL (1 Qty per 365 days) |
| TECHLITE LANCETS 28 GAUGE (<i>lancets</i>) | | T3 | QL (200 QY per 30 DYs) |
| THINPRO INSULIN SYRINGE SYRINGE 0.3 ML 31 X 3/8" (<i>syringe with needle,insulin,0.3 ml</i>) | | T3 | QL (200 QY per 30 DYs) |
| TRUEPLUS INSULIN SYRINGE 0.5 ML 31 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" (<i>syringe with needle,insulin,0.5 ml</i>) | | T3 | QL (200 QY per 30 DYs) |
| TRUEPLUS INSULIN SYRINGE 1 ML 31 GAUGE X 5/16 (<i>syringe with needle,disposable,insulin 1 ml</i>) | | T3 | QL (200 QY per 30 DYs) |
| ULTICARE SYRINGE 0.5 ML 30 GAUGE X 1/2" (<i>syringe with needle,insulin,0.5 ml</i>) | | T3 | QL (200 QY per 30 DYs) |
| ULTICARE SYRINGE 1 ML 30 GAUGE X 1/2" (<i>syringe with needle,disposable,insulin 1 ml</i>) | | T3 | QL (200 QY per 30 DYs) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| ULTILET CLASSIC LANCETS 28 GAUGE, 30 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| ULTILET LANCETS 28 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| ULTRA CMFT INS SYR (HALF UNIT) SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16" (syringe with needle,insulin 0.3 ml (half unit mark)) | T3 | QL (200 QY per 30 DYs) |
| ULTRA COMFORT INSULIN SYRINGE SYRINGE 0.3 ML 30 GAUGE X 5/16" (syringe with needle,insulin,0.3 ml) | T3 | QL (200 QY per 30 DYs) |
| ULTRA COMFORT INSULIN SYRINGE SYRINGE 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1/2 ML 28 GAUGE (syringe with needle,insulin,0.5 ml) | T3 | QL (200 QY per 30 DYs) |
| ULTRA COMFORT INSULIN SYRINGE SYRINGE 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16 (syringe with needle,disposable,insulin 1 ml) | T3 | QL (200 QY per 30 DYs) |
| ULTRA COMFORT INSULIN SYRINGE SYRINGE 1/2 ML 28 GAUGE X 1/2" (syringe with needle,insulin,0.5 ml) | T3 | QL (200 Qty per 30 days) |
| ULTRA THIN LANCETS 28 GAUGE, 33 GAUGE (<i>lancets</i>) | T3 | QL (200 QY per 30 DYs) |
| VIOS AEROSOL DELIVERY SYSTEM DEVICE (nebulizer and compressor) | T3 | QL (1 Qty per 365 days) |
| VORTEX HOLDING CHAMBER CHILD SPACER (<i>inhaler,assist device with medium mask</i>) | T2 | QL (2 QY per 365 DYs) |
| VORTEX HOLDING CHAMBER SPACER (inhaler, assist devices) | T2 | QL (2 QY per 365 DYs) |
| VORTEX HOLDING CHAMBER TODDLER SPACER (<i>inhaler,assist device with small mask</i>) | T2 | QL (2 QY per 365 DYs) |
| VORTEX VHC FROG MASK-CHILD SPACER (<i>inhaler,assist device with medium mask</i>) | T2 | QL (2 QY per 365 DYs) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|--|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| VORTEX VHC LADYBUG MASK-TODDLR SPACER <i>(inhaler, assist device with small mask)</i> | T2 | QL (2 QY per 365 DYs) |
| WING TIP TUBING <i>(nebulizer accessories)</i> | T3 | QL (1 Qty per 365 days) |
| Diagnostic Agents | | |
| Adrenocortical Insufficiency | | |
| ACTHAR H.P. INJECTION GEL 80 UNIT/ML <i>(corticotropin)</i> | T3 | PA |
| ACTHAR INJECTION GEL 80 UNIT/ML <i>(corticotropin)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Diabetes Mellitus | | |
| FREESTYLE INSULINX STRIP <i>(blood sugar diagnostic)</i> | T3 | |
| FREESTYLE INSULINX TEST STRIPS STRIP <i>(blood sugar diagnostic)</i> | T3 | |
| FREESTYLE LITE STRIPS STRIP <i>(blood sugar diagnostic)</i> | T3 | |
| FREESTYLE TEST STRIP <i>(blood sugar diagnostic)</i> | T3 | |
| PRECISION XTRA TEST STRIP <i>(blood sugar diagnostic)</i> | T3 | |
| Ketones | | |
| KETONE URINE TEST STRIP <i>(urine acetone test, strips)</i> | T3 | QL (100 Qty per 30 days) |
| Myasthenia Gravis | | |
| BLOXIVERZ INTRAVENOUS SOLUTION 0.5 MG/ML, 1 MG/ML <i>(neostigmine methylsulfate)</i> | T3 | PA |
| ENLON INJECTION SOLUTION 10 MG/ML <i>(edrophonium chloride)</i> | T2 | PA |
| Sugar | | |
| DIASTIX STRIP <i>(urine glucose test strip)</i> | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| Electrolytic, Caloric, And Water Balance | | |
| Acidifying Agents | | |
| K-PHOS ORIGINAL ORAL TABLET,SOLUBLE 500 MG (<i>potassium phosphate,monobasic</i>) | T3 | |
| Alkalizing Agents | | |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg)</i> | T2 | QL (180 EA per 30 days) |
| <i>potassium citrate oral tablet extended release 5 meq (540 mg)</i> | T2 | QL (60 Qty per 30 days) |
| Ammonia Detoxicants | | |
| <i>lactulose</i> (Generlac Oral Solution 10 Gram/15 MI) | Tier 1 | |
| <i>lactulose oral solution 10 gram/15 ml</i> | T2 | |
| <i>lactulose oral solution 10 gram/15 ml (15 ml), 20 gram/30 ml</i> | T2 | |
| Carbonic Anhydrase Inhibitors - Drugs For Water Balance | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | T2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | T2 | |
| Diuretics, Miscellaneous - Drugs For Water Balance | | |
| THEO-24 ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 200 MG, 300 MG, 400 MG (<i>theophylline anhydrous</i>) | T3 | |
| THEOCHRON ORAL TABLET EXTENDED RELEASE 12 HR 300 MG (<i>theophylline anhydrous</i>) | T2 | |
| <i>theophylline oral elixir 80 mg/15 ml</i> | T2 | |
| <i>theophylline oral tablet extended release 12 hr 450 mg</i> | T2 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | T2 | |
| <i>theophylline oral tablet extended release 600 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| Irrigating Solutions | | |
| <i>sodium chloride irrigation solution 0.9 %</i> | T2 | SP (Quantity limit of 20,000 ml per 30 days) |
| Loop Diuretics - Drugs For Water Balance | | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | ST |
| <i>furosemide oral solution 10 mg/ml</i> | T2 | PA |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | T2 | |
| Phosphate-Removing Agents | | |
| <i>AURYXIA ORAL TABLET 210 MG IRON (ferric citrate)</i> | T3 | PA |
| <i>calcium acetate(phosphat bind) oral capsule 667 mg</i> | T2 | |
| <i>calcium acetate(phosphat bind) oral tablet 667 mg</i> | T2 | |
| <i>FOSRENOL ORAL POWDER IN PACKET 1,000 MG, 750 MG (lanthanum carbonate)</i> | T3 | PA |
| <i>lanthanum oral tablet, chewable 1,000 mg, 500 mg, 750 mg</i> | T2 | PA |
| <i>sevelamer carbonate oral powder in packet 0.8 gram, 2.4 gram</i> | T2 | PA |
| <i>sevelamer carbonate oral tablet 800 mg</i> | T2 | ST |
| <i>sevelamer hcl oral tablet 400 mg, 800 mg</i> | T2 | PA |
| <i>VELPHORO ORAL TABLET,CHEWABLE 500 MG (sucroferric oxyhydroxide)</i> | T3 | PA |
| Potassium-Removing Agents | | |
| <i>LOKELMA ORAL POWDER IN PACKET 10 GRAM, 5 GRAM (sodium zirconium cyclosilicate)</i> | T3 | QL (34 EA per 30 days) |
| <i>SODIUM POLYSTYRENE (SORB FREE) ORAL SUSPENSION 15 GRAM/60 ML (sodium polystyrene sulfonate)</i> | T2 | |
| <i>sodium polystyrene sulfonate oral powder</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| VELTASSA ORAL POWDER IN PACKET 16.8 GRAM, 25.2 GRAM, 8.4 GRAM (<i>patiromer calcium sorbitex</i>) | T3 | ST ; QL (30 EA per 30 days) |
| Potassium-Sparing Diuretics - Drugs For Water Balance | | |
| <i>amiloride oral tablet 5 mg</i> | T2 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | T2 | |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | T2 | |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | T2 | |
| Replacement Preparations | | |
| <i>potassium chloride</i> (Klor-Con Oral Packet 20 Meq) | T2 | |
| KLOR-CON/25 ORAL PACKET 25 MEQ (<i>potassium chloride</i>) | T2 | |
| MYNATAL ORAL CAPSULE 65 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| MYNATAL-Z ORAL TABLET 65 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| O-CAL FA ORAL TABLET 66 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i> | T2 | |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i> | T2 | |
| <i>potassium chloride oral tablet extended release 10 meq, 20 meq, 8 meq</i> | T2 | |
| <i>potassium chloride oral tablet,er particles/crystals 10 meq, 20 meq</i> | T2 | |
| PRENATABS FA ORAL TABLET 29-1 MG (<i>prenatal vits with calcium no.78/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| PRENATABS RX ORAL TABLET 29 MG IRON- 1 MG <i>(prenatal vitamin with calcium no.76/iron,carbonyl/folic acid)</i> | | T2 | AL (Max 50 Years) |
| PRENATAL LOW IRON ORAL TABLET 27 MG IRON- 1 MG <i>(prenatal vits with calcium no.74/ferrous fumarate/folic acid)</i> | | T2 | AL (Max 50 Years) |
| PRENATAL PLUS ORAL TABLET 29 MG IRON- 1 MG <i>(prenatal vits with calcium no.72/iron,carbonyl/folic acid)</i> | | T2 | AL (Max 50 Years) |
| PRENATAL VITAMIN PLUS LOW IRON ORAL TABLET 27 MG IRON- 1 MG <i>(prenatal vits with calcium no.72/ferrous fumarate/folic acid)</i> | | T2 | AL (Max 50 Years) |
| PRENATAL VITAMIN WITH MINERALS ORAL TABLET 28 MG IRON- 800 MCG <i>(prenatal vitamins with calcium/ferrous fumarate/folic acid)</i> | | T2 | AL (Max 50 Years) |
| sodium chloride inhalation solution for nebulization 0.9 % | | T2 | |
| TRINATE ORAL TABLET 28 MG IRON- 1 MG <i>(prenatal vits with calcium no.73/ferrous fumarate/folic acid)</i> | | T2 | AL (Max 50 Years) |
| TRUST NATAL DHA ORAL COMBO PACK 29-1-250-200 MG <i>(prenatal vitamin no.52/iron/folic acid/omega-3/dha)</i> | | T2 | AL (Max 50 Years) |
| VINATE ONE ORAL TABLET 60 MG IRON-1 MG <i>(prenatal vitamin 27 with calcium/ferrous fumarate/folic acid)</i> | | T2 | AL (Max 50 Years) |
| Thiazide Diuretics - Drugs For Water Balance | | | |
| <i>amlodipine-valsartan-hctiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | | T2 | PA |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | | T2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | T2 | PA |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | T2 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | T2 | |
| <i>hydrochlorothiazide oral tablet 12.5 mg</i> | T2 | |
| <i>hydrochlorothiazide oral tablet 25 mg, 50 mg</i> | T2 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | T2 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | T2 | |
| <i>methyldopa-hydrochlorothiazide oral tablet 250-15 mg, 250-25 mg</i> | T2 | |
| <i>olmesartan-amldipin-hcthiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | T2 | PA |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | T2 | |
| <i>propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg</i> | T2 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | T2 | |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | T2 | |
| <i>TEKTURNA HCT ORAL TABLET 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG (aliskiren hemifumarate/hydrochlorothiazide)</i> | T3 | PA |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | |
|---|--|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | T2 | |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | T2 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | T2 | QL (30 Qty per 30 days) |
| Thiazide-Like Diuretics - Drugs For Water Balance | | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | T2 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | T2 | |
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG (azilsartan medoxomil/chlorthalidone) | T3 | PA |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | T2 | |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | T2 | ST ; QL (30 Qty per 30 days) |
| Uricosuric Agents | | |
| <i>probencid oral tablet 500 mg</i> | T2 | |
| <i>probencid-colchicine oral tablet 500-0.5 mg</i> | T2 | |
| Enzymes | | |
| Enzymes | | |
| ALDURAZYME INTRAVENOUS SOLUTION 2.9 MG/5 ML (<i>laronidase</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| PULMOZYME INHALATION SOLUTION 1 MG/ML (<i>dornase alfa</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Eye, Ear, Nose And Throat (Eent) Preps. | | |
| Alpha-Adrenergic Agonists (Eent) - Drugs For The Eye | | |
| <i>brimonidine ophthalmic (eye) drops 0.2 %</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| Antiallergic Agents - Drugs For Allergy | | |
| ALAWAY OPHTHALMIC (EYE) DROPS 0.025 % (0.035 %) <i>(ketotifen fumarate)</i> | T2 | QL (10 ML per 30 days) |
| <i>azelastine nasal aerosol,spray 137 mcg (0.1 %)</i> | T2 | |
| <i>azelastine ophthalmic (eye) drops 0.05 %</i> | T2 | |
| <i>bepotastine besilate ophthalmic (eye) drops 1.5 %</i> | T2 | PA |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | T2 | |
| EMADINE OPHTHALMIC (EYE) DROPS 0.05 % <i>(emedastine difumarate)</i> | T3 | PA |
| <i>epinastine ophthalmic (eye) drops 0.05 %</i> | T2 | ST ; QL (5 ML per 30 days) |
| LASTACRAFT OPHTHALMIC (EYE) DROPS 0.25 % <i>(alcaftadine)</i> | T3 | PA |
| <i>olopatadine ophthalmic (eye) drops 0.1 %</i> | T2 | ST ; QL (5 ML per 30 days) |
| <i>olopatadine ophthalmic (eye) drops 0.2 %</i> | T2 | ST ; QL (2.5 ML per 30 days) |
| Antibacterials (Eent) - Drugs For Infections | | |
| AZASITE OPHTHALMIC (EYE) DROPS 1 % <i>(azithromycin)</i> | T3 | PA |
| <i>bacitracin ophthalmic (eye) ointment 500 unit/gram</i> | T2 | |
| <i>sulfacetamide sodium</i> (Bleph-10 Ophthalmic (Eye) Drops 10 %) | T2 | |
| CILOXAN OPHTHALMIC (EYE) OINTMENT 0.3 % <i>(ciprofloxacin hcl)</i> | T3 | ST |
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i> | Tier 1 | QL (2 fills per 365 days) |
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i> | T2 | QL (2 fills per 365 days) |
| <i>gatifloxacin ophthalmic (eye) drops 0.5 %</i> | T2 | PA |
| <i>gentamicin sulfate</i> (Gentak Ophthalmic (Eye) Ointment 0.3 % (3 Mg/Gram)) | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i> | T2 | QL (2 fills per 365 days) |
| <i>moxifloxacin ophthalmic (eye) drops, viscous 0.5 %</i> | T2 | PA |
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | T2 | |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | T2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> | T2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> | T2 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i> | T2 | |
| <i>neomycin-polymyxin-hc otic (ear) drops,suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | T2 | |
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i> | T2 | |
| <i>ofloxacin ophthalmic (eye) drops 0.3 %</i> | T2 | QL (2 fills per 365 days) |
| <i>ofloxacin otic (ear) drops 0.3 %</i> | T2 | |
| <i>bacitracin/polymyxin b sulfate (Polycin Ophthalmic (Eye) Ointment 500-10,000 Unit/Gram)</i> | T2 | |
| <i>polymyxin b sulf-trimethoprim ophthalmic (eye) drops 10,000 unit- 1 mg/ml</i> | T2 | |
| <i>sulfacetamide sodium ophthalmic (eye) ointment 10 %</i> | T2 | |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %)</i> | T2 | |
| <i>TOBRADEX OPHTHALMIC (EYE) OINTMENT 0.3-0.1 % (tobramycin/dexamethasone)</i> | T3 | QL (2 fills per 365 days) |
| <i>tobramycin ophthalmic (eye) drops 0.3 %</i> | T2 | QL (2 fills per 365 days) |
| Antivirals (Ent) - Drugs For Infections | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|---|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>trifluridine ophthalmic (eye) drops 1 %</i> | T2 | |
| Beta-Adrenergic Blocking Agents (Eent) - Drugs For The Eye | | |
| <i>dorzolamide-timolol ophthalmic (eye) drops 22.3-6.8 mg/ml</i> | T2 | |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | T2 | |
| <i>metipranolol ophthalmic (eye) drops 0.3 %</i> | T2 | |
| <i>timolol maleate ophthalmic (eye) drops 0.25 %, 0.5 %</i> | T2 | |
| Carbonic Anhydrase Inhibitors (Eent) - Drugs For The Eye | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | T2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | T2 | |
| <i>dorzolamide ophthalmic (eye) drops 2 %</i> | T2 | |
| <i>dorzolamide-timolol ophthalmic (eye) drops 22.3-6.8 mg/ml</i> | T2 | |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | T2 | |
| Corticosteroids (Eent) - Drugs For Inflammation | | |
| <i>dexamethasone sodium phosphate ophthalmic (eye) drops 0.1 %</i> | T2 | |
| <i>DUREZOL OPHTHALMIC (EYE) DROPS 0.05 % (difluprednate)</i> | T3 | PA ; QL (5 ML per 30 days) |
| <i>flunisolide nasal spray,non-aerosol 25 mcg (0.025 %)</i> | T2 | ST |
| <i>fluorometholone ophthalmic (eye) drops,suspension 0.1 %</i> | T2 | |
| <i>fluticasone propionate nasal spray,suspension 50 mcg/actuation</i> | T2 | |
| <i>hydrocortisone-acetic acid otic (ear) drops 1-2 %</i> | T2 | |
| <i>MAXIDEX OPHTHALMIC (EYE) DROPS,SUSPENSION 0.1 % (dexamethasone)</i> | T3 | |
| <i>mometasone nasal spray,non-aerosol 50 mcg/actuation</i> | T2 | ST ; QL (17 GM per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | T2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> | T2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> | T2 | |
| PRED MILD OPHTHALMIC (EYE) DROPS,SUSPENSION 0.12 % (<i>prednisolone acetate</i>) | T3 | |
| <i>prednisolone acetate ophthalmic (eye) drops,suspension 1 %</i> | T2 | |
| <i>prednisolone sodium phosphate ophthalmic (eye) drops 1 %</i> | T2 | |
| TOBRADEX OPHTHALMIC (EYE) OINTMENT 0.3-0.1 % (<i>tobramycin/dexamethasone</i>) | T3 | QL (2 fills per 365 days) |
| <i>triamcinolone acetonide nasal aerosol,spray 55 mcg</i> | T2 | |
| Ent Anti-Infectives, Miscellaneous - Drugs For Infections | | |
| <i>acetic acid otic (ear) solution 2 %</i> | T2 | |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 %</i> | T2 | |
| <i>hydrocortisone-acetic acid otic (ear) drops 1-2 %</i> | T2 | |
| Ent Anti-Inflammatory Agents, Misc. - Drugs For Inflammation | | |
| RESTASIS MULTIDOSE OPHTHALMIC (EYE) DROPS 0.05 % (<i>cyclosporine</i>) | T3 | ST |
| RESTASIS OPHTHALMIC (EYE) DROPPERETTE 0.05 % (<i>cyclosporine</i>) | T3 | ST |
| XIIDRA OPHTHALMIC (EYE) DROPPERETTE 5 % (<i>lifitegrast</i>) | T3 | ST |
| Ent Drugs, Miscellaneous | | |
| <i>apraclonidine ophthalmic (eye) drops 0.5 %</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|-----------|----------------------------------|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| ARTIFICIAL TEARS (PETRO/MIN) OPHTHALMIC (EYE) OINTMENT 83-15 % (<i>mineral oil/petrolatum,white</i>) | T2 | QL (15 GM per 30 days) | |
| ARTIFICIAL TEARS (PF) OPHTHALMIC (EYE) DROPPERETTE (<i>dextran 70/hypromellose</i>) | T2 | QL (60 EA per 30 days) | |
| ARTIFICIAL TEARS (PF) OPHTHALMIC (EYE) DROPPERETTE 0.1-0.3 % (<i>dextran 70/hypromellose/pf</i>) | T2 | QL (60 EA per 30 days) | |
| ARTIFICIAL TEARS (POLYVIN ALC) OPHTHALMIC (EYE) DROPS 1.4 % (<i>polyvinyl alcohol</i>) | T2 | QL (60 ML per 30 days) | |
| ARTIFICIAL TEARS(DEXT70-HYPRO) OPHTHALMIC (EYE) DROPS , 0.1-0.3 % (<i>dextran 70/hypromellose</i>) | T2 | QL (60 ML per 30 days) | |
| ARTIFICIAL TEARS(GLYCERIN-PEG) OPHTHALMIC (EYE) DROPS 1-0.3 % (<i>glycerin/propylene glycol</i>) | T2 | QL (60 ML per 30 days) | |
| ARTIFICIAL TEARS(PVALCH-POVID) OPHTHALMIC (EYE) DROPS 0.5-0.6 % (<i>polyvinyl alcohol/povidone</i>) | T2 | QL (60 ML per 30 days) | |
| DRY EYE RELIEF OPHTHALMIC (EYE) DROPS 1-0.2-0.2 % (<i>polyethylene glycol 400/hypromellose/glycerin</i>) | T2 | QL (60 ML per 30 days) | |
| FOR STY RELIEF OPHTHALMIC (EYE) OINTMENT (<i>mineral oil/petrolatum,white</i>) | T2 | QL (15 GM per 30 days) | |
| FRESHKOTE OPHTHALMIC (EYE) DROPS 2-0.9-1.8 % (<i>eye lubricant combination no.1</i>) | T2 | QL (60 ML per 30 days) | |
| GENTEAL MILD OPHTHALMIC (EYE) DROPS 0.2 % (<i>hypromellose</i>) | T2 | QL (60 ML per 30 days) | |
| GENTEAL SEVERE OPHTHALMIC (EYE) GEL 0.3 % (<i>hypromellose</i>) | T2 | QL (60 GM per 30 days) | |
| GENTEAL TEARS MODERATE OPHTHALMIC (EYE) DROPS 0.1-0.3-0.2 % (<i>dextran/hypromellose/glycerin</i>) | T2 | QL (60 ML per 30 days) | |
| HYPOTEARS OPHTHALMIC (EYE) DROPS 1-1 % (<i>polyethylene glycol 400/polyvinyl alcohol</i>) | T2 | QL (60 ML per 30 days) | |
| ISOPTO TEARS OPHTHALMIC (EYE) DROPS 0.5 % (<i>hypromellose</i>) | T2 | QL (60 ML per 30 days) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| LUBRICANT DRY EYE RELIEF OPHTHALMIC (EYE) DROPS, LIQUID GEL 1 % (<i>carboxymethylcellulose sodium</i>) | T2 | QL (60 ML per 30 days) |
| LUBRICANT EYE (CMC-GLYCER)(PF) OPHTHALMIC (EYE) DROPPERETTE 0.5-0.9 % (<i>carboxymethylcellulose sodium/glycerin/pf</i>) | T2 | |
| LUBRICANT EYE (PROPYL GLYCOL) OPHTHALMIC (EYE) DROPS 0.6 % (<i>propylene glycol</i>) | T2 | QL (60 ML per 30 days) |
| LUBRICANT EYE DROPS OPHTHALMIC (EYE) DROPPERETTE 0.5 % (<i>carboxymethylcellulose sodium</i>) | T2 | QL (60 EA per 30 days) |
| LUBRICANT EYE DROPS OPHTHALMIC (EYE) DROPS 0.5 % (<i>carboxymethylcellulose sodium</i>) | T2 | QL (60 ML per 30 days) |
| LUBRICANT EYE OPHTHALMIC (EYE) OINTMENT 56.8-41.5 %, 57.3-42.5 %, 57.7-31.9 % (<i>mineral oil/petrolatum,white</i>) | T2 | QL (15 GM per 30 days) |
| LUBRICANT EYE(DEXTRAN70-HYPML) OPHTHALMIC (EYE) DROPPERETTE (<i>dextran 70/hypromellose</i>) | T2 | QL (60 EA per 30 days) |
| LUBRICANT GEL OPHTHALMIC (EYE) DROPS, LIQUID GEL 0.25-0.3 % (<i>carboxymethylcellulose sodium/hypromellose</i>) | T2 | QL (60 ML per 30 days) |
| LUBRICATING DROPS OPHTHALMIC (EYE) DROPS 0.5-0.9 % (<i>carboxymethylcellulose sodium/glycerin</i>) | T2 | QL (60 ML per 30 days) |
| LUBRICATING RELIEF OPHTHALMIC (EYE) DROPS 0.4-0.3 % (<i>propylene glycol/polyethylene glycol 400</i>) | T2 | QL (60 ML per 30 days) |
| PURALUBE OPHTHALMIC (EYE) OINTMENT 85-15 % (<i>mineral oil/petrolatum,white</i>) | T2 | QL (15 GM per 30 days) |
| PURE AND GENTLE EYE OPHTHALMIC (EYE) DROPS 0.3 % (<i>hypromellose</i>) | T2 | QL (60 ML per 30 days) |
| REFRESH CELUVISC OPHTHALMIC (EYE) DROPPERETTE,GEL 1 % (<i>carboxymethylcellulose sodium</i>) | T2 | QL (60 EA per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| REFRESH CLASSIC (PF) OPHTHALMIC (EYE) DROPPERETTE 1.4-0.6 % (<i>polyvinyl alcohol/povidone/pf</i>) | T2 | QL (60 EA per 30 days) |
| REFRESH CONTACTS OPHTHALMIC (EYE) DROPS (<i>carboxymethylcellulose sodium</i>) | T2 | QL (60 ML per 30 days) |
| REFRESH LACRI-LUBE OPHTHALMIC (EYE) OINTMENT 56.8-42.5 % (<i>mineral oil/petrolatum,white</i>) | T2 | QL (15 GM per 30 days) |
| REFRESH OPTIVE ADVANCED (PF) OPHTHALMIC (EYE) DROPPERETTE 0.5-1-0.5 % (<i>carboxymethylcellulose sodium/glycerin/polysorbate 80/pf</i>) | T2 | QL (60 EA per 30 days) |
| REFRESH OPTIVE ADVANCED OPHTHALMIC (EYE) DROPS 0.5-1-0.5 % (<i>carboxymethylcellulose sodium/glycerin/polysorbate 80</i>) | T2 | QL (60 ML per 30 days) |
| REFRESH OPTIVE OPHTHALMIC (EYE) DROPS, GEL 1-0.9 % (<i>carboxymethylcellulose sodium/glycerin</i>) | T2 | QL (60 ML per 30 days) |
| REFRESH OPTIVE SENSITIVE (PF) OPHTHALMIC (EYE) DROPPERETTE 0.5-0.9 % (<i>carboxymethylcellulose sodium/glycerin/pf</i>) | T2 | |
| RETAINE HPMC (PF) OPHTHALMIC (EYE) DROPS 0.3 % (<i>hypromellose/pf</i>) | T2 | QL (60 ML per 30 days) |
| RETAINE PM OPHTHALMIC (EYE) OINTMENT 80-20 % (<i>mineral oil/petrolatum,white</i>) | T2 | QL (15 GM per 30 days) |
| SOOTHE HYDRATION OPHTHALMIC (EYE) DROPS 1.25 % (<i>povidone</i>) | T2 | QL (60 ML per 30 days) |
| SOOTHE LUBRICANT OPHTHALMIC (EYE) DROPPERETTE 0.6-0.6 % (<i>glycerin/propylene glycol</i>) | T2 | QL (60 EA per 30 days) |
| STERILE LUBRICANT OPHTHALMIC (EYE) DROPS, LIQUID GEL 0.7 % (<i>carboxymethylcellulose sodium</i>) | T2 | QL (60 ML per 30 days) |
| SYSTANE (PF) OPHTHALMIC (EYE) DROPPERETTE 0.4-0.3 % (<i>propylene glycol/polyethylene glycol 400/pf</i>) | T2 | QL (60 EA per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| SYSTANE (PROPYLENE GLYCOL) OPHTHALMIC (EYE) DROPS 0.4-0.3 % (<i>propylene glycol/polyethylene glycol 400</i>) | T2 | QL (60 ML per 30 days) |
| SYSTANE BALANCE OPHTHALMIC (EYE) DROPS 0.6 % (<i>propylene glycol</i>) | T2 | QL (60 ML per 30 days) |
| SYSTANE GEL OPHTHALMIC (EYE) DROPS, GEL 0.4-0.3 % (<i>propylene glycol/polyethylene glycol 400</i>) | T2 | QL (60 ML per 30 days) |
| SYSTANE GEL OPHTHALMIC (EYE) GEL 0.3 % (<i>hypromellose</i>) | T2 | QL (60 GM per 30 days) |
| SYSTANE LIQUID GEL OPHTHALMIC (EYE) DROPS, LIQUID GEL 0.4-0.3 % (<i>propylene glycol/polyethylene glycol 400</i>) | T2 | QL (60 ML per 30 days) |
| SYSTANE NIGHTTIME OPHTHALMIC (EYE) OINTMENT 94-3 % (<i>mineral oil/petrolatum,white</i>) | T2 | QL (15 GM per 30 days) |
| TEARS NATURALE FORTE OPHTHALMIC (EYE) DROPS 0.1-0.3-0.2 % (<i>dextran/hypromellose/glycerin</i>) | T2 | QL (60 ML per 30 days) |
| THERATEARS OPHTHALMIC (EYE) DROPPERETTE 0.25 % (<i>carboxymethylcellulose sodium</i>) | T2 | QL (60 EA per 30 days) |
| THERATEARS OPHTHALMIC (EYE) DROPPERETTE, GEL 1 % (<i>carboxymethylcellulose sodium</i>) | T2 | QL (60 EA per 30 days) |
| THERATEARS OPHTHALMIC (EYE) DROPS 0.25 % (<i>carboxymethylcellulose sodium</i>) | T2 | QL (60 ML per 30 days) |
| ULTRA FRESH PM OPHTHALMIC (EYE) OINTMENT (<i>lanolin/mineral oil/petrolatum,white</i>) | T2 | QL (15 GM per 30 days) |
| VISINE TIRED EYE RELIEF OPHTHALMIC (EYE) DROPS 1-0.36-0.2 % (<i>polyethylene glycol 400/hypromellose/glycerin</i>) | T2 | QL (60 ML per 30 days) |
| Ent Nonsteroidal Anti-Inflam. Agents - Drugs For Inflammation | | |
| ACUVAIL (PF) OPHTHALMIC (EYE) DROPPERETTE 0.45 % (<i>ketorolac tromethamine/pf</i>) | T3 | PA |
| <i>bromfenac ophthalmic (eye) drops 0.09 %</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>diclofenac sodium ophthalmic (eye) drops 0.1 %</i> | T2 | |
| <i>flurbiprofen sodium ophthalmic (eye) drops 0.03 %</i> | T2 | |
| ILEVRO OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3 % (<i>nepafenac</i>) | T3 | PA |
| <i>ketorolac ophthalmic (eye) drops 0.4 %</i> | T2 | PA |
| <i>ketorolac ophthalmic (eye) drops 0.5 %</i> | T2 | QL (2 FL per 365 DYs) |
| NEVANAC OPHTHALMIC (EYE) DROPS,SUSPENSION 0.1 % (<i>nepafenac</i>) | T3 | PA |
| PROLENSA OPHTHALMIC (EYE) DROPS 0.07 % (<i>bromfenac sodium</i>) | T3 | PA |
| Local Anesthetics (Ent) - Drugs For Numbing | | |
| <i>lidocaine hcl mucous membrane jelly 2 %</i> | T2 | |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | T2 | |
| <i>lidocaine hcl</i> (Lidocaine Viscous Mucous Membrane Solution 2 %) | T2 | |
| <i>proparacaine ophthalmic (eye) drops 0.5 %</i> | Tier 1 | |
| <i>tetracaine hcl ophthalmic (eye) drops 0.5 %</i> | T2 | |
| Miotics - Drugs For The Eye | | |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i> | T2 | |
| Mydriatics - Drugs For The Eye | | |
| <i>atropine ophthalmic (eye) drops 1 %</i> | T2 | |
| <i>atropine ophthalmic (eye) ointment 1 %</i> | T2 | |
| <i>cyclopentolate ophthalmic (eye) drops 0.5 %, 1 %, 2 %</i> | T2 | |
| HOMATROPAIRE OPHTHALMIC (EYE) DROPS 5 % (<i>homatropine hbr</i>) | T2 | |
| <i>tropicamide ophthalmic (eye) drops 0.5 %, 1 %</i> | T2 | |
| Prostaglandin Analogs - Drugs For The Eye | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>latanoprost ophthalmic (eye) drops 0.005 %</i> | T2 | |
| <i>travoprost ophthalmic (eye) drops 0.004 %</i> | T2 | ST |
| Vasoconstrictors | | |
| ADRENALIN NASAL SOLUTION 1 MG/ML (<i>epinephrine hcl</i>) | T3 | QL (60 ML per 1 fill) |
| <i>phenylephrine hcl ophthalmic (eye) drops 10 %</i> | T2 | |
| Gastrointestinal Drugs | | |
| Antacids And Adsorbents | | |
| <i>magnesium oxide oral tablet 400 mg magnesium</i> | T2 | |
| Gastrointestinal Drugs - Drugs For The Stomach | | |
| 5-HT3 Receptor Antagonists - Drugs For Vomiting And Nausea | | |
| <i>gransetron (pf) intravenous solution 1 mg/ml (1 ml)</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>gransetron (pf) intravenous solution 100 mcg/ml</i> | T2 | PA |
| <i>gransetron hcl intravenous solution 1 mg/ml, 1 mg/ml (1 ml)</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>gransetron hcl oral tablet 1 mg</i> | T2 | PA |
| <i>ondansetron hcl oral tablet 24 mg</i> | T2 | PA ; QL (60 Qty per 30 days) |
| <i>ondansetron hcl oral tablet 4 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>ondansetron hcl oral tablet 8 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>ondansetron oral tablet,disintegrating 4 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>ondansetron oral tablet,disintegrating 8 mg</i> | T2 | QL (60 Qty per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| <i>palonosetron intravenous solution 0.25 mg/5 ml</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ZUPLENZ ORAL FILM 4 MG, 8 MG (<i>ondansetron</i>) | T3 | PA |
| Antidiarrhea Agents - Drugs For Diarrhea | | |
| ANTI-DIARRHEAL (LOPERAMIDE) ORAL TABLET 2 MG (<i>loperamide hcl</i>) | T2 | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml</i> | T2 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | T2 | |
| Antiemetics, Miscellaneous - Drugs For Vomiting And Nausea | | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> | T2 | PA ; QL (60 EA per 30 days) |
| Antihistamines (Gi Drugs) - Drugs For Vomiting And Nausea | | |
| <i>prochlorperazine</i> (Compro Rectal Suppository 25 Mg) | T2 | |
| <i>meclizine oral tablet 12.5 mg, 25 mg</i> | T2 | |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | T2 | |
| Anti-Inflammatory Agents (Gi Drugs) - Drugs For Inflammation | | |
| <i>balsalazide oral capsule 750 mg</i> | T2 | |
| LOTRONEX ORAL TABLET 0.5 MG, 1 MG (<i>alosetron hcl</i>) | T3 | PA |
| <i>mesalamine oral capsule (with del rel tablets) 400 mg</i> | T2 | ST |
| <i>mesalamine oral capsule,extended release 24hr 0.375 gram</i> | T2 | ST |
| <i>mesalamine oral tablet,delayed release (dr/ec) 1.2 gram</i> | T2 | ST |
| <i>mesalamine oral tablet,delayed release (dr/ec) 800 mg</i> | T2 | PA |
| <i>mesalamine rectal enema 4 gram/60 ml</i> | T2 | |
| <i>mesalamine rectal suppository 1,000 mg</i> | T2 | |
| <i>mesalamine with cleansing wipe rectal enema kit 4 gram/60 ml</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| PENTASA ORAL CAPSULE, EXTENDED RELEASE 250 MG, 500 MG (<i>mesalamine</i>) | T3 | PA |
| <i>sulfasalazine oral tablet 500 mg</i> | T2 | |
| <i>sulfasalazine oral tablet,delayed release (dr/ec) 500 mg</i> | T2 | |
| Cathartics And Laxatives - Drugs For Constipation | | |
| GAVILYTE-C ORAL RECON SOLN 240-22.72-6.72 -5.84 GRAM (<i>peg 3350/sod sulf/sod bicarb/sod chloride/potassium chloride</i>) | T2 | QL (4000 ML per 90 days) |
| <i>peg 3350/sod sulf/sod bicarb/sod chloride/potassium chloride</i> (Gavilyte-G Oral Recon Soln 236-22.74-6.74 -5.86 Gram) | T2 | QL (4000 ML per 90 days) |
| <i>sodium chloride/sodium bicarbonate/potassium chloride/peg</i> (Gavilyte-N Oral Recon Soln 420 Gram) | T2 | QL (4000 ML per 90 days) |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i> | T2 | PA |
| <i>peg 3350-electrolytes oral recon soln 236-22.74-6.74 -5.86 gram</i> | T2 | QL (4000 ML per 90 days) |
| SMOOTHLAX ORAL POWDER 17 GRAM/DOSE (<i>polyethylene glycol 3350</i>) | T2 | |
| <i>sorbitol solution 70 %</i> | T3 | |
| Cholelitholytic Agents - Drugs For The Stomach | | |
| <i>ursodiol oral capsule 300 mg</i> | T2 | |
| Digestants - Drugs For The Stomach | | |
| CREON ORAL CAPSULE,DELAYED RELEASE(DR/EC) 12,000-38,000 -60,000 UNIT, 24,000-76,000 -120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT (<i>lipase/protease/amylase</i>) | T3 | AL (Min 21 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 10,000-34,000 -55,000 UNIT, 15,000-51,000 -82,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 25,000-85,000- 136,000 UNIT, 3,000-10,000- 16,000 UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000 -27,000 UNIT, 5,000-17,000- 24,000 UNIT (<i>lipase/protease/amylase</i>) | T3 | AL (Min 21 Years) |
| ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 15,000-47,000 -63,000 UNIT, 3,000-10,000 -14,000-UNIT (<i>lipase/protease/amylase</i>) | Tier 1 | AL (Min 21 Years) |
| Gi Drugs, Miscellaneous - Drugs For The Stomach | | |
| ALLI ORAL CAPSULE 60 MG (<i>orlistat</i>) | T3 | PA |
| CIMZIA POWDER FOR RECONST SUBCUTANEOUS KIT 400 MG (200 MG X 2 VIALS) (<i>certolizumab pegol</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) (<i>certolizumab pegol</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| GATTEX 30-VIAL SUBCUTANEOUS KIT 5 MG (<i>teduglutide</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| HUMIRA PEN PSOR-UVEITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML <i>(adalimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML <i>(adalimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML <i>(adalimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML <i>(adalimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML <i>(adalimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML <i>(adalimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML <i>(adalimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML <i>(adalimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| INFLECTRA INTRAVENOUS RECON SOLN 100 MG (<i>infliximab-dyyb</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG (<i>linaclotide</i>) | T3 | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG (<i>naloxegol oxalate</i>) | T3 | PA |
| RELISTOR ORAL TABLET 150 MG (<i>methylNaltrexone bromide</i>) | T3 | PA |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6 ML (<i>methylNaltrexone bromide</i>) | T3 | PA |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML (<i>methylNaltrexone bromide</i>) | T3 | PA |
| RENFLEXIS INTRAVENOUS RECON SOLN 100 MG (<i>infliximab-abda</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| SIMPONI ARIA INTRAVENOUS SOLUTION 12.5 MG/ML (<i>golimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML (<i>golimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML (<i>golimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SYMPROIC ORAL TABLET 0.2 MG (<i>naldemedine tosylate</i>) | T3 | PA |
| TRULANCE ORAL TABLET 3 MG (<i>plecanatide</i>) | T3 | PA |
| VIBERZI ORAL TABLET 100 MG, 75 MG (<i>eluxadoline</i>) | T3 | PA |
| XENICAL ORAL CAPSULE 120 MG (<i>orlistat</i>) | T3 | PA |
| Histamine H2-Antagonists - Drugs For Ulcers And Stomach Acid | | |
| <i>cimetidine hcl oral solution 300 mg/5 ml</i> | T2 | ST |
| <i>cimetidine oral tablet 200 mg, 300 mg, 400 mg, 800 mg</i> | T2 | ST |
| <i>famotidine oral tablet 10 mg, 20 mg, 40 mg</i> | T2 | |
| Neurokinin-1 Receptor Antagonists - Drugs For Vomiting And Nausea | | |
| <i>aprepitant oral capsule 125 mg, 40 mg, 80 mg</i> | T2 | PA |
| <i>aprepitant oral capsule,dose pack 125 mg (1)- 80 mg (2)</i> | T2 | PA |
| <i>fosaprepitant intravenous recon soln 150 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Prokinetic Agents - Drugs For The Stomach | | |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i> | T2 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | T2 | |
| MOTEGRITY ORAL TABLET 1 MG, 2 MG (<i>prucalopride succinate</i>) | T3 | PA |
| Prostaglandins - Drugs For Ulcers And Stomach Acid | | |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | T2 | |
| Protectants - Drugs For Ulcers And Stomach Acid | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>sucralfate oral suspension 100 mg/ml</i> | T2 | |
| <i>sucralfate oral tablet 1 gram</i> | T2 | |
| Proton-Pump Inhibitors - Drugs For Ulcers And Stomach Acid | | |
| DEXILANT ORAL CAPSULE,BIPHASE DELAYED RELEASE 30 MG, 60 MG (<i>dexlansoprazole</i>) | T3 | PA |
| <i>esomeprazole magnesium oral capsule,delayed release(dr/ec) 20 mg</i> | T2 | ST ; QL (60 EA per 30 days) |
| <i>esomeprazole magnesium oral capsule,delayed release(dr/ec) 40 mg</i> | T2 | ST |
| <i>lansoprazole oral capsule,delayed release(dr/ec) 15 mg, 30 mg</i> | T2 | |
| <i>omeprazole oral capsule,delayed release(dr/ec) 20 mg</i> | T2 | QL (60 EA per 30 days) |
| <i>omeprazole oral capsule,delayed release(dr/ec) 40 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>pantoprazole oral tablet,delayed release (dr/ec) 20 mg, 40 mg</i> | T2 | QL (60 Qty per 30 days) |
| <i>lansoprazole/amoxicillin trihydrate/clarithromycin</i> (Prevpac Oral Combo Pack 500-500-30 Mg) | T3 | PA |
| <i>rabeprazole oral tablet,delayed release (dr/ec) 20 mg</i> | T2 | ST ; QL (60 EA per 30 days) |
| Gold Compounds | | |
| Gold Compounds | | |
| RIDAURA ORAL CAPSULE 3 MG (<i>auranofin</i>) | T3 | |
| Heavy Metal Antagonists - Drugs To Reduce Iron | | |
| Heavy Metal Antagonists - Drugs To Reduce Iron | | |
| <i>deferasirox oral granules in packet 180 mg, 360 mg, 90 mg</i> | T2 | PA |
| <i>deferasirox oral tablet 180 mg, 360 mg, 90 mg</i> | T2 | PA |
| <i>deferasirox oral tablet, dispersible 125 mg, 250 mg, 500 mg</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits |
|------------------------------|--|--|
| lowercase bold italics = | Drug Tier | AL = Age Limit Applies |
| Generic drugs | NF = Non-Formulary | PA = PA Applies |
| UPPERCASE = Brand name drugs | T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | QL = Quantity Limit SP = Specialty Product ST = ST Applies |

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>deferoxamine injection recon soln 2 gram, 500 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| DEPEN TITRATABS ORAL TABLET 250 MG (<i>penicillamine</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>penicillamine oral capsule 250 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>trientine oral capsule 250 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

Hormones And Synthetic Substitutes - Hormones

Adrenals - Hormones

| | | |
|--|----|---|
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION (<i>fluticasone propionate/salmeterol xinafoate</i>) | T3 | PA |
| ARNUITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION (<i>fluticasone furoate</i>) | T3 | QL (30 EA per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE (<i>fluticasone furoate/vilanterol trifénatate</i>) | T3 | PA |
| <i>budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml</i> | T2 | QL (120 ML per 30 days); AL (Max 8 Years) |
| <i>budesonide oral capsule,delayed,extend.release 3 mg</i> | T2 | QL (540 EA per 365 days) |
| <i>budesonide oral tablet,delayed and ext.release 9 mg</i> | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>budesonide-formoterol inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | | T2 | PA |
| <i>dexamethasone oral elixir 0.5 mg/5 ml</i> | | T2 | |
| <i>dexamethasone oral solution 0.5 mg/5 ml</i> | | T2 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1.5 mg, 4 mg, 6 mg</i> | | T2 | |
| <i>dexamethasone oral tablet 1 mg, 2 mg</i> | | T2 | |
| <i>dexamethasone</i> (Dexpak 13 Day Oral Tablets,Dose Pack 1.5 Mg (51 Tabs)) | | T3 | |
| <i>DULERA INHALATION HFA AEROSOL INHALER 100-5 MCG/ACTUATION, 200-5 MCG/ACTUATION, 50-5 MCG/ACTUATION (<i>mometasone furoate/formoterol fumarate</i>)</i> | | T3 | PA ; AL (Max 12 Years) |
| <i>EMFLAZA ORAL SUSPENSION 22.75 MG/ML (<i>deflazacort</i>)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>EMFLAZA ORAL TABLET 18 MG, 36 MG (<i>deflazacort</i>)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>EMFLAZA ORAL TABLET 30 MG, 6 MG (<i>deflazacort</i>)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>FLOVENT DISKUS INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 250 MCG/ACTUATION, 50 MCG/ACTUATION (<i>fluticasone propionate</i>)</i> | | T3 | |
| <i>FLOVENT HFA INHALATION HFA AEROSOL INHALER 110 MCG/ACTUATION, 220 MCG/ACTUATION, 44 MCG/ACTUATION (<i>fluticasone propionate</i>)</i> | | T3 | |
| <i>fludrocortisone oral tablet 0.1 mg</i> | | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>fluticasone propion-salmeterol inhalation aerosol powdr breath activated 113-14 mcg/actuation, 232-14 mcg/actuation, 55-14 mcg/actuation</i> | T2 | QL (1 EA per 30 days) |
| <i>fluticasone propion-salmeterol inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | T2 | |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | T2 | |
| MEDROL ORAL TABLET 2 MG (<i>methylprednisolone</i>) | T3 | |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | T2 | |
| <i>methylprednisolone oral tablets,dose pack 4 mg</i> | T2 | |
| MILLIPRED ORAL TABLET 5 MG (<i>prednisolone</i>) | T3 | |
| <i>prednisolone oral solution 15 mg/5 ml</i> | T2 | |
| <i>prednisolone sodium phosphate oral solution 15 mg/5 ml (3 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | T2 | |
| PREDNISONE INTENSOL ORAL CONCENTRATE 5 MG/ML (<i>prednisone</i>) | T3 | |
| <i>prednisone oral solution 5 mg/5 ml</i> | T2 | |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | T2 | |
| <i>prednisone oral tablets,dose pack 10 mg, 5 mg</i> | T2 | |
| QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION, 80 MCG/ACTUATION (<i>beclomethasone dipropionate</i>) | T3 | |
| UCERIS RECTAL FOAM 2 MG/ACTUATION (<i>budesonide</i>) | T3 | PA |
| <i>fluticasone propionate/salmeterol xinafoate</i> (Wixela Inhub Inhalation Blister With Device 100-50 Mcg/Dose, 250-50 Mcg/Dose, 500-50 Mcg/Dose) | T2 | |
| Alpha-Glucosidase Inhibitors - Drugs For Diabetes | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | | Coverage Requirements and Limits |
|--|------------------|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| Amylinomimetics - Drugs For Diabetes | | | |
| SYMLINPEN 120 SUBCUTANEOUS PEN INJECTOR 2,700 MCG/2.7 ML (<i>pramlintide acetate</i>) | T3 | PA | |
| SYMLINPEN 60 SUBCUTANEOUS PEN INJECTOR 1,500 MCG/1.5 ML (<i>pramlintide acetate</i>) | T3 | PA | |
| Androgens - Hormones | | | |
| ANDROGEL TRANSDERMAL GEL IN PACKET 1 % (25 MG/2.5GRAM), 1 % (50 MG/5 GRAM) (<i>testosterone</i>) | T3 | PA | |
| COVARYX H.S. ORAL TABLET 0.625-1.25 MG (<i>estrogens,esterified/methyltestosterone</i>) | T2 | | |
| COVARYX ORAL TABLET 1.25-2.5 MG (<i>estrogens,esterified/methyltestosterone</i>) | T2 | | |
| <i>testosterone cypionate intramuscular oil 100 mg/ml</i> | T2 | QL (10 ML per 30 days) | |
| <i>testosterone cypionate intramuscular oil 200 mg/ml</i> | T2 | QL (5 ML per 30 days) | |
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i> | T2 | PA ; QL (5 ML per 30 days) | |
| <i>testosterone transdermal gel 50 mg/5 gram (1 %)</i> | T2 | PA | |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)</i> | T2 | QL (300 GM per 30 days) | |
| <i>testosterone transdermal solution in metered pump w/app 30 mg/actuation (1.5 ml)</i> | T2 | PA | |
| Antiestrogens - Drugs For Women | | | |
| <i>anastrozole oral tablet 1 mg</i> | T2 | | |
| <i>exemestane oral tablet 25 mg</i> | T2 | | |
| <i>letrozole oral tablet 2.5 mg</i> | T2 | | |
| Antigonadotropins - Hormones | | | |
| ORIAHNN ORAL CAPSULE, SEQUENTIAL 300-1- 0.5MG(AM) /300 MG(PM) (<i>elagolix sodium/estradiol/norethindrone acetate</i>) | T3 | PA | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| ORILISSA ORAL TABLET 150 MG, 200 MG (<i>elagolix sodium</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Antiparathyroid Agents - Drugs For Bones | | |
| <i>calcitonin (salmon) nasal spray,non-aerosol 200 unit/actuation</i> | T2 | |
| <i>cinacalcet oral tablet 30 mg, 60 mg, 90 mg</i> | T2 | |
| Antithyroid Agents - Drugs For The Thyroid | | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>propylthiouracil oral tablet 50 mg</i> | T2 | |
| SSKI ORAL SOLUTION 1 GRAM/ML (<i>potassium iodide</i>) | T2 | |
| Biguanides - Drugs For Diabetes | | |
| <i>alogliptin-metformin oral tablet 12.5-1,000 mg, 12.5-500 mg</i> | T2 | ST |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | T2 | |
| JANUMET ORAL TABLET 50-1,000 MG, 50-500 MG (<i>sitagliptin phosphate/metformin hcl</i>) | T3 | PA ; QL (60 Qty per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-1,000 MG, 50-500 MG (<i>sitagliptin phosphate/metformin hcl</i>) | T3 | PA |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG (<i>linagliptin/metformin hcl</i>) | T3 | ST |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG (<i>linagliptin/metformin hcl</i>) | T3 | ST |
| KOMBIGLYZE XR ORAL TABLET, ER MULTIPHASE 24 HR 2.5-1,000 MG, 5-1,000 MG, 5-500 MG (<i>saxagliptin hcl/metformin hcl</i>) | T3 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>metformin oral tablet 1,000 mg, 500 mg, 850 mg</i> | T2 | |
| <i>metformin oral tablet extended release 24 hr 500 mg, 750 mg</i> | T2 | |
| SEGLUROMET ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 7.5-1,000 MG, 7.5-500 MG (<i>ertugliflozin pidolate/metformin hcl</i>) | T3 | ST |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 12.5-2.5-1,000 MG, 25-5-1,000 MG, 5-2.5-1,000 MG (<i>empagliflozin/linagliptin/metformin hcl</i>) | T3 | PA |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-1,000 MG, 5-500 MG (<i>dapagliflozin propanediol/metformin hcl</i>) | T3 | PA |
| Contraceptives - Drugs For Women | | |
| AMETHIA LO ORAL TABLETS,DOSE PACK,3 MONTH 0.10 MG-20 MCG (84)/10 MCG (7) (<i>levonorgestrel/ethinyl estradiol and ethinyl estradiol</i>) | T2 | PA |
| <i>levonorgestrel/ethinyl estradiol and ethinyl estradiol</i> (Amethia Oral Tablets,Dose Pack,3 Month 0.15 Mg-30 Mcg (84)/10 Mcg (7)) | T2 | PA |
| <i>levonorgestrel/ethinyl estradiol</i> (Amethyst (28) Oral Tablet 90-20 Mcg (28)) | T2 | |
| <i>desogestrel-ethinyl estradiol</i> (Aprí Oral Tablet 0.15-0.03 Mg) | T2 | |
| <i>norethindrone-ethinyl estradiol</i> (Aranelle (28) Oral Tablet 0.5/1/0.5-35 Mg-Mcg) | T2 | |
| <i>norethindrone-ethinyl estradiol</i> (Balziva (28) Oral Tablet 0.4-35 Mg-Mcg) | T2 | |
| CAMRESE LO ORAL TABLETS,DOSE PACK,3 MONTH 0.10 MG-20 MCG (84)/10 MCG (7) (<i>levonorgestrel/ethinyl estradiol and ethinyl estradiol</i>) | T2 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|-----------|----------------------------------|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| CAMRESE ORAL TABLETS,DOSE PACK,3 MONTH 0.15 MG-30 MCG (84)/10 MCG (7) (<i>levonorgestrel/ethinyl estradiol and ethinyl estradiol</i>) | T2 | PA | |
| <i>norgestrel-ethinyl estradiol</i> (Cryselle (28) Oral Tablet 0.3-30 Mg-Mcg) | T2 | | |
| <i>drospirenone-e.estradiol-Im.fa oral tablet 3-0.02-0.451 mg (24) (4), 3-0.03-0.451 mg (21) (7)</i> | T2 | PA | |
| ELLA ORAL TABLET 30 MG (<i>ulipristal acetate</i>) | T3 | | |
| <i>levonorgestrel/ethinyl estradiol</i> (Enpresse Oral Tablet 50-30 (6)/75-40 (5)/125-30(10)) | T2 | | |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr</i> | T2 | | |
| GIANVI (28) ORAL TABLET 3-0.02 MG (<i>ethinyl estradiol/drospirenone</i>) | T2 | | |
| <i>levonorgestrel/ethinyl estradiol</i> (Introvale Oral Tablets,Dose Pack,3 Month 0.15 Mg-30 Mcg (91)) | T2 | | |
| JOLESSA ORAL TABLETS,DOSE PACK,3 MONTH 0.15 MG-30 MCG (91) (<i>levonorgestrel/ethinyl estradiol</i>) | T2 | | |
| <i>norethindrone acetate-ethinyl estradiol</i> (Junel 1.5/30 (21) Oral Tablet 1.5-30 Mg-Mcg) | T2 | | |
| <i>norethindrone acetate-ethinyl estradiol</i> (Junel 1/20 (21) Oral Tablet 1-20 Mg-Mcg) | T2 | | |
| <i>norethindrone acetate-ethinyl estradiol/ferrous fumarate</i> (Junel Fe 1.5/30 (28) Oral Tablet 1.5 Mg-30 Mcg (21)/75 Mg (7)) | T2 | | |
| <i>norethindrone acetate-ethinyl estradiol/ferrous fumarate</i> (Junel Fe 1/20 (28) Oral Tablet 1 Mg-20 Mcg (21)/75 Mg (7)) | T2 | | |
| <i>desogestrel-ethinyl estradiol/ethinyl estradiol</i> (Kariva (28) Oral Tablet 0.15-0.02 Mgx21 /0.01 Mg X 5) | T2 | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>ethynodiol diacetate-ethinyl estradiol</i> (Kelnor 1/35 (28) Oral Tablet 1-35 Mg-Mcg) | T2 | |
| <i>I norgest/e.estradol-e.estrad oral tablets,dose pack,3 month 0.10 mg-20 mcg (84)/10 mcg (7), 0.15 mg-20 mcg/ 0.15 mg-25 mcg</i> | T2 | PA |
| <i>norethindrone acetate-ethinyl estradiol/ferrous fumarate</i> (Larin 24 Fe Oral Tablet 1 Mg-20 Mcg (24)/75 Mg (4)) | T2 | |
| <i>levonorgestrel/ethinyl estradiol</i> (Lessina Oral Tablet 0.1-20 Mg-Mcg) | T2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.15-0.03 mg</i> | T2 | |
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | T2 | |
| LO LOESTRIN FE ORAL TABLET 1 MG-10 MCG (24)/10 MCG (2) (<i>norethindrone acetate-ethinyl estradiol/ferrous fumarate</i>) | T3 | PA |
| <i>ethinyl estradiol/drospirenone</i> (Loryna (28) Oral Tablet 3-0.02 Mg) | T2 | |
| <i>levonorgestrel/ethinyl estradiol</i> (Lutera (28) Oral Tablet 0.1-20 Mg-Mcg) | T2 | |
| <i>norethindrone acetate-ethinyl estradiol/ferrous fumarate</i> (Mibelas 24 Fe Oral Tablet, Chewable 1 Mg-20 Mcg(24) /75 Mg (4)) | T2 | PA |
| MY WAY ORAL TABLET 1.5 MG (<i>levonorgestrel</i>) | T2 | |
| NATAZIA ORAL TABLET 3 MG/2 MG-2 MG/ 2 MG-3 MG/1 MG (<i>estradiol valerate/dienogest</i>) | T3 | PA |
| <i>norethindrone-ethinyl estradiol</i> (Necon 0.5/35 (28) Oral Tablet 0.5-35 Mg-Mcg) | T2 | |
| NECON 7/7/7 (28) ORAL TABLET 0.5/0.75/1 MG- 35 MCG (<i>norethindrone-ethinyl estradiol</i>) | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>noreth-ethinyl estradiol-iron oral tablet, chewable 0.8mg-25mcg(24) and 75 mg (4)</i> | | T2 | PA |
| <i>norethindrone (contraceptive) oral tablet 0.35 mg</i> | | T2 | |
| <i>norethindrone-e.estradiol-iron oral tablet, chewable 1 mg-20 mcg(24) /75 mg (4)</i> | | T2 | PA |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | | T2 | |
| <i>norethindrone-ethinyl estradiol</i> (Nortrel 0.5/35 (28) Oral Tablet 0.5-35 Mg-Mcg) | | T2 | |
| <i>NORTREL 1/35 (21) ORAL TABLET 1-35 MG-MCG (21) (norethindrone-ethinyl estradiol)</i> | | T2 | |
| <i>norethindrone-ethinyl estradiol</i> (Nortrel 7/7/7 (28) Oral Tablet 0.5/0.75/1 Mg- 35 Mcg) | | T2 | |
| <i>OCELLA ORAL TABLET 3-0.03 MG (ethinyl estradiol/drospirenone)</i> | | T2 | |
| <i>OGESTREL (28) ORAL TABLET 0.5-50 MG-MCG (norgestrel-ethinyl estradiol)</i> | | T2 | |
| <i>levonorgestrel/ethinyl estradiol</i> (Portia 28 Oral Tablet 0.15-0.03 Mg) | | T2 | |
| <i>levonorgestrel/ethinyl estradiol</i> (Quasense Oral Tablets,Dose Pack,3 Month 0.15 Mg-30 Mcg (91)) | | T2 | |
| <i>drospirenone/ethinyl estradiol/levomefolate calcium</i> (Rajani Oral Tablet 3-0.02-0.451 Mg (24) (4)) | | T2 | PA |
| <i>desogestrel-ethinyl estradiol</i> (Reclipsen (28) Oral Tablet 0.15-0.03 Mg) | | T2 | |
| <i>norgestimate-ethinyl estradiol</i> (Sprintec (28) Oral Tablet 0.25-35 Mg-Mcg) | | T2 | |
| <i>norethindrone acetate-ethinyl estradiol/ferrous fumarate</i> (Tri-Legest Fe Oral Tablet 1-20(5)/1-30(7) /1Mg-35Mcg (9)) | | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>norgestimate-ethynodiol estradiol</i> (Tri-Lo-Sprintec Oral Tablet 0.18/0.215/0.25 Mg-25 Mcg) | T2 | |
| <i>norgestimate-ethynodiol estradiol</i> (Tri-Sprintec (28) Oral Tablet 0.18/0.215/0.25 Mg-35 Mcg (28)) | T2 | |
| <i>desogestrel-ethynodiol estradiol</i> (Velvet Triphasic Regimen (28) Oral Tablet 0.1/.125/.15-25 Mg-Mcg) | T2 | |
| XULANE TRANSDERMAL PATCH WEEKLY 150-35 MCG/24 HR (<i>norelgestromin/ethynodiol estradiol</i>) | T2 | |
| <i>ethynodiol diacetate-ethynodiol estradiol</i> (Zovia 1/35E (28) Oral Tablet 1-35 Mg-Mcg) | T2 | |
| <i>ethynodiol diacetate-ethynodiol estradiol</i> (Zovia 1/50E (28) Oral Tablet 1-50 Mg-Mcg) | T2 | |
| Dipeptidyl Peptidase-4(Dpp-4) Inhibitors - Drugs For Diabetes | | |
| <i>alogliptin oral tablet</i> 12.5 mg, 25 mg, 6.25 mg | T2 | ST |
| <i>alogliptin-metformin oral tablet</i> 12.5-1,000 mg, 12.5-500 mg | T2 | ST |
| <i>alogliptin-pioglitazone oral tablet</i> 12.5-15 mg, 12.5-30 mg, 12.5-45 mg, 25-15 mg, 25-30 mg, 25-45 mg | T2 | ST |
| JANUMET ORAL TABLET 50-1,000 MG, 50-500 MG (<i>sitagliptin phosphate/metformin hcl</i>) | T3 | PA ; QL (60 Qty per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-1,000 MG, 50-500 MG (<i>sitagliptin phosphate/metformin hcl</i>) | T3 | PA |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG (<i>sitagliptin phosphate</i>) | T3 | PA ; QL (30 Qty per 30 days) |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG (<i>linagliptin/metformin hcl</i>) | T3 | ST |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG (<i>linagliptin/metformin hcl</i>) | T3 | ST |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| KOMBIGLYZE XR ORAL TABLET, ER MULTIPHASE 24 HR 2.5-1,000 MG, 5-1,000 MG, 5-500 MG (<i>saxagliptin hcl/metformin hcl</i>) | T3 | PA |
| ONGLYZA ORAL TABLET 2.5 MG, 5 MG (<i>saxagliptin hcl</i>) | T3 | PA |
| TRADJENTA ORAL TABLET 5 MG (<i>linagliptin</i>) | T3 | PA |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 12.5-2.5-1,000 MG, 25-5-1,000 MG, 5-2.5-1,000 MG (<i>empagliflozin/linagliptin/metformin hcl</i>) | T3 | PA |
| Estrogen Agonist-Antagonists - Drugs For Women | | |
| <i>raloxifene oral tablet 60 mg</i> | T2 | PA |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML (<i>tamoxifen citrate</i>) | T3 | |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | T2 | |
| <i>toremifene oral tablet 60 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.); AL (Min 21 Years) |
| Estrogens - Drugs For Women | | |
| COVARYX H.S. ORAL TABLET 0.625-1.25 MG (<i>estrogens,esterified/methyltestosterone</i>) | T2 | |
| COVARYX ORAL TABLET 1.25-2.5 MG (<i>estrogens,esterified/methyltestosterone</i>) | T2 | |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | T2 | QL (8 EA per 28 days); AL (Min 40 Years) |
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | T2 | QL (4 EA per 28 days); AL (Min 40 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| <i>estradiol vaginal cream 0.01 % (0.1 mg/gram)</i> | T2 | |
| <i>estradiol vaginal tablet 10 mcg</i> | T2 | |
| <i>estradiol valerate intramuscular oil 20 mg/ml, 40 mg/ml</i> | T2 | QL (5 ML per 30 days) |
| <i>estrogens,esterified</i> (Menest Oral Tablet 0.3 Mg, 0.625 Mg, 1.25 Mg) | T3 | |
| ORIAHNN ORAL CAPSULE, SEQUENTIAL 300-1-0.5MG(AM) /300 MG(PM) (<i>elagolix sodium/estradiol/norethindrone acetate</i>) | T3 | PA |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG (<i>estrogens, conjugated</i>) | T3 | |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM (<i>estrogens, conjugated</i>) | T3 | |
| PREMPHASE ORAL TABLET 0.625 MG (14)/ 0.625MG-5MG(14) (<i>estrogens, conjugated/medroxyprogesterone acetate</i>) | T3 | |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG (<i>estrogens, conjugated/medroxyprogesterone acetate</i>) | T3 | |
| Glycogenolytic Agents - Hormones | | |
| BAQSIMI NASAL SPRAY,NON-AEROSOL 3 MG/ACTUATION (<i>glucagon</i>) | T3 | QL (1 EA per 30 days) |
| <i>glucagon</i> (Glucagon Emergency Kit (Human) Injection Recon Soln 1 Mg) | T2 | QL (1 Qty per 30 days) |
| Gonadotropins - Hormones | | |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG, 22.5 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 7.5 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| LUPRON DEPOT-PED INTRAMUSCULAR KIT 11.25 MG, 15 MG, 7.5 MG (PED) (<i>leuprolide acetate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SYNAREL NASAL SPRAY, NON-AEROSOL 2 MG/ML (<i>nafarelin acetate</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

Incretin Mimetics - Drugs For Diabetes

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| BYDUREON BCISE SUBCUTANEOUS AUTO-INJECTOR 2 MG/0.85 ML (<i>exenatide microspheres</i>) | T3 | PA |
| BYDUREON SUBCUTANEOUS PEN INJECTOR 2 MG/0.65 ML (<i>exenatide microspheres</i>) | T3 | PA |
| BYDUREON SUBCUTANEOUS SUSPENSION, EXTENDED REL RECON 2 MG (<i>exenatide microspheres</i>) | T3 | PA |
| BYETTA SUBCUTANEOUS PEN INJECTOR 10 MCG/DOSE(250 MCG/ML) 2.4 ML, 5 MCG/DOSE (250 MCG/ML) 1.2 ML (<i>exenatide</i>) | T3 | PA |
| OZEMPIK SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG(2 MG/1.5 ML), 1 MG/DOSE (2 MG/1.5 ML), 1 MG/DOSE (4 MG/3 ML) (<i>semaglutide</i>) | T3 | ST |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG (<i>semaglutide</i>) | T3 | ST ; QL (30 EA per 30 days) |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML (<i>dulaglutide</i>) | T3 | ST |
| VICTOZA 2-PAK SUBCUTANEOUS PEN INJECTOR 0.6 MG/0.1 ML (18 MG/3 ML) (<i>liraglutide</i>) | T3 | PA |
| VICTOZA 3-PAK SUBCUTANEOUS PEN INJECTOR 0.6 MG/0.1 ML (18 MG/3 ML) (<i>liraglutide</i>) | T3 | PA |
| Insulins - Drugs For Diabetes | | |
| ADMELOG SOLOSTAR U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (<i>insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| ADMELOG U-100 INSULIN LISPRO SUBCUTANEOUS SOLUTION 100 UNIT/ML (<i>insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| BASAGLAR KWIKPEN U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) (<i>insulin glargine, human recombinant analog</i>) | T3 | QL (30 ML per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| HUMALOG MIX 50-50 INSULN U-100 SUBCUTANEOUS SUSPENSION 100 UNIT/ML (50-50) (<i>insulin lispro protamine and insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| HUMALOG MIX 50-50 KWIKPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (50-50) (<i>insulin lispro protamine and insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| HUMALOG MIX 75-25(U-100)INSULN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (75-25) (<i>insulin lispro protamine and insulin lispro</i>) | T3 | QL (30 QY per 30 DYs) |
| HUMULIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) (<i>insulin nph human isophane/insulin regular, human</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN 70/30 U-100 KWIKPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) (<i>insulin nph human isophane/insulin regular, human</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN N NPH INSULIN KWIKPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) (<i>insulin nph human isophane</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (<i>insulin nph human isophane</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN R REGULAR U-100 INSULN INJECTION SOLUTION 100 UNIT/ML (<i>insulin regular, human</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML (<i>insulin regular, human</i>) | T3 | QL (20 ML per 30 days) |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) (<i>insulin regular, human</i>) | T3 | QL (15 ML per 30 days) |
| <i>insulin asp prt-insulin aspart subcutaneous insulin pen 100 unit/ml (70-30)</i> | T2 | QL (30 ML per 30 days) |
| <i>insulin asp prt-insulin aspart subcutaneous solution 100 unit/ml (70-30)</i> | T2 | QL (30 ML per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| <i>insulin lispro protamin-lispro subcutaneous insulin pen 100 unit/ml (75-25)</i> | T2 | QL (30 ML per 30 days) |
| <i>insulin lispro subcutaneous insulin pen, half-unit 100 unit/ml</i> | T2 | QL (30 ML per 30 days) |
| Intermediate-Acting Insulins - Drugs For Diabetes | | |
| HUMALOG MIX 50-50 INSULN U-100 SUBCUTANEOUS SUSPENSION 100 UNIT/ML (50-50) (<i>insulin lispro protamine and insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| HUMALOG MIX 50-50 KWIKPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (50-50) (<i>insulin lispro protamine and insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| HUMALOG MIX 75-25(U-100)INSULN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (75-25) (<i>insulin lispro protamine and insulin lispro</i>) | T3 | QL (30 QY per 30 DYs) |
| HUMULIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) (<i>insulin nph human isophane/insulin regular, human</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN 70/30 U-100 KWIKPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) (<i>insulin nph human isophane/insulin regular, human</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN N NPH INSULIN KWIKPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) (<i>insulin nph human isophane</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (<i>insulin nph human isophane</i>) | T3 | QL (30 ML per 30 days) |
| <i>insulin asp prt-insulin aspart subcutaneous insulin pen 100 unit/ml (70-30)</i> | T2 | QL (30 ML per 30 days) |
| <i>insulin asp prt-insulin aspart subcutaneous solution 100 unit/ml (70-30)</i> | T2 | QL (30 ML per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|--|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>insulin lispro protamin-lispro subcutaneous insulin pen 100 unit/ml (75-25)</i> | T2 | QL (30 ML per 30 days) |
| Long-Acting Insulins - Drugs For Diabetes | | |
| BASAGLAR KWIKPEN U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) (<i>insulin glargine, human recombinant analog</i>) | T3 | QL (30 ML per 30 days) |
| Meglitinides - Drugs For Diabetes | | |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | T2 | |
| Parathyroid Agents - Drugs For Bones | | |
| FORTEO SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (600MCG/2.4ML) (<i>teriparatide</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) (<i>abaloparatide</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Pituitary - Hormones | | |
| ACTHAR H.P. INJECTION GEL 80 UNIT/ML (<i>corticotropin</i>) | T3 | PA |
| ACTHAR INJECTION GEL 80 UNIT/ML (<i>corticotropin</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| DDAVP NASAL SOLUTION 0.1 MG/ML (REFRIGERATE) (<i>desmopressin acetate</i>) | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml)</i> | | T2 | |
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg</i> | | T2 | |
| Progestins - Drugs For Women | | | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SYRINGE 104 MG/0.65 ML (<i>medroxyprogesterone acetate</i>) | | T3 | |
| <i>hydroxyprogesterone cap(ppres) intramuscular oil 250 mg/ml (1 ml)</i> | | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>hydroxyprogesterone cap(ppres) intramuscular oil 250 mg/ml</i> | | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| MAKENA (PF) SUBCUTANEOUS AUTO-INJECTOR 275 MG/1.1 ML (<i>hydroxyprogesterone caproate/pf</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>medroxyprogesterone intramuscular suspension 150 mg/ml</i> | | Tier 1 | QL (1 ML per 90 days) |
| <i>medroxyprogesterone intramuscular syringe 150 mg/ml</i> | | T2 | QL (1 ML per 90 days) |
| <i>medroxyprogesterone oral tablet 10 mg, 2.5 mg, 5 mg</i> | | T2 | |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml)</i> | | T2 | |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | | T2 | |
| <i>norethindrone acetate oral tablet 5 mg</i> | | T2 | |
| ORIAHNN ORAL CAPSULE, SEQUENTIAL 300-1-0.5MG(AM) /300 MG(PM) (<i>elagolix sodium/estradiol/norethindrone acetate</i>) | | T3 | PA |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> | | T2 | |
| Rapid-Acting Insulins - Drugs For Diabetes | | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|----------------------------------|
| ADMELOG SOLOSTAR U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (<i>insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| ADMELOG U-100 INSULIN LISPRO SUBCUTANEOUS SOLUTION 100 UNIT/ML (<i>insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| HUMALOG MIX 50-50 INSULN U-100 SUBCUTANEOUS SUSPENSION 100 UNIT/ML (50-50) (<i>insulin lispro protamine and insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| HUMALOG MIX 50-50 KWIKPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (50-50) (<i>insulin lispro protamine and insulin lispro</i>) | T3 | QL (30 ML per 30 days) |
| HUMALOG MIX 75-25(U-100)INSULN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (75-25) (<i>insulin lispro protamine and insulin lispro</i>) | T3 | QL (30 QY per 30 DYs) |
| <i>insulin asp prt-insulin aspart subcutaneous insulin pen 100 unit/ml (70-30)</i> | T2 | QL (30 ML per 30 days) |
| <i>insulin asp prt-insulin aspart subcutaneous solution 100 unit/ml (70-30)</i> | T2 | QL (30 ML per 30 days) |
| <i>insulin lispro protamin-lispro subcutaneous insulin pen 100 unit/ml (75-25)</i> | T2 | QL (30 ML per 30 days) |
| <i>insulin lispro subcutaneous insulin pen, half-unit 100 unit/ml</i> | T2 | QL (30 ML per 30 days) |
| Short-Acting Insulins - Drugs For Diabetes | | |
| HUMULIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) (<i>insulin nph human isophane/insulin regular, human</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN 70/30 U-100 KWIKPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) (<i>insulin nph human isophane/insulin regular, human</i>) | T3 | QL (30 ML per 30 days) |
| HUMULIN R REGULAR U-100 INSULN INJECTION SOLUTION 100 UNIT/ML (<i>insulin regular, human</i>) | T3 | QL (30 ML per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML (<i>insulin regular, human</i>) | T3 | QL (20 ML per 30 days) |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) (<i>insulin regular, human</i>) | T3 | QL (15 ML per 30 days) |
| Sodium-Gluc Cotransport 2 (Sglt2) Inhib - Drugs For Diabetes | | |
| FARXIGA ORAL TABLET 10 MG, 5 MG (<i>dapagliflozin propanediol</i>) | T3 | PA |
| JARDIANCE ORAL TABLET 10 MG, 25 MG (<i>empagliflozin</i>) | T3 | PA |
| SEGLUROMET ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 7.5-1,000 MG, 7.5-500 MG (<i>ertugliflozin pidolate/metformin hcl</i>) | T3 | ST |
| STEGLATRO ORAL TABLET 15 MG, 5 MG (<i>ertugliflozin pidolate</i>) | T3 | ST |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 12.5-2.5-1,000 MG, 25-5-1,000 MG, 5-2.5-1,000 MG (<i>empagliflozin linagliptin/metformin hcl</i>) | T3 | PA |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-1,000 MG, 5-500 MG (<i>dapagliflozin propanediol/metformin hcl</i>) | T3 | PA |
| Sulfonylureas - Drugs For Diabetes | | |
| <i>glimepiride oral tablet 1 mg, 2 mg, 4 mg</i> | T2 | |
| <i>glipizide oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>glipizide oral tablet extended release 24hr 10 mg, 2.5 mg, 5 mg</i> | T2 | |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | T2 | |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | T2 | AL (Max 65 Years) |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|---|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>tolazamide oral tablet 250 mg, 500 mg</i> | T2 | |
| Thiazolidinediones - Drugs For Diabetes | | |
| <i>alogliptin-pioglitazone oral tablet 12.5-15 mg, 12.5-30 mg, 12.5-45 mg, 25-15 mg, 25-30 mg, 25-45 mg</i> | T2 | ST |
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i> | T2 | |
| Thyroid Agents - Drugs For The Thyroid | | |
| ARMOUR THYROID ORAL TABLET 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG (<i>thyroid,pork</i>) | T3 | |
| <i>levothyroxine oral tablet 112 mcg</i> | Tier 1 | |
| <i>liothyronine oral tablet 25 mcg, 5 mcg, 50 mcg</i> | T2 | |
| NATURE-THROID ORAL TABLET 130 MG, 16.25 MG, 195 MG, 32.5 MG, 65 MG (<i>thyroid,pork</i>) | T2 | |
| NP THYROID ORAL TABLET 120 MG, 15 MG (<i>thyroid,pork</i>) | T2 | |
| SYNTHROID ORAL TABLET 100 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG (<i>levothyroxine sodium</i>) | T3 | |
| Miscellaneous Therapeutic Agents | | |
| 5-Alpha-Reductase Inhibitors | | |
| <i>dutasteride oral capsule 0.5 mg</i> | T2 | |
| <i>finasteride oral tablet 5 mg</i> | T2 | |
| Alcohol Deterrents - Drugs For Alcohol Dependence | | |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | T2 | |
| <i>naltrexone oral tablet 50 mg</i> | T2 | |
| Antidotes - Drugs For Overdose Or Poisoning | | |
| BAQSIMI NASAL SPRAY, NON-AEROSOL 3 MG/ACTUATION (<i>glucagon</i>) | T3 | QL (1 EA per 30 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| <i>deferoxamine injection recon soln 2 gram, 500 mg</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| FOSRENOL ORAL POWDER IN PACKET 1,000 MG, 750 MG (<i>lanthanum carbonate</i>) | T3 | PA |
| <i>glucagon</i> (Glucagon Emergency Kit (Human) Injection Recon Soln 1 Mg) | T2 | QL (1 Qty per 30 days) |
| <i>lanthanum oral tablet, chewable 1,000 mg, 500 mg, 750 mg</i> | T2 | PA |
| <i>leucovorin calcium oral tablet 10 mg</i> | T2 | AL (Min 21 Years) |
| <i>leucovorin calcium oral tablet 15 mg</i> | T2 | |
| <i>leucovorin calcium oral tablet 25 mg</i> | T2 | |
| <i>leucovorin calcium oral tablet 5 mg</i> | T2 | AL (Min 21 Years) |
| <i>naloxone injection solution 0.4 mg/ml</i> | T3 | |
| <i>naloxone injection syringe 0.4 mg/ml, 1 mg/ml</i> | T3 | |
| NARCAN NASAL SPRAY, NON-AEROSOL 4 MG/ACTUATION (<i>naloxone hcl</i>) | T3 | |
| <i>physostigmine salicylate injection solution 1 mg/ml</i> | T2 | PA |
| <i>phytonadione (vitamin k1) oral tablet 5 mg</i> | T2 | |
| <i>sevelamer carbonate oral powder in packet 0.8 gram, 2.4 gram</i> | T2 | PA |
| <i>sevelamer carbonate oral tablet 800 mg</i> | T2 | ST |
| <i>sevelamer hcl oral tablet 400 mg, 800 mg</i> | T2 | PA |
| SODIUM POLYSTYRENE (SORB FREE) ORAL SUSPENSION 15 GRAM/60 ML (<i>sodium polystyrene sulfonate</i>) | T2 | |
| <i>sodium polystyrene sulfonate oral powder</i> | T2 | |
| SSKI ORAL SOLUTION 1 GRAM/ML (<i>potassium iodide</i>) | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| Antigout Agents - Drugs For Gout | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | T2 | |
| <i>colchicine oral capsule 0.6 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>colchicine oral tablet 0.6 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | T2 | PA |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | T2 | |
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | T2 | |
| <i>probenecid oral tablet 500 mg</i> | T2 | |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i> | T2 | |
| Bone Anabolic Agents | | |
| FORTEO SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (600MCG/2.4ML) (teriparatide) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) (abaloparatide) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Bone Resorption Inhibitors - Drugs For Bone Loss | | |
| <i>alendronate oral solution 70 mg/75 ml</i> | T2 | QL (300 ML per 30 days) |
| <i>alendronate oral tablet 10 mg, 5 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>alendronate oral tablet 35 mg, 70 mg</i> | T2 | |
| <i>calcitonin (salmon) nasal spray,non-aerosol 200 unit/actuation</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|--|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>ibandronate intravenous syringe 3 mg/3 ml</i> | | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>ibandronate oral tablet 150 mg</i> | | T2 | |
| <i>pamidronate intravenous recon soln 30 mg, 90 mg</i> | | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| PROLIA SUBCUTANEOUS SYRINGE 60 MG/ML <i>(denosumab)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>raloxifene oral tablet 60 mg</i> | | T2 | PA |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) <i>(denosumab)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>zoledronic acid intravenous solution 4 mg/5 ml</i> | | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml</i> | | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Cariostatic Agents - Vitamins And Fluoride | | | |
| FLUOR-A-DAY ORAL DROPS 2.5 MG (5.56 MG SOD.FLUORID)/ML <i>(fluoride (sodium))</i> | | T3 | |
| <i>fluoride (sodium) dental solution 0.2 %</i> | | T2 | |
| <i>fluoride (sodium) oral drops 0.5 mg (1.1 mg sod.fluorid)/ml</i> | | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|-----------|---|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| <i>fluoride (sodium) oral tablet, chewable 0.25 mg(0.55 mg sod. fluoride), 0.5 mg (1.1 mg sodium fluorid), 1 mg (2.2 mg sod. fluoride)</i> | T2 | | |
| FLUORITAB ORAL TABLET,CHEWABLE 0.5 MG (1.1 MG SODIUM FLUORID) (<i>fluoride (sodium)</i>) | T2 | | |
| FLURA-DROPS ORAL DROPS 0.25 MG(0.55 MG SOD.FLUOR)/DROP (<i>fluoride (sodium)</i>) | T3 | | |
| MULTI-VIT WITH FLUORIDE-IRON ORAL DROPS 0.25MG FLUORIDE -10 MG IRON/ML (<i>pediatric multivitamin no.45/sodium fluoride/ferrous sulfate</i>) | T2 | AL (Max 5 Years) | |
| MULTI-VITAMIN WITH FLUORIDE ORAL DROPS 0.25 MG/ML (<i>pediatric multivitamin no.2/sodium fluoride</i>) | T2 | AL (Min 5 Years) | |
| MULTI-VITAMIN WITH FLUORIDE ORAL TABLET,CHEWABLE 0.25 MG, 0.5 MG, 1 MG (<i>pediatric multivitamins no.17 with sodium fluoride</i>) | T2 | | |
| TRI-VIT WITH FLUORIDE AND IRON ORAL DROPS 0.25-10 MG/ML (<i>fluoride/iron/vitamins a,c, and d</i>) | T2 | AL (Max 5 Years) | |
| TRI-VITAMIN WITH FLUORIDE ORAL DROPS 0.25 MG FLUOR. (0.55 MG)/ML, 0.5 MG FLUORIDE (1.1 MG)/ML (<i>pediatric multivit with a,c,d3 no.21/sodium fluoride</i>) | T2 | AL (Max 5 Years) | |
| Disease-Modifying Antirheumatic Agents - Drugs For Arthritis | | | |
| ACTEMRA ACTPEN SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML (<i>tocilizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) (<i>tocilizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| ACTEMRA SUBCUTANEOUS SYRINGE 162 MG/0.9 ML (<i>tocilizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| AZASAN ORAL TABLET 100 MG, 75 MG (<i>azathioprine</i>) | T3 | AL (Min 21 Years) |
| <i>azathioprine oral tablet 50 mg</i> | T2 | AL (Min 21 Years) |
| CIMZIA POWDER FOR RECONST SUBCUTANEOUS KIT 400 MG (200 MG X 2 VIALS) (<i>certolizumab pegol</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) (<i>certolizumab pegol</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | T2 | AL (Min 21 Years) |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | T2 | AL (Min 21 Years) |
| DEPEN TITRATABS ORAL TABLET 250 MG (<i>penicillamine</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL SUBCUTANEOUS RECON SOLN 25 MG (1 ML) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML (<i>etanercept</i>) | T3 | PA |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| cyclosporine, modified (Gengraf Oral Solution 100 Mg/Ml) | T2 | AL (Min 21 Years) |
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA PEN PSOR-UVEITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>hydroxychloroquine oral tablet 200 mg</i> | T2 | |
| INFLECTRA INTRAVENOUS RECON SOLN 100 MG (<i>infliximab-dyyb</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| KEVZARA SUBCUTANEOUS PEN INJECTOR 150 MG/1.14 ML, 200 MG/1.14 ML (<i>sarilumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| KEVZARA SUBCUTANEOUS SYRINGE 150 MG/1.14 ML, 200 MG/1.14 ML (<i>sarilumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| KINERET SUBCUTANEOUS SYRINGE 100 MG/0.67 ML (<i>anakinra</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | T2 | |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | T2 | |
| ORENCIA (WITH MALTOSE) INTRAVENOUS RECON SOLN 250 MG (<i>abatacept/maltose</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ORENCIA CLICKJECT SUBCUTANEOUS AUTO-INJECTOR 125 MG/ML (<i>abatacept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML (<i>abatacept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|-----------|---|--|
| | | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies | |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML, 87.5 MG/0.7 ML (<i>abatacept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| OTEZLA ORAL TABLET 30 MG (<i>apremilast</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47), 10 MG (4)-20 MG (4)-30 MG(19) (<i>apremilast</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| OTREXUP (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.4 ML, 15 MG/0.4 ML, 20 MG/0.4 ML, 25 MG/0.4 ML (<i>methotrexate/pf</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| OTREXUP (PF) SUBCUTANEOUS AUTO-INJECTOR 12.5 MG/0.4 ML, 17.5 MG/0.4 ML, 22.5 MG/0.4 ML (<i>methotrexate/pf</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| <i>penicillamine oral capsule 250 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML (<i>methotrexate/pf</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| RENFLEXIS INTRAVENOUS RECON SOLN 100 MG (<i>infliximab-abda</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| RIDAURA ORAL CAPSULE 3 MG (<i>auranofin</i>) | T3 | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| SANDIMMUNE ORAL SOLUTION 100 MG/ML <i>(cyclosporine)</i> | T3 | AL (Min 21 Years) |
| SIMPONI ARIA INTRAVENOUS SOLUTION 12.5 MG/ML <i>(golimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML <i>(golimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML <i>(golimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML <i>(ustekinumab)</i> | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML <i>(ustekinumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| sulfasalazine oral tablet 500 mg | T2 | |
| sulfasalazine oral tablet, delayed release (dr/ec) 500 mg | T2 | |
| TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG <i>(methotrexate sodium)</i> | T3 | |
| XELJANZ ORAL SOLUTION 1 MG/ML <i>(tofacitinib citrate)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| XELJANZ ORAL TABLET 10 MG, 5 MG (<i>tofacitinib citrate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG (<i>tofacitinib citrate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Immunomodulatory Agents - Drugs For The Immune System | | |
| ACTEMRA ACTPEN SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML (<i>tocilizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) (<i>tocilizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ACTEMRA SUBCUTANEOUS SYRINGE 162 MG/0.9 ML (<i>tocilizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| AUBAGIO ORAL TABLET 14 MG, 7 MG (<i>teriflunomide</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| AVONEX (WITH ALBUMIN) INTRAMUSCULAR KIT 30 MCG (<i>interferon beta-1a/albumin human</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT 30 MCG/0.5 ML (<i>interferon beta-1a</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| AVONEX INTRAMUSCULAR SYRINGE KIT 30 MCG/0.5 ML (<i>interferon beta-1a</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| AZASAN ORAL TABLET 100 MG, 75 MG (<i>azathioprine</i>) <i>azathioprine oral tablet 50 mg</i> | T3 T2 | AL (Min 21 Years) AL (Min 21 Years) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG (<i>interferon beta-1b</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| CIMZIA POWDER FOR RECONST SUBCUTANEOUS KIT 400 MG (200 MG X 2 VIALS) (<i>certolizumab pegol</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) (<i>certolizumab pegol</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | T2 | AL (Min 21 Years) |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | T2 | AL (Min 21 Years) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|---|---|
| | | Drug Tier | AL = Age Limit Applies |
| | | NF = Non-Formulary | PA = PA Applies |
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | | T2 = Formulary Generic Drugs | QL = Quantity Limit |
| | | T3 = Formulary Brand Drugs | SP = Specialty Product |
| | | | ST = ST Applies |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| ENBREL SUBCUTANEOUS RECON SOLN 25 MG (1 ML) <i>(etanercept)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML <i>(etanercept)</i> | | T3 | PA |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5) <i>(etanercept)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) <i>(etanercept)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| EXTAVIA SUBCUTANEOUS KIT 0.3 MG <i>(interferon beta-1b)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| EXTAVIA SUBCUTANEOUS RECON SOLN 0.3 MG <i>(interferon beta-1b)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| cyclosporine, modified (Gengraf Oral Solution 100 Mg/MI) | | T2 | AL (Min 21 Years) |
| GILENYA ORAL CAPSULE 0.5 MG <i>(fingolimod hcl)</i> | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|---|--|---|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml</i> | | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>glatiramer acetate</i> (Glatopa Subcutaneous Syringe 20 Mg/ML) | | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML (<i>adalimumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA PEN PSOR-UVEITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML (<i>adalimumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML (<i>adalimumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>hydroxychloroquine oral tablet 200 mg</i> | T2 | |
| INFLECTRA INTRAVENOUS RECON SOLN 100 MG (<i>infliximab-dyyb</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| KEVZARA SUBCUTANEOUS PEN INJECTOR 150 MG/1.14 ML, 200 MG/1.14 ML (<i>sarilumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| KEVZARA SUBCUTANEOUS SYRINGE 150 MG/1.14 ML, 200 MG/1.14 ML (<i>sarilumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|---|
| KINERET SUBCUTANEOUS SYRINGE 100 MG/0.67 ML (<i>anakinra</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | T2 | |
| MAYZENT ORAL TABLET 0.25 MG, 2 MG (<i>siponimod</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| MAYZENT STARTER PACK ORAL TABLETS,DOSE PACK 0.25 MG (12 TABS) (<i>siponimod</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | T2 | |
| ORENCIA (WITH MALTOSE) INTRAVENOUS RECON SOLN 250 MG (<i>abatacept/maltose</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ORENCIA CLICKJECT SUBCUTANEOUS AUTO-INJECTOR 125 MG/ML (<i>abatacept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|---|--|---|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML (<i>abatacept</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML, 87.5 MG/0.7 ML (<i>abatacept</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| OTEZLA ORAL TABLET 30 MG (<i>apremilast</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47), 10 MG (4)-20 MG (4)-30 MG(19) (<i>apremilast</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| OTREXUP (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.4 ML, 15 MG/0.4 ML, 20 MG/0.4 ML, 25 MG/0.4 ML (<i>methotrexate/pf</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| OTREXUP (PF) SUBCUTANEOUS AUTO-INJECTOR 12.5 MG/0.4 ML, 17.5 MG/0.4 ML, 22.5 MG/0.4 ML (<i>methotrexate/pf</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| PLEGRIDY INTRAMUSCULAR SYRINGE 125 MCG/0.5 ML (<i>peginterferon beta-1a</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML (<i>peginterferon beta-1a</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML (<i>peginterferon beta-1a</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML (<i>methotrexate/pf</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| REBIF (WITH ALBUMIN) SUBCUTANEOUS SYRINGE 22 MCG/0.5 ML, 44 MCG/0.5 ML (<i>interferon beta-1a/albumin human</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML, 8.8MCG/0.2ML-22 MCG/0.5ML (6) (<i>interferon beta-1a/albumin human</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| REBIF TITRATION PACK SUBCUTANEOUS SYRINGE 8.8MCG/0.2ML-22 MCG/0.5ML (6) (<i>interferon beta-1a/albumin human</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| RENFLEXIS INTRAVENOUS RECON SOLN 100 MG (<i>infliximab-abda</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| REVLIMID ORAL CAPSULE 10 MG, 15 MG, 25 MG, 5 MG (<i>lenalidomide</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| REVLIMID ORAL CAPSULE 2.5 MG, 20 MG <i>(lenalidomide)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 22 Years) |
| RIDAURA ORAL CAPSULE 3 MG (<i>auranofin</i>) | T3 | |
| SANDIMMUNE ORAL SOLUTION 100 MG/ML <i>(cyclosporine)</i> | T3 | AL (Min 21 Years) |
| SIMPONI ARIA INTRAVENOUS SOLUTION 12.5 MG/ML <i>(golimumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML (<i>golimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML (<i>golimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML <i>(ustekinumab)</i> | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML (<i>ustekinumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>sulfasalazine oral tablet 500 mg</i> | T2 | |
| <i>sulfasalazine oral tablet,delayed release (dr/ec) 500 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | |
|--|---|---|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| THALOMID ORAL CAPSULE 100 MG, 150 MG <i>(thalidomide)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| THALOMID ORAL CAPSULE 200 MG, 50 MG <i>(thalidomide)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG <i>(methotrexate sodium)</i> | T3 | |
| XELJANZ ORAL SOLUTION 1 MG/ML (<i>tofacitinib citrate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| XELJANZ ORAL TABLET 10 MG, 5 MG (<i>tofacitinib citrate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG (<i>tofacitinib citrate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

Immunosuppressive Agents - Drugs For Transplant

| | | |
|--|----|-------------------|
| AZASAN ORAL TABLET 100 MG, 75 MG (<i>azathioprine</i>) | T3 | AL (Min 21 Years) |
| <i>azathioprine oral tablet 50 mg</i> | T2 | AL (Min 21 Years) |
| CELLCEPT ORAL SUSPENSION FOR RECONSTITUTION 200 MG/ML (<i>mycophenolate mofetil</i>) | T3 | AL (Min 21 Years) |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | T2 | AL (Min 21 Years) |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | T2 | AL (Min 21 Years) |
| <i>cyclosporine, modified</i> (Gengraf Oral Solution 100 Mg/MI) | T2 | AL (Min 21 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| LUPKYNIS ORAL CAPSULE 7.9 MG (<i>voclosporin</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>mercaptopurine oral tablet 50 mg</i> | T2 | |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | T2 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | T2 | |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | T2 | AL (Min 21 Years) |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | T2 | AL (Min 21 Years) |
| MYFORTIC ORAL TABLET,DELAYED RELEASE (DR/EC) 180 MG, 360 MG (<i>mycophenolate sodium</i>) | T3 | AL (Min 21 Years) |
| OTREXUP (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.4 ML, 15 MG/0.4 ML, 20 MG/0.4 ML, 25 MG/0.4 ML (<i>methotrexate/pf</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| OTREXUP (PF) SUBCUTANEOUS AUTO-INJECTOR 12.5 MG/0.4 ML, 17.5 MG/0.4 ML, 22.5 MG/0.4 ML (<i>methotrexate/pf</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>pimecrolimus topical cream 1 %</i> | T2 | ST ; AL (Min 2 Years) |
| RAPAMUNE ORAL SOLUTION 1 MG/ML (<i>sirolimus</i>) | T3 | AL (Min 21 Years) |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML (<i>methotrexate/pf</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|--|--|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| SANDIMMUNE ORAL SOLUTION 100 MG/ML (<i>cyclosporine</i>) | T3 | AL (Min 21 Years) |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | T2 | AL (Min 21 Years) |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg</i> | T2 | AL (Min 21 Years) |
| <i>tacrolimus oral capsule 5 mg</i> | T2 | AL (Max 21 Years) |
| TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG (<i>methotrexate sodium</i>) | T3 | |
| ZORTRESS ORAL TABLET 0.25 MG, 0.5 MG, 0.75 MG (<i>everolimus</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); AL (Min 21 Years) |
| Other Miscellaneous Therapeutic Agents | | |
| <i>dalfampridine oral tablet extended release 12 hr 10 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| EVOTAZ ORAL TABLET 300-150 MG (<i>atazanavir sulfate/cobicistat</i>) | T3 | |
| ICAPS AREDS ORAL TABLET,DELAYED RELEASE (DR/EC) 7,160-113-100 UNIT-MG-UNIT (<i>beta-carotene/ascorbic acid/vite ac/zinc oxide/cupric oxide</i>) | T2 | |
| <i>levocarnitine (with sugar) oral solution 100 mg/ml</i> | T2 | |
| <i>levocarnitine oral solution 100 mg/ml</i> | T2 | |
| <i>melatonin oral capsule 10 mg</i> | T2 | |
| <i>melatonin oral liquid 1 mg/ml</i> | T2 | |
| <i>melatonin oral tablet 1 mg, 5 mg</i> | T2 | |
| <i>melatonin oral tablet 3 mg</i> | T2 | |
| PREZCOBIX ORAL TABLET 800-150 MG-MG (<i>darunavir ethanolate/cobicistat</i>) | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| SYMTUZA ORAL TABLET 800-150-200-10 MG (<i>darunavir eth/cobicistat/emtricitabine/tenofovir alafenamide</i>) | T3 | |
| XEOMIN INTRAMUSCULAR RECON SOLN 100 UNIT, 200 UNIT, 50 UNIT (<i>incobotulinumtoxina</i>) | T3 | PA |
| Protective Agents | | |
| ELMIRON ORAL CAPSULE 100 MG (<i>pentosan polysulfate sodium</i>) | T3 | QL (90 EA per 30 days); AL (Min 16 Years) |
| MESNEX ORAL TABLET 400 MG (<i>mesna</i>) | T3 | AL (Min 21 Years) |
| Nonhormonal Contraceptives - Drugs For Women | | |
| Nonhormonal Contraceptives - Drugs For Women | | |
| CAYA CONTOURED VAGINAL DIAPHRAGM 65-80 MM (<i>diaphragms, contoured</i>) | T3 | |
| CONCEPTROL VAGINAL GEL 4 % (<i>nonoxynol 9</i>) | T3 | |
| CONDOMS-PREM LUBRICATED DEVICE (<i>condoms, latex, lubricated</i>) | T2 | |
| DUREX AVANTI BARE REAL FEEL (<i>condoms, non-latex, lubricated</i>) | Tier 1 | |
| FC2 FEMALE CONDOM (<i>condoms, female</i>) | T2 | |
| FEMCAP VAGINAL DEVICE 22 MM, 26 MM, 30 MM (<i>cervical cap</i>) | T3 | |
| GYNOL II VAGINAL GEL 3 % (<i>nonoxynol 9</i>) | T2 | |
| KIMONO CONDOMS(NON-LUBRICATED) DEVICE (<i>condoms, latex, non-lubricated</i>) | T2 | |
| TODAY CONTRACEPTIVE SPONGE VAGINAL CONTRACEPTIVE SPONGE 1,000 MG (<i>nonoxynol 9</i>) | T3 | |
| TRUSTEX NON-LUB CONDOMS DEVICE (<i>condoms, latex, non-lubricated</i>) | T2 | |
| TRUSTEX-RIA NON-LUB CONDOMS DEVICE (<i>condoms, latex, non-lubricated</i>) | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| VAGINAL CONTRACEPTIVE FILM VAGINAL FILM 28 % <i>(nonoxynol 9)</i> | T3 | |
| VAGINAL CONTRACEPTIVE FOAM VAGINAL FOAM 12.5 % <i>(nonoxynol 9)</i> | T2 | |
| VCF CONTRACEPTIVE GEL VAGINAL GEL 4 % <i>(nonoxynol 9)</i> | T2 | |
| WIDE-SEAL DIAPHRAGM 60 VAGINAL DIAPHRAGM 60 MM <i>(diaphragms, wide seal)</i> | T3 | |
| WIDE-SEAL DIAPHRAGM 65 VAGINAL DIAPHRAGM 65 MM <i>(diaphragms, wide seal)</i> | T3 | |
| WIDE-SEAL DIAPHRAGM 70 VAGINAL DIAPHRAGM 70 MM <i>(diaphragms, wide seal)</i> | T3 | |
| WIDE-SEAL DIAPHRAGM 75 VAGINAL DIAPHRAGM 75 MM <i>(diaphragms, wide seal)</i> | T3 | |
| WIDE-SEAL DIAPHRAGM 80 VAGINAL DIAPHRAGM 80 MM <i>(diaphragms, wide seal)</i> | T3 | |
| WIDE-SEAL DIAPHRAGM 85 VAGINAL DIAPHRAGM 85 MM <i>(diaphragms, wide seal)</i> | T3 | |
| WIDE-SEAL DIAPHRAGM 90 VAGINAL DIAPHRAGM 90 MM <i>(diaphragms, wide seal)</i> | T3 | |
| WIDE-SEAL DIAPHRAGM 95 VAGINAL DIAPHRAGM 95 MM <i>(diaphragms, wide seal)</i> | T3 | |
| Oxytocics - Drugs For Women | | |
| Oxytocics - Drugs For Women | | |
| <i>methylergonovine oral tablet 0.2 mg</i> | T2 | |
| Respiratory Tract Agents - Drugs For The Lungs | | |
| Alpha And Beta Adrenergic Agonist(Respr) - Drugs For Asthma/Copd | | |
| APRODINE ORAL TABLET 2.5-60 MG (<i>triprolidine hcl/pseudoephedrine hcl</i>) | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| cetirizine-pseudoephedrine oral tablet extended release 12 hr 5-120 mg | T2 | |
| epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml | T2 | |
| fexofenadine-pseudoephedrine oral tablet extended release 12 hr 60-120 mg | T2 | ST |
| LORATADINE-D ORAL TABLET EXTENDED RELEASE 12 HR 5-120 MG (<i>loratadine/pseudoephedrine sulfate</i>) | T2 | |
| loratadine-pseudoephedrine oral tablet extended release 24 hr 10-240 mg | T2 | |
| SYMJEPI INJECTION SYRINGE 0.15 MG/0.3 ML, 0.3 MG/0.3 ML (<i>epinephrine</i>) | T3 | |
| WAL-FEX D 24 HOUR ORAL TABLET EXTENDED RELEASE 24 HR 180-240 MG (<i>fexofenadine hcl/pseudoephedrine hcl</i>) | T2 | ST |
| WAL-PHED ORAL TABLET 4-60 MG (<i>chlorpheniramine maleate/pseudoephedrine hcl</i>) | T2 | |
| Anticholinergic Agents (Respir.Tract) - Drugs For Asthma/Copd | | |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION (<i>ipratropium bromide</i>) | T3 | |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION (<i>budesonide/glycopyrrolate/formoterol fumarate</i>) | T3 | PA |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION (<i>ipratropium bromide/albuterol sulfate</i>) | T3 | |
| INCRUSE ELLIPTA INHALATION BLISTER WITH DEVICE 62.5 MCG/ACTUATION (<i>umeclidinium bromide</i>) | T3 | QL (30 EA per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | T2 | |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION (<i>tiotropium bromide</i>) | T3 | QL (4 GM per 30 days) |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION (<i>tiotropium bromide/olodaterol hcl</i>) | T3 | QL (4 GM per 30 days) |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200-62.5-25 MCG (<i>fluticasone furoate/umeclidinium bromide/vilanterol trifenat</i>) | T3 | PA |
| Antifibrotic Agents - Drugs For The Lungs | | |
| ESBRIET ORAL CAPSULE 267 MG (<i>pirfenidone</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ESBRIET ORAL TABLET 267 MG, 801 MG (<i>pirfenidone</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| OFEV ORAL CAPSULE 100 MG, 150 MG (<i>nintedanib esylate</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Antitussives - Drugs For Cough And Cold | | |
| <i>benzonatate oral capsule 100 mg</i> | T2 | QL (180 Qty per 30 days) |
| <i>benzonatate oral capsule 200 mg</i> | T2 | QL (90 Qty per 30 days) |
| <i>codeine-guaifenesin oral liquid 10-100 mg/5 ml</i> | T2 | QL (480 ML per 30 days); AL (Min 6 Years) |
| <i>dextromethorphan-guaifenesin oral syrup 10-100 mg/5 ml</i> | T2 | |
| <i>hydrocodone-homatropine oral syrup 5-1.5 mg/5 ml</i> | T2 | QL (240 ML per 30 days); AL (Min 6 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| NUEDEXTA ORAL CAPSULE 20-10 MG (<i>dextromethorphan hbr/quinidine sulfate</i>) | T3 | PA |
| <i>promethazine/phenylephrine hcl/codeine</i> (Promethazine Vc-Codeine Oral Syrup 6.25-5-10 Mg/5 MI) | T2 | AL (Min 12 Years) |
| <i>promethazine-codeine oral syrup 6.25-10 mg/5 ml</i> | T2 | QL (240 ML per 30 days); AL (Min 12 Years) |
| <i>promethazine-dm oral syrup 6.25-15 mg/5 ml</i> | T2 | QL (240 ML per 30 days); AL (Min 4 Years) |
| <i>promethazine-phenyleph-codeine oral syrup 6.25-5-10 mg/5 ml</i> | T2 | AL (Min 12 Years) |
| Cystic Fibrosis (Cftr) Correctors - Drugs For The Lungs | | |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG (<i>lumacaftor/ivacaftor</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ORKAMBI ORAL GRANULES IN PACKET 150-188 MG (<i>lumacaftor/ivacaftor</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ORKAMBI ORAL TABLET 100-125 MG (<i>lumacaftor/ivacaftor</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ORKAMBI ORAL TABLET 200-125 MG (<i>lumacaftor/ivacaftor</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) (<i>tezacaftor/ivacaftor</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) <i>(elexacaftor/tezacaftor/ivacaftor)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| Cystic Fibrosis (Cftr) Potentiators - Drugs For The Lungs | | |
| KALYDECO ORAL GRANULES IN PACKET 25 MG <i>(ivacaftor)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| KALYDECO ORAL GRANULES IN PACKET 50 MG, 75 MG <i>(ivacaftor)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| KALYDECO ORAL TABLET 150 MG <i>(ivacaftor)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG <i>(lumacaftor/ivacaftor)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ORKAMBI ORAL GRANULES IN PACKET 150-188 MG <i>(lumacaftor/ivacaftor)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ORKAMBI ORAL TABLET 100-125 MG <i>(lumacaftor/ivacaftor)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ORKAMBI ORAL TABLET 200-125 MG <i>(lumacaftor/ivacaftor)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|------------------|---|------------------------|
| | | AL = Age Limit Applies | PA = PA Applies |
| | | QL = Quantity Limit | SP = Specialty Product |
| | | ST = ST Applies | |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) (<i>tezacaftor/ivacaftor</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) (<i>elexacaftor/tezacaftor/ivacaftor</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| Expectorants - Drugs For The Lungs | | | |
| <i>codeine-guaifenesin oral liquid 10-100 mg/5 ml</i> | T2 | QL (480 ML per 30 days); AL (Min 6 Years) | |
| <i>dextromethorphan-guaifenesin oral syrup 10-100 mg/5 ml</i> | T2 | | |
| <i>guaifenesin oral liquid 100 mg/5 ml</i> | T2 | | |
| <i>guaifenesin oral tablet 200 mg, 400 mg</i> | T2 | | |
| <i>guaifenesin oral tablet extended release 600 mg</i> | T2 | | |
| SSKI ORAL SOLUTION 1 GRAM/ML (<i>potassium iodide</i>) | T2 | | |
| First Generation Antihist.(Respir Tract) - Drugs For Allergy | | | |
| APRODINE ORAL TABLET 2.5-60 MG (<i>triprolidine hcl/pseudoephedrine hcl</i>) | T2 | | |
| <i>clemastine oral tablet 2.68 mg</i> | T2 | | |
| <i>ciproheptadine oral syrup 2 mg/5 ml</i> | T2 | | |
| <i>ciproheptadine oral tablet 4 mg</i> | T2 | | |
| <i>diphenhydramine hcl oral capsule 50 mg</i> | T2 | | |
| <i>promethazine oral syrup 6.25 mg/5 ml</i> | T2 | | |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | T2 | | |
| <i>phenylephrine hcl/promethazine hcl</i> (Promethazine Vc Oral Syrup 6.25-5 Mg/5 MI) | T2 | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>promethazine/phenylephrine hcl/codeine</i> (Promethazine Vc-Codeine Oral Syrup 6.25-5-10 Mg/5 ML) | T2 | AL (Min 12 Years) |
| <i>promethazine-codeine oral syrup 6.25-10 mg/5 ml</i> | T2 | QL (240 ML per 30 days); AL (Min 12 Years) |
| <i>promethazine-dm oral syrup 6.25-15 mg/5 ml</i> | T2 | QL (240 ML per 30 days); AL (Min 4 Years) |
| <i>promethazine-phenyleph-codeine oral syrup 6.25-5-10 mg/5 ml</i> | T2 | AL (Min 12 Years) |
| SLEEP AID (DOXYLAMINE) ORAL TABLET 25 MG (<i>doxylamine succinate</i>) | T2 | |
| WAL-PHED ORAL TABLET 4-60 MG (<i>chlorpheniramine maleate/pseudoephedrine hcl</i>) | T2 | |
| Interleukin Antagonists - Drugs For Inflammation | | |
| CINQAIR INTRAVENOUS SOLUTION 10 MG/ML (<i>reslizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML (<i>dupilumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML (<i>dupilumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML (<i>benralizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML <i>(benralizumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML <i>(mepolizumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG <i>(mepolizumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML <i>(mepolizumab)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

Leukotriene Modifiers - Drugs For Inflammation

| | | |
|---|----|--|
| <i>montelukast oral granules in packet 4 mg</i> | T2 | QL (30 Qty per 30 days); AL (Min 4 Years and Max 18 Years) |
| <i>montelukast oral tablet 10 mg</i> | T2 | QL (30 Qty per 30 days) |
| <i>montelukast oral tablet, chewable 4 mg</i> | T2 | QL (30 Qty per 30 days); AL (Min 5 Years) |
| <i>montelukast oral tablet, chewable 5 mg</i> | T2 | QL (30 Qty per 30 days); AL (Max 5 Years) |

Mast-Cell Stabilizers - Drugs For Inflammation

| | | |
|---|----|--|
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i> | T2 | |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | T2 | |
| <i>cromolyn oral concentrate 100 mg/5 ml</i> | T2 | |

Mucolytic Agents - Drugs For The Lungs

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| PULMOZYME INHALATION SOLUTION 1 MG/ML <i>(dornase alfa)</i> | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Nasal Preparations (Steroids) - Drugs For Inflammation | | |
| <i>flunisolide nasal spray,non-aerosol 25 mcg (0.025 %)</i> | T2 | ST |
| <i>fluticasone propionate nasal spray,suspension 50 mcg/actuation</i> | T2 | |
| <i>mometasone nasal spray,non-aerosol 50 mcg/actuation</i> | T2 | ST ; QL (17 GM per 30 days) |
| <i>triamcinolone acetonide nasal aerosol,spray 55 mcg</i> | T2 | |
| Non-Select.Beta-Adrenergic Agont(Respir) - Drugs For Asthma/Copd | | |
| ISUPREL INJECTION SOLUTION 0.2 MG/ML <i>(isoproterenol hcl)</i> | T3 | |
| Orally Inhaled Preparations (Steroids) - Drugs For Inflammation | | |
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION (<i>fluticasone propionate/salmeterol xinafoate</i>) | T3 | PA |
| ARNUITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION (<i>fluticasone furoate</i>) | T3 | QL (30 EA per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE (<i>fluticasone furoate/vilanterol trifénatate</i>) | T3 | PA |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION (<i>budesonide/glycopyrrolate/formoterol fumarate</i>) | T3 | PA |
| <i>budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml</i> | T2 | QL (120 ML per 30 days); AL (Max 8 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>budesonide-formoterol inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | | T2 | PA |
| DULERA INHALATION HFA AEROSOL INHALER 100-5 MCG/ACTUATION, 200-5 MCG/ACTUATION, 50-5 MCG/ACTUATION (<i>mometasone furoate/formoterol fumarate</i>) | | T3 | PA ; AL (Max 12 Years) |
| FLOVENT DISKUS INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 250 MCG/ACTUATION, 50 MCG/ACTUATION (<i>fluticasone propionate</i>) | | T3 | |
| FLOVENT HFA INHALATION HFA AEROSOL INHALER 110 MCG/ACTUATION, 220 MCG/ACTUATION, 44 MCG/ACTUATION (<i>fluticasone propionate</i>) | | T3 | |
| <i>fluticasone propion-salmeterol inhalation aerosol powdr breath activated 113-14 mcg/actuation, 232-14 mcg/actuation, 55-14 mcg/actuation</i> | | T2 | QL (1 EA per 30 days) |
| <i>fluticasone propion-salmeterol inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | | T2 | |
| QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION, 80 MCG/ACTUATION (<i>beclomethasone dipropionate</i>) | | T3 | |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200-62.5-25 MCG (<i>fluticasone furoate/umeclidinium bromide/vilanterol trifenat</i>) | | T3 | PA |
| <i>fluticasone propionate/salmeterol xinafoate</i> (Wixela Inhub Inhalation Blister With Device 100-50 Mcg/Dose, 250-50 Mcg/Dose, 500-50 Mcg/Dose) | | T2 | |
| Phosphodiesterase Type 4 Inhibitors - Drugs For The Lungs | | | |
| DALIRESP ORAL TABLET 250 MCG, 500 MCG (<i>roflumilast</i>) | | T3 | PA |
| Respiratory Tract Agents, Miscellaneous - Drugs For The Lungs | | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|--|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG (<i>omalizumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML (<i>omalizumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| Second Generation Antihist(Respir Tract) - Drugs For Allergy | | | |
| ALL DAY ALLERGY (CETIRIZINE) ORAL TABLET 10 MG (<i>cetirizine hcl</i>) | | T2 | |
| ALLERGY RELIEF (LORATADINE) ORAL TABLET,DISINTEGRATING 10 MG (<i>loratadine</i>) | | T2 | |
| <i>cetirizine oral solution 1 mg/ml</i> | | T2 | |
| <i>cetirizine oral tablet 5 mg</i> | | T2 | |
| <i>cetirizine-pseudoephedrine oral tablet extended release 12 hr 5-120 mg</i> | | T2 | |
| <i>desloratadine oral tablet 5 mg</i> | | T2 | |
| <i>fexofenadine oral suspension 30 mg/5 ml</i> | | T2 | |
| <i>fexofenadine oral tablet 180 mg, 60 mg</i> | | T2 | |
| <i>fexofenadine-pseudoephedrine oral tablet extended release 12 hr 60-120 mg</i> | | T2 | ST |
| <i>levocetirizine oral solution 2.5 mg/5 ml</i> | | T2 | |
| <i>levocetirizine oral tablet 5 mg</i> | | T2 | |
| <i>loratadine oral tablet 10 mg</i> | | T2 | |
| LORATADINE-D ORAL TABLET EXTENDED RELEASE 12 HR 5-120 MG (<i>loratadine/pseudoephedrine sulfate</i>) | | T2 | |
| <i>loratadine-pseudoephedrine oral tablet extended release 24 hr 10-240 mg</i> | | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | |
|---|---|---|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| WAL-FEX D 24 HOUR ORAL TABLET EXTENDED RELEASE 24 HR 180-240 MG (<i>fexofenadine hcl/pseudoephedrine hcl</i>) | T2 | ST |
| WAL-ITIN ORAL SOLUTION 5 MG/5 ML (<i>loratadine</i>) | T2 | QL (300 ML per 30 days) |
| Select.Beta-2-Adrenergic Agonist(Respir) - Drugs For Asthma/Copd | | |
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION (<i>fluticasone propionate/salmeterol xinafoate</i>) | T3 | PA |
| <i>albuterol hfa 90 mcg inhaler 90 mcg/actuation</i> | T2 | QL (2 INH per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 5 mg/ml</i> | T2 | |
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i> | T2 | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | T2 | |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE (<i>fluticasone furoate/vilanterol trifenatate</i>) | T3 | PA |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION (<i>budesonide/glycopyrrolate/formoterol fumarate</i>) | T3 | PA |
| <i>budesonide-formoterol inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | T2 | PA |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION (<i>ipratropium bromide/albuterol sulfate</i>) | T3 | |
| DULERA INHALATION HFA AEROSOL INHALER 100-5 MCG/ACTUATION, 200-5 MCG/ACTUATION, 50-5 MCG/ACTUATION (<i>mometasone furoate/formoterol fumarate</i>) | T3 | PA ; AL (Max 12 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>fluticasone propion-salmeterol inhalation aerosol powdr breath activated 113-14 mcg/actuation, 232-14 mcg/actuation, 55-14 mcg/actuation</i> | T2 | QL (1 EA per 30 days) |
| <i>fluticasone propion-salmeterol inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | T2 | |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | T2 | |
| <i>levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml</i> | T2 | ST |
| <i>levalbuterol tartrate inhalation hfa aerosol inhaler 45 mcg/actuation</i> | T2 | ST |
| <i>metaproterenol oral syrup 10 mg/5 ml</i> | T2 | |
| <i>metaproterenol oral tablet 10 mg, 20 mg</i> | T2 | |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE (<i>salmeterol xinafoate</i>) | T3 | |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION (<i>tiotropium bromide/olodaterol hcl</i>) | T3 | QL (4 GM per 30 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i> | T2 | |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200-62.5-25 MCG (<i>fluticasone furoate/umeclidinium bromide/vilanterol trifenat</i>) | T3 | PA |
| <i>fluticasone propionate/salmeterol xinafoate</i> (Wixela Inhub Inhalation Blister With Device 100-50 Mcg/Dose, 250-50 Mcg/Dose, 500-50 Mcg/Dose) | T2 | |
| Vasodilating Agents (Respiratory Tract) - Drugs For The Lungs | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG (<i>riociguat</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|--|
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| OPSUMIT ORAL TABLET 10 MG (<i>macitentan</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG (<i>treprostinil diolamine</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>sildenafil (pulm.hypertension) oral suspension for reconstitution 10 mg/ml</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug); QL (90 EA per 30 days) |
| <i>tadalafil (pulm. hypertension) oral tablet 20 mg</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| TRACLEER ORAL TABLET FOR SUSPENSION 32 MG (<i>bosentan</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|------------------|--|--|
| | | Drug Tier AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies | |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| <i>treprostinil sodium injection solution 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml</i> | T2 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| TYVASO INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) (<i>treprostinil</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| TYVASO REFILL KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) (<i>treprostinil/nebulizer accessories</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| TYVASO STARTER KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (<i>treprostinil/nebulizer and accessories</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| UPTRAVI ORAL TABLET 1,000 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG (<i>selexipag</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| UPTRAVI ORAL TABLET 1,200 MCG, 1,400 MCG, 1,600 MCG (<i>selexipag</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)-800 MCG (60) (<i>selexipag</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) | |
| VENTAVIS INHALATION SOLUTION FOR NEBULIZATION 10 MCG/ML, 20 MCG/ML (<i>iloprost tromethamine</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) | |
| Xanthine Derivatives - Drugs For Asthma/Copd | | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| THEO-24 ORAL CAPSULE, EXTENDED RELEASE 24HR 100 MG, 200 MG, 300 MG, 400 MG (<i>theophylline anhydrous</i>) | T3 | |
| THEOCHRON ORAL TABLET EXTENDED RELEASE 12 HR 300 MG (<i>theophylline anhydrous</i>) | T2 | |
| <i>theophylline oral elixir 80 mg/15 ml</i> | T2 | |
| <i>theophylline oral tablet extended release 12 hr 450 mg</i> | T2 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | T2 | |
| <i>theophylline oral tablet extended release 600 mg</i> | T2 | |
| Skin And Mucous Membrane Agents - Drugs For The Skin | | |
| Allylamines (Skin And Mucous Membrane) - Drugs For The Skin | | |
| <i>terbinafine hcl topical cream 1 %</i> | T2 | |
| Antibacterials (Skin, Mucous Membrane) - Drugs For The Skin | | |
| <i>bacitracin-polymyxin b topical ointment 500-10,000 unit/gram</i> | T2 | |
| <i>clindamycin phosphate topical gel 1 %</i> | T2 | QL (60 GM per 30 days) |
| <i>clindamycin phosphate topical lotion 1 %</i> | T2 | QL (6 fills per 365 days) |
| <i>clindamycin phosphate topical solution 1 %</i> | T2 | QL (6 fills per 365 days) |
| <i>clindamycin phosphate topical swab 1 %</i> | T2 | QL (6 fills per 365 days) |
| <i>clindamycin phosphate vaginal cream 2 %</i> | T2 | |
| <i>ERY PADS TOPICAL SWAB 2 % (erythromycin base in ethanol)</i> | T2 | QL (6 fills per 365 days) |
| <i>erythromycin with ethanol topical gel 2 %</i> | T2 | QL (6 fills per 365 days) |
| <i>erythromycin with ethanol topical solution 2 %</i> | T2 | QL (6 fills per 365 days) |
| <i>erythromycin-benzoyl peroxide topical gel 3-5 %</i> | T2 | QL (6 fills per 365 days) |
| <i>gentamicin topical cream 0.1 %</i> | T2 | QL (2 fills per 365 days) |
| <i>gentamicin topical ointment 0.1 %</i> | T2 | QL (2 fills per 365 days) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| <i>metronidazole topical cream 0.75 %</i> | T2 | |
| <i>metronidazole topical gel 0.75 %</i> | T2 | |
| <i>mupirocin topical ointment 2 %</i> | T2 | QL (30 GM per 30 days) |
| VANDAZOLE VAGINAL GEL 0.75 % (<i>metronidazole</i>) | T3 | |
| Antipruritics And Local Anesthetics - Drugs For The Skin | | |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> | T2 | PA |
| <i>lidocaine topical ointment 5 %</i> | T2 | QL (71 GM per 30 days) |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i> | T2 | QL (30 GM per 30 days) |
| <i>phenazopyridine oral tablet 100 mg, 200 mg</i> | T2 | |
| <i>hydrocortisone acetate/pramoxine hcl</i> (Proctofoam Hc Rectal Foam 1-1 %) | T3 | PA |
| Azoles (Skin And Mucous Membrane) - Drugs For The Skin | | |
| <i>clotrimazole mucous membrane troche 10 mg</i> | T2 | |
| <i>clotrimazole topical cream 1 %</i> | T2 | |
| <i>clotrimazole topical solution 1 %</i> | T2 | |
| <i>clotrimazole-betamethasone topical cream 1-0.05 %</i> | T2 | |
| <i>econazole topical cream 1 %</i> | T2 | QL (30 GM per 30 days) |
| <i>ketoconazole topical cream 2 %</i> | T2 | QL (60 GM per 30 days) |
| <i>ketoconazole topical shampoo 2 %</i> | T2 | |
| <i>miconazole nitrate vaginal cream 2 %</i> | T2 | |
| MICONAZOLE-3 VAGINAL SUPPOSITORY 200 MG (<i>miconazole nitrate</i>) | T2 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | T2 | |
| Basic Lotions And Liniments - Drugs For The Skin | | |
| <i>ammonium lactate topical lotion 12 %</i> | T2 | |
| Cell Stimulants And Proliferants - Drugs For The Skin | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | |
|--|---|---|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|--|
| AVITA TOPICAL GEL 0.025 % (<i>tretinoin</i>) | T2 | QL (45 GM per 30 days); AL (Max 20 Years) |
| <i>tretinoin topical cream 0.025 %</i> | T2 | PA ; QL (45 GM per 30 days); AL (Max 20 Years) |
| <i>tretinoin topical cream 0.05 %, 0.1 %</i> | T2 | PA ; QL (45 QY per 30 DYs); AL (Max 21 Years) |
| <i>tretinoin topical gel 0.01 %</i> | T2 | PA ; QL (45 QY per 30 DYs); AL (Max 21 Years) |
| <i>tretinoin topical gel 0.025 %</i> | T2 | PA ; QL (45 GM per 30 days); AL (Max 20 Years) |
| <i>tretinoin topical gel 0.05 %</i> | T2 | PA ; QL (45 GM per 30 days); AL (Max 21 Years) |

Corticosteroids (Skin, Mucous Membrane) - Drugs For The Skin

| | | |
|---|----|--|
| <i>hydrocortisone</i> (Ala-Scalp Topical Lotion 2 %) | T2 | |
| <i>alclometasone topical cream 0.05 %</i> | T2 | |
| <i>alclometasone topical ointment 0.05 %</i> | T2 | |
| ANTI-ITCH (HC) TOPICAL LOTION 1 % (<i>hydrocortisone</i>) | T2 | |
| <i>betamethasone dipropionate topical cream 0.05 %</i> | T2 | |
| <i>betamethasone dipropionate topical lotion 0.05 %</i> | T2 | |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | T2 | |
| <i>betamethasone valerate topical cream 0.1 %</i> | T2 | |
| <i>betamethasone valerate topical lotion 0.1 %</i> | T2 | |
| <i>betamethasone valerate topical ointment 0.1 %</i> | T2 | |
| <i>betamethasone, augmented topical cream 0.05 %</i> | T2 | |
| <i>clobetasol topical cream 0.05 %</i> | T2 | |
| <i>clobetasol topical ointment 0.05 %</i> | T2 | |
| <i>clotrimazole-betamethasone topical cream 1-0.05 %</i> | T2 | |
| <i>hydrocortisone</i> (Colocort Rectal Enema 100 Mg/60 MI) | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| <i>clobetasol propionate</i> (Cormax Scalp Solution 0.05 %) | T2 | |
| CORTIFOAM RECTAL FOAM 10 % (80 MG) <i>(hydrocortisone acetate)</i> | T3 | PA |
| <i>desonide topical ointment 0.05 %</i> | T2 | |
| <i>desoximetasone topical ointment 0.25 %</i> | T2 | |
| <i>fluocinolone topical cream 0.025 %</i> | T2 | |
| <i>fluocinolone topical ointment 0.025 %</i> | T2 | |
| <i>fluocinonide topical cream 0.05 %</i> | T2 | |
| <i>fluocinonide topical gel 0.05 %</i> | T2 | |
| <i>fluocinonide topical ointment 0.05 %</i> | T2 | |
| <i>fluocinonide topical solution 0.05 %</i> | T2 | |
| <i>fluocinonide/emollient base</i> (Fluocinonide-E Topical Cream 0.05 %) | T2 | |
| <i>fluticasone propionate topical cream 0.05 %</i> | T2 | |
| <i>fluticasone propionate topical ointment 0.005 %</i> | T2 | |
| <i>hydrocortisone acetate rectal suppository 25 mg</i> | T2 | |
| <i>hydrocortisone acetate rectal suppository 30 mg</i> | T2 | PA |
| <i>hydrocortisone acetate topical cream 0.5 %, 1 %</i> | T2 | |
| <i>hydrocortisone acetate topical ointment 1 %</i> | T2 | |
| <i>hydrocortisone topical cream 0.5 %, 1 %, 2.5 %</i> | T2 | |
| <i>hydrocortisone topical lotion 1 %, 2.5 %</i> | T2 | |
| <i>hydrocortisone topical ointment 1 %, 2.5 %</i> | T2 | |
| <i>mometasone topical cream 0.1 %</i> | T2 | |
| <i>mometasone topical ointment 0.1 %</i> | T2 | |
| <i>hydrocortisone acetate/pramoxine hcl</i> (Proctofoam Hc Rectal Foam 1-1 %) | T3 | PA |
| <i>hydrocortisone</i> (Proctozone-Hc Topical Cream With Perineal Applicator 2.5 %) | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| SCALPICIN ANTI-ITCH TOPICAL SOLUTION 1 % (<i>hydrocortisone</i>) | T2 | |
| <i>triamcinolone acetonide topical cream 0.025 %, 0.1 %, 0.5 %</i> | T2 | |
| <i>triamcinolone acetonide topical lotion 0.025 %, 0.1 %</i> | T2 | |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | T2 | |
| Hydroxypyridones (Skin, Mucous Membrane) - Drugs For The Skin | | |
| <i>ciclopirox topical solution 8 %</i> | T2 | |
| <i>ciclopirox topical suspension 0.77 %</i> | T2 | |
| Keratolytic Agents - Drugs For The Skin | | |
| <i>benzoyl peroxide topical gel 10 %, 2.5 %, 5 %</i> | T2 | |
| PANOXYL TOPICAL CLEANSER 10 % (<i>benzoyl peroxide</i>) | T2 | |
| <i>sulfacetamide sodium-sulfur topical cleanser 10-5 % (w/w)</i> | T2 | |
| <i>sulfacetamide sodium-sulfur topical lotion 10-5 % (w/v)</i> | T2 | |
| <i>urea topical cream 40 %</i> | T2 | QL (200 GM per 30 days) |
| Local Anti-Infectives, Miscellaneous - Drugs For The Skin | | |
| ALCOHOL PREP PADS TOPICAL PADS, MEDICATED (<i>alcohol antiseptic pads</i>) | T3 | |
| <i>chlorhexidine gluconate (bulk) solution 20 %</i> | T2 | |
| DY-O-DERM SOLUTION (<i>isopropyl alcohol</i>) | T2 | |
| <i>selenium sulfide topical lotion 2.5 %</i> | T2 | |
| <i>silver sulfadiazine topical cream 1 %</i> | T2 | |
| <i>sulfacetamide sodium (acne) topical suspension 10 %</i> | T2 | |
| <i>sulfacetamide sodium-sulfur topical cleanser 10-5 % (w/w)</i> | T2 | |
| <i>sulfacetamide sodium-sulfur topical lotion 10-5 % (w/v)</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| ULESFIA TOPICAL LOTION 5 % (<i>benzyl alcohol</i>) | T3 | ST |
| Nonsteroidal Anti-Inflammat.Agents(Skin) - Drugs For The Skin | | |
| <i>diclofenac epolamine transdermal patch 12 hour 1.3 %</i> | T2 | PA |
| <i>diclofenac sodium topical drops 1.5 %</i> | T2 | PA |
| <i>diclofenac sodium topical gel 1 %</i> | T2 | QL (200 GM per 25 days) |
| <i>diclofenac sodium topical gel 3 %</i> | T2 | PA |
| PENNSAID TOPICAL SOLUTION IN METERED-DOSE PUMP 20 MG/GRAM /ACTUATION(2 %) (<i>diclofenac sodium</i>) | T3 | PA |
| Polyenes (Skin And Mucous Membrane) - Drugs For The Skin | | |
| <i>nystatin topical cream 100,000 unit/gram</i> | T2 | |
| <i>nystatin topical ointment 100,000 unit/gram</i> | T2 | |
| <i>nystatin topical powder 100,000 unit/gram</i> | T2 | |
| <i>nystatin-triamcinolone topical cream 100,000-0.1 unit/g-%</i> | T2 | |
| <i>nystatin-triamcinolone topical ointment 100,000-0.1 unit/gram-%</i> | T2 | |
| Scabicides And Pediculicides - Drugs For The Skin | | |
| COMPLETE LICE TREATMENT TOPICAL KIT 4-0.33-0.5 % (<i>piperonyl butoxide/pyrethrins/permethrin</i>) | T2 | |
| EURAX TOPICAL CREAM 10 % (<i>crotamiton</i>) | T3 | |
| <i>ivermectin topical lotion 0.5 %</i> | T2 | ST |
| LICE KILLING (PERMETHRIN) TOPICAL LIQUID 1 % (<i>permethrin</i>) | T2 | |
| LICE KILLING TOPICAL SHAMPOO 0.33-4 % (<i>piperonyl butoxide/pyrethrins</i>) | T2 | |
| <i>malathion topical lotion 0.5 %</i> | T2 | ST |
| <i>permethrin topical cream 5 %</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|--|----------------------------------|--|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| <i>spinosad topical suspension 0.9 %</i> | | T2 | ST |
| ULESFIA TOPICAL LOTION 5 % (<i>benzyl alcohol</i>) | | T3 | ST |
| Skin And Mucous Membrane Agents, Misc. - Drugs For The Skin | | | |
| ABSORICA LD ORAL CAPSULE 16 MG, 24 MG, 32 MG, 8 MG (<i>isotretinoin, micronized</i>) | | T3 | PA |
| <i>isotretinoin</i> (Amnesteem Oral Capsule 10 Mg, 20 Mg, 40 Mg) | | T2 | PA |
| <i>calcipotriene scalp solution 0.005 %</i> | | T2 | ST |
| <i>calcipotriene topical cream 0.005 %</i> | | T2 | ST |
| <i>calcipotriene topical ointment 0.005 %</i> | | T2 | ST |
| <i>isotretinoin</i> (Claravis Oral Capsule 10 Mg, 20 Mg, 30 Mg, 40 Mg) | | T2 | PA |
| CONDYLOX TOPICAL GEL 0.5 % (<i>podofilox</i>) | | T3 | |
| COSENTYX (2 SYRINGES) SUBCUTANEOUS SYRINGE 150 MG/ML (<i>secukinumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| COSENTYX PEN (2 PENS) SUBCUTANEOUS PEN INJECTOR 150 MG/ML (<i>secukinumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| COSENTYX PEN SUBCUTANEOUS PEN INJECTOR 150 MG/ML (<i>secukinumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| COSENTYX SUBCUTANEOUS SYRINGE 150 MG/ML (<i>secukinumab</i>) | | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML (<i>secukinumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| DIFFERIN TOPICAL GEL 0.1 % (<i>adapalene</i>) | T3 | |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML (<i>dupilumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML (<i>dupilumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL SUBCUTANEOUS RECON SOLN 25 MG (1 ML) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML (<i>etanercept</i>) | T3 | PA |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) (<i>etanercept</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>fluorouracil topical cream 5 %</i> | T2 | |
| <i>fluorouracil topical solution 2 %, 5 %</i> | T2 | |
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA PEN PSOR-UVEITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML (<i>adalimumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>imiquimod topical cream in packet 5 %</i> | T2 | |
| INFLECTRA INTRAVENOUS RECON SOLN 100 MG (<i>infliximab-dyyb</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg</i> | T2 | PA |
| <i>isotretinoin</i> (Myorisan Oral Capsule 10 Mg, 20 Mg, 30 Mg, 40 Mg) | T2 | PA |
| OTEZLA ORAL TABLET 30 MG (<i>apremilast</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|---|-----------|---|
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47), 10 MG (4)-20 MG (4)-30 MG(19) (<i>apremilast</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>pimecrolimus topical cream 1 %</i> | T2 | ST ; AL (Min 2 Years) |
| <i>podofilox topical solution 0.5 %</i> | T2 | |
| RENFLEXIS INTRAVENOUS RECON SOLN 100 MG (<i>infliximab-abda</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM (<i>collagenase clostridium histolyticum</i>) | T3 | PA |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML (<i>ustekinumab</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML (<i>ustekinumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug) |
| <i>tacrolimus topical ointment 0.03 %</i> | T2 | ST ; QL (30 Qty per 30 days); AL (Min 2 Years) |
| <i>tacrolimus topical ointment 0.1 %</i> | T2 | ST ; QL (30 Qty per 30 days); AL (Min 16 Years) |
| TALTZ AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML (<i>ixekizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| TALTZ SYRINGE SUBCUTANEOUS SYRINGE 80 MG/ML (<i>ixekizumab</i>) | T3 | PA ; SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| Coverage Requirements and Limits | | |
|---|---|--|
| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| TARGRETIN TOPICAL GEL 1 % (<i>bexarotene</i>) | T3 | SP (Drug may require distribution through a specialty pharmacy or is a limited distribution drug.) |
| <i>isotretinoin</i> (Zenatane Oral Capsule 10 Mg, 20 Mg, 30 Mg, 40 Mg) | T2 | PA |
| Smooth Muscle Relaxants - Drugs To Relax Muscles | | |
| Antimuscarinics - Drugs For The Urinary System | | |
| <i>darifenacin oral tablet extended release 24 hr 15 mg, 7.5 mg</i> | T2 | PA |
| <i>flavoxate oral tablet 100 mg</i> | T2 | PA |
| GELNIQUE TRANSDERMAL GEL IN METERED-DOSE PUMP 100 MG/GRAM (10 %) (<i>oxybutynin chloride</i>) | T3 | PA |
| GELNIQUE TRANSDERMAL GEL IN PACKET 10 % (100 MG/GRAM) (<i>oxybutynin chloride</i>) | T3 | PA |
| <i>oxybutynin chloride oral syrup 5 mg/5 ml</i> | T2 | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | T2 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 15 mg, 5 mg</i> | T2 | |
| <i>solifenacin oral tablet 10 mg, 5 mg</i> | T2 | PA |
| <i>tolterodine oral capsule,extended release 24hr 2 mg, 4 mg</i> | T2 | ST |
| <i>tolterodine oral tablet 1 mg, 2 mg</i> | T2 | ST |
| TOVIAZ ORAL TABLET EXTENDED RELEASE 24 HR 4 MG, 8 MG (<i>fesoterodine fumarate</i>) | T3 | PA |
| <i>trospium oral capsule,extended release 24hr 60 mg</i> | T2 | ST |
| <i>trospium oral tablet 20 mg</i> | T2 | ST |
| Respiratory Smooth Muscle Relaxants - Drugs For Lungs | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|--|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| THEO-24 ORAL CAPSULE, EXTENDED RELEASE 24HR 100 MG, 200 MG, 300 MG, 400 MG (<i>theophylline anhydrous</i>) | T3 | |
| THEOCHRON ORAL TABLET EXTENDED RELEASE 12 HR 300 MG (<i>theophylline anhydrous</i>) | T2 | |
| <i>theophylline oral elixir 80 mg/15 ml</i> | T2 | |
| <i>theophylline oral tablet extended release 12 hr 450 mg</i> | T2 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | T2 | |
| <i>theophylline oral tablet extended release 600 mg</i> | T2 | |
| Selective Beta-3-Adrenergic Agonists - Drugs For The Urinary System | | |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR 25 MG, 50 MG (<i>mirabegron</i>) | T3 | PA |
| Vitamins | | |
| Multivitamin Preparations | | |
| CERTA PLUS ORAL TABLET 18-0.4-250 MG-MG-MCG (<i>folic acid/multivit with iron, minerals/lutein</i>) | T2 | |
| COMPLETENATE ORAL TABLET, CHEWABLE 29 MG IRON- 1 MG (<i>prenatal vitamins no.14/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| DAILY MULTI-VITAMIN ORAL TABLET (<i>multivitamin</i>) | T2 | |
| KPN ORAL TABLET (<i>prenatal vitamin calcium,iron,folic acid (less than 1 mg)</i>) | T2 | AL (Max 50 Years) |
| MULTI-VIT WITH FLUORIDE-IRON ORAL DROPS 0.25MG FLUORIDE -10 MG IRON/ML (<i>pediatric multivitamin no.45/sodium fluoride/ferrous sulfate</i>) | T2 | AL (Max 5 Years) |
| MULTI-VITAMIN WITH FLUORIDE ORAL DROPS 0.25 MG/ML, 0.5 MG/ML (<i>pediatric multivitamin no.2/sodium fluoride</i>) | T2 | AL (Min 5 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| MULTI-VITAMIN WITH FLUORIDE ORAL TABLET,CHEWABLE 0.25 MG, 0.5 MG, 1 MG (<i>pediatric multivitamins no.17 with sodium fluoride</i>) | T2 | |
| MYNATAL ORAL CAPSULE 65 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| MYNATAL-Z ORAL TABLET 65 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| O-CAL FA ORAL TABLET 66 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATABS FA ORAL TABLET 29-1 MG (<i>prenatal vits with calcium no.78/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATABS RX ORAL TABLET 29 MG IRON- 1 MG (<i>prenatal vitamin with calcium no.76/iron,carbonyl/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATAL 19 ORAL TABLET,CHEWABLE 29 MG IRON- 1 MG (<i>prenatal vits with calcium no.115/iron fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATAL LOW IRON ORAL TABLET 27 MG IRON- 1 MG (<i>prenatal vits with calcium no.74/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATAL MULTIVITAMINS ORAL TABLET 28 MG IRON- 800 MCG (<i>prenatal vits with calcium 95/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATAL PLUS ORAL TABLET 29 MG IRON- 1 MG (<i>prenatal vits with calcium no.72/iron,carbonyl/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATAL VITAMIN PLUS LOW IRON ORAL TABLET 27 MG IRON- 1 MG (<i>prenatal vits with calcium no.72/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| PRENATAL VITAMIN WITH MINERALS ORAL TABLET 28 MG IRON- 800 MCG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| lowercase bold italics = Generic drugs UPPERCASE = Brand name drugs | Drug Tier NF = Non-Formulary T2 = Formulary Generic Drugs T3 = Formulary Brand Drugs | Coverage Requirements and Limits AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
|---|---|---|
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
| PRENATAL-U ORAL CAPSULE 106.5-1 MG (<i>multivitamin combination no.51/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| SE-NATAL 19 CHEWABLE ORAL TABLET,CHEWABLE 29 MG IRON- 1 MG (<i>prenatal vits with calcium 118/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| TRICARE ORAL TABLET 27 MG IRON- 1 MG (<i>prenatal vits with calcium 103/ferrous fumarate/folic acid</i>) | T3 | AL (Max 50 Years) |
| TRINATE ORAL TABLET 28 MG IRON- 1 MG (<i>prenatal vits with calcium no.73/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| TRI-VI-SOL ORAL DROPS 250 MCG-50 MG- 10 MCG/ML (<i>vitamin a palmitate/ascorbic acid/cholecalciferol (vit d3)</i>) | T3 | |
| TRI-VIT WITH FLUORIDE AND IRON ORAL DROPS 0.25-10 MG/ML (<i>fluoride/iron/vitamins a,c, and d</i>) | T2 | AL (Max 5 Years) |
| TRI-VITAMIN WITH FLUORIDE ORAL DROPS 0.25 MG FLUOR. (0.55 MG)/ML, 0.5 MG FLUORIDE (1.1 MG)/ML (<i>pediatric multivit with a,c,d3 no.21/sodium fluoride</i>) | T2 | AL (Max 5 Years) |
| TRUST NATAL DHA ORAL COMBO PACK 29-1-250-200 MG (<i>prenatal vitamin no.52/iron/folic acid/omega-3/dha</i>) | T2 | AL (Max 50 Years) |
| VINATE II ORAL TABLET 29 MG IRON- 1 MG (<i>prenatal vitamins with calcium/iron fum,b-g/folic acid</i>) | T2 | AL (Max 50 Years) |
| VINATE M ORAL TABLET 27 MG IRON-1 MG (<i>prenatal vits with calcium 136/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| VINATE ONE ORAL TABLET 60 MG IRON-1 MG (<i>prenatal vitamin 27 with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) |
| Vitamin A | | |
| TRI-VI-SOL ORAL DROPS 250 MCG-50 MG- 10 MCG/ML (<i>vitamin a palmitate/ascorbic acid/cholecalciferol (vit d3)</i>) | T3 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|---|--|----------------------------------|---|
| | | AL = Age Limit Applies | |
| | | PA = PA Applies | |
| | | QL = Quantity Limit | |
| | | SP = Specialty Product | |
| | | ST = ST Applies | |
| Prescription Drug Name | | Drug Tier | Coverage Requirements and Limits |
| TRI-VITAMIN WITH FLUORIDE ORAL DROPS 0.25 MG FLUOR. (0.55 MG)/ML, 0.5 MG FLUORIDE (1.1 MG)/ML (<i>pediatric multivit with a,c,d3 no.21/sodium fluoride</i>) | | T2 | AL (Max 5 Years) |
| Vitamin B Complex | | | |
| CERTA PLUS ORAL TABLET 18-0.4-250 MG-MG-MCG (<i>folic acid/multivit with iron, minerals/lutein</i>) | | T2 | |
| <i>cyanocobalamin (vitamin b-12) injection solution 1,000 mcg/ml</i> | | T2 | |
| <i>cyanocobalamin (vitamin b-12) oral tablet extended release 1,000 mcg</i> | | T2 | |
| <i>folic acid oral tablet 1 mg</i> | | T2 | |
| MYNATAL ORAL CAPSULE 65 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | | T2 | AL (Max 50 Years) |
| MYNATAL-Z ORAL TABLET 65 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | | T2 | AL (Max 50 Years) |
| NEPHRO-VITE RX ORAL TABLET 1-60-300 MG-MG-MCG (<i>vitamin b complex no.3/folic acid/ascorbic acid(vitc)/biotin</i>) | | T2 | |
| O-CAL FA ORAL TABLET 66 MG IRON- 1 MG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | | T2 | AL (Max 50 Years) |
| PRENATABS FA ORAL TABLET 29-1 MG (<i>prenatal vits with calcium no.78/ferrous fumarate/folic acid</i>) | | T2 | AL (Max 50 Years) |
| PRENATABS RX ORAL TABLET 29 MG IRON- 1 MG (<i>prenatal vitamin with calcium no.76/iron,carbonyl/folic acid</i>) | | T2 | AL (Max 50 Years) |
| PRENATAL 19 ORAL TABLET,CHEWABLE 29 MG IRON- 1 MG (<i>prenatal vits with calcium no.115/iron fumarate/folic acid</i>) | | T2 | AL (Max 50 Years) |
| PRENATAL LOW IRON ORAL TABLET 27 MG IRON- 1 MG (<i>prenatal vits with calcium no.74/ferrous fumarate/folic acid</i>) | | T2 | AL (Max 50 Years) |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

| | | Coverage Requirements and Limits | |
|--|-----------|----------------------------------|---|
| | | Drug Tier | AL = Age Limit Applies PA = PA Applies QL = Quantity Limit SP = Specialty Product ST = ST Applies |
| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits | |
| PRENATAL MULTIVITAMINS ORAL TABLET 28 MG IRON- 800 MCG (<i>prenatal vits with calcium 95/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| PRENATAL PLUS ORAL TABLET 29 MG IRON- 1 MG (<i>prenatal vits with calcium no.72/iron,carbonyl/folic acid</i>) | T2 | AL (Max 50 Years) | |
| PRENATAL VITAMIN PLUS LOW IRON ORAL TABLET 27 MG IRON- 1 MG (<i>prenatal vits with calcium no.72/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| PRENATAL VITAMIN WITH MINERALS ORAL TABLET 28 MG IRON- 800 MCG (<i>prenatal vitamins with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| SE-NATAL 19 CHEWABLE ORAL TABLET,CHEWABLE 29 MG IRON- 1 MG (<i>prenatal vits with calcium 118/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| TRICARE ORAL TABLET 27 MG IRON- 1 MG (<i>prenatal vits with calcium 103/ferrous fumarate/folic acid</i>) | T3 | AL (Max 50 Years) | |
| TRINATE ORAL TABLET 28 MG IRON- 1 MG (<i>prenatal vits with calcium no.73/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| TRUST NATAL DHA ORAL COMBO PACK 29-1-250-200 MG (<i>prenatal vitamin no.52/iron/folic acid/omega-3/dha</i>) | T2 | AL (Max 50 Years) | |
| VINATE M ORAL TABLET 27 MG IRON-1 MG (<i>prenatal vits with calcium 136/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| VINATE ONE ORAL TABLET 60 MG IRON-1 MG (<i>prenatal vitamin 27 with calcium/ferrous fumarate/folic acid</i>) | T2 | AL (Max 50 Years) | |
| VITAMIN B-1 ORAL TABLET 100 MG (<i>thiamine hcl</i>) | T2 | | |
| VITAMIN B-6 ORAL TABLET 100 MG, 25 MG, 50 MG (<i>pyridoxine hcl (vitamin b6)</i>) | T2 | | |
| Vitamin C | | | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

lowercase bold italics = Generic drugs
UPPERCASE = Brand name drugs

Drug Tier
NF = Non-Formulary
T2 = Formulary Generic Drugs
T3 = Formulary Brand Drugs

Coverage Requirements and Limits
AL = Age Limit Applies
PA = PA Applies
QL = Quantity Limit
SP = Specialty Product
ST = ST Applies

| Prescription Drug Name | Drug Tier | Coverage Requirements and Limits |
|--|-----------|----------------------------------|
| NEPHRO-VITE RX ORAL TABLET 1-60-300 MG-MG-MCG <i>(vitamin b complex no.3/folic acid/ascorbic acid(vitc)/biotin)</i> | T2 | |
| TRI-VI-SOL ORAL DROPS 250 MCG-50 MG- 10 MCG/ML <i>(vitamin a palmitate/ascorbic acid/cholecalciferol (vit d3))</i> | T3 | |
| TRI-VITAMIN WITH FLUORIDE ORAL DROPS 0.25 MG FLUOR. (0.55 MG)/ML, 0.5 MG FLUORIDE (1.1 MG)/ML <i>(pediatric multivit with a,c,d3 no.21/sodium fluoride)</i> | T2 | AL (Max 5 Years) |
| Vitamin D | | |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | T2 | |
| <i>cholecalciferol (vitamin d3) oral capsule 125 mcg (5,000 unit)</i> | T2 | |
| <i>ergocalciferol (vitamin d2) oral capsule 1,250 mcg (50,000 unit)</i> | T2 | |
| <i>ergocalciferol (vitamin d2) oral drops 200 mcg/ml (8,000 unit/ml)</i> | T2 | |
| TRI-VI-SOL ORAL DROPS 250 MCG-50 MG- 10 MCG/ML <i>(vitamin a palmitate/ascorbic acid/cholecalciferol (vit d3))</i> | T3 | |
| TRI-VITAMIN WITH FLUORIDE ORAL DROPS 0.25 MG FLUOR. (0.55 MG)/ML, 0.5 MG FLUORIDE (1.1 MG)/ML <i>(pediatric multivit with a,c,d3 no.21/sodium fluoride)</i> | T2 | AL (Max 5 Years) |
| VITAMIN D3 ORAL CAPSULE 50 MCG (2,000 UNIT) <i>(cholecalciferol (vitamin d3))</i> | T2 | |
| VITAMIN D3 ORAL TABLET 10 MCG (400 UNIT) <i>(cholecalciferol (vitamin d3))</i> | T2 | |
| Vitamin K Activity | | |
| <i>phytonadione (vitamin k1) oral tablet 5 mg</i> | T2 | |

PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limits; AL = Age Limits; SP = Specialty Product; T2 = Formulary Generic Drugs, T3 = Formulary Brand Drugs; QY = Quantity; DY = Day; EA = Each; GM = Gram; ML = Milliliter; MIN = Minimum; MAX = Maximum

Alameda IHSS Formulary

A

| | |
|--------------------------------------|-------------------|
| abacavir | 12 |
| abacavir-lamivudine | 12 |
| abacavir-lamivudine-zidovudine | 12 |
| ABILIFY MAINTENA ... | 77, 80 |
| abiraterone | 19 |
| ABSORICA LD | 190 |
| acamprosate | 84 |
| acarbose | 127 |
| ACCU-CHEK SOFTCLIX LANCETS | 94 |
| acetaminophen-codeine ... | 73, 86 |
| acetazolamide ... | 57, 102, 110 |
| acetic acid | 111 |
| ACTEMRA..... | 149, 150, 156 |
| ACTEMRA ACTPEN | 149, 156 |
| ACTHAR | 101, 141 |
| ACTHAR H.P. | 101, 141 |
| ACTHIB (PF)..... | 28 |
| ACUVAIL (PF)..... | 115 |
| acyclovir | 16 |
| ADACEL(TDAP ADOLESN/ADULT)(PF) | . 27 |
| adefovir | 16 |
| ADEMPAS..... | 68, 181 |
| ADMELOG SOLOSTAR U-100 INSULIN | 138, 143 |
| ADMELOG U-100 INSULIN LISPRO | 138, 143 |
| ADRENALIN..... | 117 |
| ADVAIR HFA.... | 38, 125, 177, 180 |
| ADVOCATE LANCET | 94 |
| ADVOCATE SYRINGES ... | 94 |
| AEMCOLO | 18 |
| AEROCHAMBER PLUS FLOW-VU,M MSK | 94 |
| AEROCHAMBER PLUS Z STAT | 94 |
| AEROCHAMBER PLUS Z STAT LG MSK..... | 94 |
| AEROCHAMBER PLUS Z STAT MD MSK | 94 |
| AEROCHAMBER PLUS Z STAT SM MSK | 94 |

| | |
|--------------------------------------|----------|
| AEROCHAMBER Z-STAT PLUS-FLW SG | 94 |
| AFINITOR | 20 |
| AFINITOR DISPERZ..... | 19 |
| AFLURIA QD 2020-21(3YR UP)(PF) | 28 |
| AFLURIA QD 2020-21(6-35MO)(PF)..... | 28 |
| AFLURIA QUAD 2020-2021(6MO UP) | 28 |
| AIMOVIG AUTOINJECTOR | 83 |
| AIMOVIG AUTOINJECTOR (2 PACK) | 83 |
| AIR TUBE WITH AIR PLUGS | 94 |
| AIRS ADULT AEROSOL MASK | 94 |
| AIRS DISPOSABLE NEBULIZER | 94 |
| AJOVY AUTOINJECTOR.. | 83 |
| AJOVY SYRINGE | 83 |
| Ala-Scalp..... | 186 |
| ALAWAY | 108 |
| albuterol sulfate..... | 38, 180 |
| alclometasone | 186 |
| ALCOHOL PREP PADS.. | 188 |
| ALDURAZYME..... | 107 |
| alendronate | 147 |
| alfuzosin | 38 |
| aliskiren | 66 |
| ALL DAY ALLERGY (CETIRIZINE) | 2, 179 |
| ALLERGY RELIEF (LORATADINE) | 2, 179 |
| ALLI..... | 120 |
| allopurinol..... | 147 |
| alogliptin | 134 |
| alogliptin-metformin. | 129, 134 |
| alogliptin-pioglitazone..... | 134, 145 |
| amantadine hcl..... | 4, 71 |
| ambrisentan | 68, 182 |
| Amethia | 130 |
| AMETHIA LO | 130 |
| Amethyst (28)..... | 130 |
| amiloride..... | 66, 104 |
| amiodarone | 59 |

| | |
|--------------------------------------|-----------------------------|
| amitriptyline | 93 |
| amlodipine . | 54, 60, 61, 63, 68 |
| amlodipine-benazepril | 49, 50, 54, 60, 61, 63, 69 |
| amlodipine-valsartan .. | 46, 48, 54, 60, 61, 66, 105 |
| ammonium lactate | 185 |
| Amnesteem | 190 |
| amoxicillin..... | 5 |
| amoxicillin-pot clavulanate .. | 5 |
| ampicillin | 5 |
| anastrozole..... | 20, 128 |
| ANDROGEL | 128 |
| ANTI-DIARRHEAL (LOPERAMIDE)..... | 118 |
| ANTI-ITCH (HC) | 186 |
| apraclonidine | 111 |
| aprepitant | 123 |
| Apri..... | 130 |
| APRODINE ... | 2, 32, 169, 174 |
| APTIOM | 74 |
| APTIVUS | 14 |
| APTIVUS (WITH VITAMIN E) | 14 |
| Aranelle (28)..... | 130 |
| ARANESP (IN POLYSORBATE)..... | 41 |
| ARIKAYCE | 4 |
| aripiprazole..... | 77, 81 |
| armodafinil..... | 93 |
| ARMOUR THYROID | 145 |
| ARNUITY ELLIPTA . | 125, 177 |
| ARTIFICIAL TEARS (PETRO/MIN) | 112 |
| ARTIFICIAL TEARS (PF) | 112 |
| ARTIFICIAL TEARS (POLYVIN ALC)..... | 112 |
| ARTIFICIAL TEARS(DEXT70-HYPRO) | 112 |
| ARTIFICIAL TEARS(GLYCERIN-PEG) | 112 |

| | |
|--------------------------------|-------------------------|
| ARTIFICIAL TEARS(PVALCH-POVID) | 112 |
| aspirin-dipyridamole | 46, 69, 91 |
| ASSURE HAEMOLANCE PLUS | 94 |
| ASSURE LANCE | 94 |
| atazanavir | 14 |
| atenolol | 39, 51, 52, 58 |
| atenolol-chlorthalidone | 39, 51, 52, 58, 68, 107 |
| atomoxetine | 84 |
| atorvastatin | 62 |
| atovaquone-proguanil | 6 |
| atropine | 116 |
| ATROVENT HFA | 34, 170 |
| AUBAGIO | 156 |
| AUGMENTIN | 5 |
| AURYXIA | 103 |
| AVITA | 186 |
| AVONEX | 156, 157 |
| AVONEX (WITH ALBUMIN) | 156 |
| AZASAN | 150, 157, 165 |
| AZASITE | 108 |
| azathioprine | 150, 157, 165 |
| azelastine | 108 |
| azithromycin | 17 |
| B | |
| bacitracin | 108 |
| bacitracin-polymyxin b | 184 |
| baclofen | 36 |
| balsalazide | 118 |
| Balziva (28) | 130 |
| BAQSIMI | 136, 145 |
| BARACLUDÉ | 16 |
| BASAGLAR KWIKPEN U-100 INSULIN | 138, 141 |
| BD AUTOSHIELD DUO PEN NEEDLE | 94 |
| BD INSULIN SYRINGE | 95 |
| BD INSULIN SYRINGE (HALF UNIT) | 95 |
| BD INSULIN SYRINGE MICRO-FINE | 95 |
| BD INSULIN SYRINGE SAFETY-LOK | 95 |
| BD INSULIN SYRINGE ULTRA-FINE | 95 |
| BD LO-DOSE MICRO-FINE IV | 95 |
| BD LUER-LOK SYRINGE | 95 |
| BD NANO 2ND GEN PEN NEEDLE | 95 |
| BD SAFETYGLIDE INSULIN SYRINGE | 96 |
| BD ULTRA FINE LANCETS | 96 |
| BD ULTRA-FINE II LANCETS | 96 |
| BD ULTRA-FINE MICRO PEN NEEDLE | 96 |
| BD ULTRA-FINE MINI PEN NEEDLE | 96 |
| BD ULTRA-FINE NANO PEN NEEDLE | 96 |
| BD ULTRA-FINE ORIG PEN NEEDLE | 96 |
| BD ULTRA-FINE SHORT PEN NEEDLE | 96 |
| benazepril | 49, 50 |
| benazepril-hydrochlorothiazide | 49, 50, 67, 105 |
| benzonatate | 171 |
| benzoyl peroxide | 188 |
| benztropine | 35, 74 |
| bepotastine besilate | 108 |
| betamethasone dipropionate | 186 |
| betamethasone valerate | 186 |
| betamethasone, augmented | 186 |
| BETASERON | 157 |
| bethanechol chloride | 37 |
| bexarotene | 20 |
| BEXSERO | 28 |
| bicalutamide | 20 |
| BIDIL | 62, 64 |
| BIKTARVY | 10, 12 |
| bisoprolol fumarate | 39, 51, 52, 58 |
| bisoprolol-hydrochlorothiazide | 39, 51, 52, 58, 67, 105 |
| Bleph-10 | 108 |
| BLOXIVERZ | 37, 101 |
| BOOSTRIX TDAP | 27, 28 |
| bosentan | 69, 182 |
| BOSULIF | 20 |
| BREO ELLIPTA 38 | 125, 177, 180 |
| BREZTRI AEROSPHERE | 170, 177, 180 |
| BRILINTA | 46 |
| brimonidine | 107 |
| bromfenac | 115 |
| bromocriptine | 85 |
| BUBBLES THE FISH PEDI MASK | 96 |
| budesonide | 125, 177 |
| budesonide-formoterol | 38, 126, 178, 180 |
| bumetanide | 64, 103 |
| buprenorphine hcl | 88 |
| buprenorphine-naloxone | 88 |
| bupropion hcl | 76 |
| bupropion hcl (smoking deter) | 76 |
| buspirone | 79 |
| butalbital-acetaminop-caf-cod | 73, 78, 82, 87, 90 |
| butalbital-acetaminophen-caff | 73, 79, 82, 90 |
| butorphanol | 88 |
| BYDUREON | 138 |
| BYDUREON BCISE | 138 |
| BYETTA | 138 |
| C | |
| CABENUVA | 10 |
| cabergoline | 85 |
| Cafergot | 37, 79 |
| calcipotriene | 190 |
| calcitonin (salmon) | 129, 147 |
| calcitriol | 201 |
| calcium acetate(phosphat bind) | 103 |
| CAMRESE | 131 |
| CAMRESE LO | 130 |
| candesartan | 46, 48 |
| candesartan-hydrochlorothiazid | 47, 48, 67, 106 |
| capecitabine | 20 |
| CAPRELSA | 20 |
| captopril | 49, 50 |
| carbamazepine | 74, 77 |
| carbidopa-levodopa | 85 |

| | |
|------------------------------|---------------------|
| carbidopa-levodopa- | |
| entacapone..... | 84, 85 |
| carvedilol.. | 36, 38, 46, 51, 59, |
| 63 | |
| CAYA CONTOURED | 168 |
| CAYSTON..... | 16 |
| cefaclor | 3 |
| cefazolin..... | 3 |
| cefdinir | 3, 4 |
| cefuroxime axetil | 3 |
| celecoxib | 85 |
| CELLCEPT..... | 165 |
| cephalexin..... | 3 |
| CERTA PLUS.... | 44, 196, 199 |
| CERVARIX VACCINE (PF)28 | |
| cetirizine | 2, 179 |
| cetirizine-pseudoephedrine | 2, |
| 33, 170, 179 | |
| CHANTIX | 35 |
| CHANTIX CONTINUING | |
| MONTH BOX..... | 35 |
| CHANTIX STARTING | |
| MONTH BOX..... | 35 |
| chlordiazepoxide hcl..... | 82 |
| chlorhexidine gluconate .. | 111 |
| chlorhexidine gluconate | |
| (bulk) | 188 |
| chloroquine phosphate..... | 6 |
| chlorpromazine..... | 89 |
| chlorthalidone..... | 68, 107 |
| cholecalciferol (vitamin d3) | |
| | 201 |
| cholestyramine (with sugar) | |
| | 53 |
| Cholestyramine Light | 53 |
| choline,magnesium salicylate | |
| | 91 |
| ciclopirox | 188 |
| cilostazol | 46, 65 |
| CILOXAN | 108 |
| CIMDUO | 12 |
| cimetidine | 123 |
| cimetidine hcl | 123 |
| CIMZIA..... | 120, 150, 157 |
| CIMZIA POWDER FOR | |
| RECONST ... | 120, 150, 157 |
| cinacalcet | 129 |
| CINQAIR | 175 |
| ciprofloxacin hcl.... | 6, 18, 108 |
| citalopram..... | 92 |
| Claravis | 190 |
| clarithromycin | 6, 17 |
| clemastine | 1, 174 |
| clindamycin hcl..... | 16 |
| clindamycin palmitate hcl .. | 16 |
| clindamycin phosphate.... | 184 |
| clobetasol | 186 |
| clomipramine | 93 |
| clonazepam..... | 82, 83 |
| clonidine | 33, 57 |
| clonidine hcl | 33, 57 |
| clopidogrel..... | 46 |
| clotrimazole | 185 |
| clotrimazole-betamethasone | |
| | 185, 186 |
| clozapine | 81 |
| codeine-guaifenesin . | 87, 171, |
| 174 | |
| colchicine | 147 |
| COLESTID FLAVORED | 53 |
| Colocort..... | 186 |
| COMBIVENT RESPIMAT. | 34, |
| 38, 170, 180 | |
| COMP-AIR ELITE COMP | |
| NEB SYSTEM | 96 |
| COMP-AIR XLT | |
| COMPRESSOR NEB | 96 |
| COMPLERA | 11, 13 |
| COMPLETE LICE | |
| TREATMENT..... | 189 |
| COMPLETENATE | 196 |
| Compro | 89, 118 |
| CONCEPTROL | 168 |
| CONDOMS-PREM | |
| LUBRICATED | 168 |
| CONDYLOX | 190 |
| CORLANOR..... | 57 |
| Cormax..... | 187 |
| CORTIFOAM..... | 187 |
| COSENTYX | 190, 191 |
| COSENTYX (2 SYRINGES) | |
| | 190 |
| COSENTYX PEN | 190 |
| COSENTYX PEN (2 PENS) | |
| | 190 |
| COVARYX..... | 128, 135 |
| COVARYX H.S..... | 128, 135 |
| CREON | 119 |
| CRIXIVAN | 14 |
| cromolyn..... | 108, 176 |
| Cryselle (28)..... | 131 |
| CUVPOSA..... | 34 |
| cyanocobalamin (vitamin b- | |
| 12) | 199 |
| cyclobenzaprine | 36 |
| cyclopentolate | 116 |
| cycloserine | 6 |
| cyclosporine | 150, 157, 165 |
| cyclosporine modified.... | 150, |
| 157, 165 | |
| cyproheptadine..... | 1, 174 |
| D | |
| DAILY MULTI-VITAMIN .. | 196 |
| dalfampridine..... | 167 |
| DALIRESP | 178 |
| dapsone | 6 |
| darifenacin..... | 195 |
| DAYTRANA..... | 90 |
| DDAVP | 43, 141 |
| deferasirox | 124 |
| deferoxamine | 125, 146 |
| DELSTRIGO | 11, 13 |
| DEPEN TITRATABS | 125, 150 |
| DEPO-SUBQ PROVERA | 104 |
| | 142 |
| DESCOVY | 13 |
| desipramine..... | 93 |
| desloratadine..... | 2, 179 |
| desmopressin | 43, 142 |
| desonide..... | 187 |
| desoximetasone | 187 |
| desvenlafaxine succinate .. | 91 |
| DEVILBISS COMPACT | |
| COMPRESSOR..... | 96 |
| DEVILBISS PULMO-AIDE | |
| COMPRESSR..... | 96 |
| DEVILBISS TRAVELER | |
| COMPRESSOR..... | 96 |
| dexamethasone | 126 |
| dexamethasone sodium | |
| phosphate | 110 |
| DEXILANT | 124 |
| dexmethylphenidate | 90 |
| Dexpak 13 Day..... | 126 |
| dextroamphetamine..... | 72 |
| dextroamphetamine- | |
| amphetamine | 72 |
| dextromethorphan- | |
| guaifenesin | 171, 174 |
| DIASTIX | 101 |

| | | | | | |
|-----------------------------|-------------------|--|--------------------|------------------------------------|--------------------|
| diazepam | 82, 83 | EASY TOUCH INSULIN SYRINGE | 96, 97 | ERGOMAR | 37, 79 |
| diclofenac epolamine | 88, 189 | EASY TOUCH TWIST LANCETS | 97 | erlotinib | 20 |
| diclofenac sodium | 20, 89, | econazole | 185 | ERWINAZE | 21 |
| 116, 189 | | EDARBI | 47, 48 | ERY PADS | 184 |
| dicloxacillin | 18 | EDARBYCLOR ... | 47, 48, 68, | Erythrocin (As Stearate) | 8 |
| dicyclomine | 34 | 107 | | erythromycin | 8, 108 |
| didanosine | 13 | EDLUAR | 80 | erythromycin ethylsuccinate | 8 |
| DIFFERIN | 191 | EDURANT | 11 | erythromycin with ethanol | 184 |
| digoxin | 50, 57 | efavirenz | 11 | erythromycin-benzoyl | |
| DILANTIN | 58, 86 | efavirenz-emtricitabin-tenofovir | 11, 13 | peroxide | 184 |
| Dilantin Extended | 58, 86 | efavirenz-lamivu-tenofov | | ESBRIET | 171 |
| Dilantin Infatabs | 58, 86 | disop | 12, 13 | escitalopram oxalate | 92 |
| DILANTIN-125 | 58, 86 | ELIQUIS | 40 | esomeprazole magnesium | |
| diltiazem hcl ... | 53, 54, 55, 56, | ELIQUIS DVT-PE TREAT | | 124 | |
| 59, 60, 69 | | 30D START | 40 | estradiol | 135, 136 |
| dimethyl fumarate | 157 | ELLA | 131 | estradiol valerate | 136 |
| diphenhydramine hcl ... | 1, 174 | ELMIRON | 168 | eszopiclone | 80 |
| diphenoxylate-atropine | 34, | EMADINE | 108 | ethambutol | 6 |
| 118 | | EMCYT | 20 | ethosuximide | 93 |
| dipyridamole | 46, 69 | EMFLAZA | 126 | etodolac | 89 |
| disulfiram | 145 | EMGALITY PEN | 84 | etonogestrel-ethynodiol | |
| divalproex | 74, 77, 79 | EMGALITY SYRINGE | 84 | 131 | |
| donepezil | 37 | emtricitabine | 13 | etoposide | 21 |
| DOPTELET (10 TAB PACK) | | emtricitabine-tenofovir (tdf) | 13 | etravirine | 12 |
| | 41 | EMTRIVA | 13 | EUFLEXXA | 97 |
| dorzolamide | 110 | enalapril maleate | 49, 50 | EURAX | 189 |
| dorzolamide-timolol | 110 | enalapril-hydrochlorothiazide | 49, 50, 67, 106 | everolimus (antineoplastic) | 21 |
| DOVATO | 10, 13 | ENBREL .. | 150, 151, 158, 191 | EVOTAZ | 15, 167 |
| doxazosin | 36, 46, 63 | ENBREL MINI .. | 150, 157, 191 | exemestane | 21, 128 |
| doxepin | 93 | ENBREL SURECLICK ... | 151, 158, 192 | EXTAVIA | 158 |
| doxycycline monohydrate .. | 19 | Endocet | 73, 87 | ezetimibe | 57 |
| dronabinol | 118 | ENGERIX-B (PF) | 28, 29 | F | |
| drospirenone-e.estradiol- | | ENLON | 101 | famciclovir | 17 |
| Im.fa | 131 | enoxaparin | 43 | famotidine | 123 |
| DROXIA | 20 | Enpresse | 131 | FARXIGA | 144 |
| DRY EYE RELIEF | 112 | entacapone | 84 | FASENRA | 176 |
| DULERA ... | 38, 126, 178, 180 | entecavir | 16 | FASENRA PEN | 175 |
| duloxetine | 85, 91 | ENTRESTO | 48, 66 | FC2 FEMALE CONDOM | 168 |
| DUPIXENT PEN | 175, 191 | EPIDIOLEX | 74 | febuxostat | 147 |
| DUPIXENT SYRINGE ... | 175, | epinastine | 108 | felodipine ... | 54, 60, 61, 63, 69 |
| 191 | | epinephrine | 33, 170 | FEMCAP | 97, 168 |
| DUREX AVANTI BARE | | EPIVIR HBV | 13 | fenofibrate | 62 |
| REAL FEEL | 168 | EPOGEN | 41 | fenofibrate micronized | 62 |
| DUREZOL | 110 | eprosartan | 47, 48 | fenofibrate nanocrystallized | 62 |
| dutasteride | 145 | ergocalciferol (vitamin d2) | 201 | fentanyl | 87 |
| DY-O-DERM | 188 | | | ferrous gluconate | 44 |
| E | | | | fexofenadine | 2, 179 |
| E.E.S. 400 | 8 | | | | |
| EASY COMFORT LANCETS | | | | | |
| | 96 | | | | |

fexofenadine-
 pseudoephedrine 3, 33,
 170, 179
 finasteride 145
 FINGERSTIX LANCETS ... 97
 FIRVANQ 8
 FISH OIL 50
 flavoxate 195
 flecainide 58
 FLOVENT DISKUS . 126, 178
 FLOVENT HFA 126, 178
 FLUAD 2020-2021 (65 YR
 UP)(PF) 29
 FLUAD QUAD 2020-21(65Y
 UP)(PF) 29
 FLUARIX QUAD 2020-2021
 (PF) 29
 FLUBLOK QUAD 2020-2021
 (PF) 29
 FLUCELVAX QUAD 2020-
 2021 29
 FLUCELVAX QUAD 2020-
 2021 (PF) 29
 fluconazole 7
 fludrocortisone 126
 FLULALVAL QUAD 2020-
 2021 (PF) 29
 FLUMIST QUAD 2020-2021
 29
 flunisolide 110, 177
 fluocinolone 187
 fluocinonide 187
 Fluocinonide-E 187
 FLUOR-A-DAY 148
 fluoride (sodium) 148, 149
 FLUORITAB 149
 fluorometholone 110
 fluorouracil 21, 192
 fluoxetine 92
 fluphenazine hcl 89
 FLURA-DROPS 149
 flurazepam 83
 flurbiprofen sodium 116
 flutamide 21
 fluticasone propionate 110,
 177, 187
 fluticasone propion-
 salmeterol 39, 127, 178,
 181
 fluvoxamine 92

FLUZONE HIGHDOSE
 QUAD 20-21 PF 29
 FLUZONE QUAD 2020-2021
 30
 FLUZONE QUAD 2020-2021
 (PF) 29, 30
 folic acid 199
 FOR STY RELIEF 112
 FORACARE LANCETS 97
 FORTEO 141, 147
 fosaprepitant 123
 fosinopril 49, 50
 fosphenytoin 86
 FOSRENOL 103, 146
 FREESTYLE FREEDOM
 LITE 97
 FREESTYLE INSULINX... 97,
 101
 FREESTYLE INSULINX
 TEST STRIPS 101
 FREESTYLE LANCETS.... 97
 FREESTYLE LITE METER97
 FREESTYLE LITE STRIPS
 101
 FREESTYLE TEST 101
 FRESHKOTE 112
 FULPHILA 41
 furosemide 64, 103
 FUZEON 10
G
 gabapentin 73, 74
 galantamine 37
 ganciclovir sodium 17
 GARDASIL (PF) 30
 GARDASIL 9 (PF) 30
 gatifloxacin 108
 GATTEX 30-VIAL 120
 GAVILYTE-C 119
 Gavilyte-G 119
 Gavilyte-N 119
 GELNIQUE 195
 gemfibrozil 62
 Generlac 102
 Gengraf 151, 158, 165
 Gentak 108
 gentamicin 109, 184
 GENTEAL MILD 112
 GENTEAL SEVERE 112
 GENTEAL TEARS
 MODERATE 112

GENVOYA 10, 13
 GIANVI (28) 131
 GILENYA 158
 glatiramer 159
 Glatopa 159
 glimepiride 144
 glipizide 144
 Glucagon Emergency Kit
 (Human) 136, 146
 glyburide 144
 glyburide micronized 144
 glyburide-metformin. 129, 144
 glycopyrrolate 34
 granisetron (pf) 117
 granisetron hcl 117
 griseofulvin microsize 6
 griseofulvin ultramicrosize ... 6
 guaifenesin 174
 guanfacine 57, 84
 GYNOL II 168
H
 haloperidol 83
 haloperidol lactate 83
 HARVONI 8, 9
 HAVRIX (PF) 30
 heparin (porcine) 43
 HEPARIN LOCK FLUSH.. 44,
 97
 HEPLISAV-B (PF) 30
 HEXALEN 21
 HOMATROPAIRE 116
 HUMALOG MIX 50-50
 INSULN U-100.... 139, 140,
 143
 HUMALOG MIX 50-50
 KWIKPEN 139, 140, 143
 HUMALOG MIX 75-25(U-
 100)INSULN 139, 140, 143
 HUMIRA . 121, 151, 152, 159,
 192
 HUMIRA PEDIATRIC
 CROHNS START 120, 151,
 159, 192
 HUMIRA PEN. 121, 151, 159,
 192
 HUMIRA PEN CROHNS-UC-
 HS START .. 120, 151, 159,
 192

| | | | | | |
|--|-----------------------|--|--------------------|--|---------------|
| HUMIRA PEN PSOR- UVEITS-ADOL HS..... | 121, 151, 159, 192 | hydroxyzine pamoate | 2, 80 | ISENTRESS | 11 |
| HUMIRA(CF).. | 122, 152, 160, 193 | hyoscyamine sulfate..... | 34 | ISENTRESS HD..... | 11 |
| HUMIRA(CF) PEDI CROHNS STARTER... 121, 152, 160, 193 | | HYPOTEARS | 112 | isometh-dichloral- acetaminophn | 73 |
| HUMIRA(CF) PEN . | 121, 152, 160, 193 | I | | isoniazid | 6, 7 |
| HUMIRA(CF) PEN CROHNS-UC-HS 121, 152, 160, 193 | | ibandronate | 148 | ISOPTO TEARS..... | 112 |
| HUMIRA(CF) PEN PSOR- UV-ADOL HS..... | 121, 152, 160, 193 | ibuprofen | 89 | isosorbide dinitrate | 64 |
| HUMULIN 70/30 U-100 INSULIN | 139, 140, 143 | ICAPS AREDS | 167 | isosorbide mononitrate | 64 |
| HUMULIN 70/30 U-100 KWIKPEN | 139, 140, 143 | ICLUSIG | 21 | isotretinoin | 193 |
| HUMULIN N NPH INSULIN KWIKPEN | 139, 140 | icosapent ethyl | 50 | ISUPREL | 37, 177 |
| HUMULIN N NPH U-100 INSULIN | 139, 140 | ILEVRO | 116 | itraconazole | 7 |
| HUMULIN R REGULAR U- 100 INSULN | 139, 143 | imatinib | 22 | ivermectin | 5, 189 |
| HUMULIN R U-500 (CONC) INSULIN | 139, 144 | imipramine hcl | 93 | J | |
| HUMULIN R U-500 (CONC) KWIKPEN | 139, 144 | imiquimod..... | 193 | JANSSEN COVID-19 VACCINE (EUA) | 31 |
| HYCAMTIN | 21 | IMOVA X RABIES VACCINE (PF)..... | 30 | JANUMET | 129, 134 |
| hydralazine..... | 62 | INCRUSE ELLIPTA... 34, 170 | | JANUMET XR | 129, 134 |
| hydrochlorothiazide ... | 67, 106 | indapamide..... | 68, 107 | JANUVIA | 134 |
| hydrocodone-acetaminophen | 73, 87 | indomethacin..... | 89, 147 | JARDIANCE | 144 |
| hydrocodone-homatropine | 34, 87, 171 | INFED | 44 | JENTADUETO | 129, 134 |
| hydrocortisone..... | 127, 187 | INFLECTRA ... 122, 152, 160, 193 | | JENTADUETO XR .. | 129, 134 |
| hydrocortisone acetate.... | 187 | INJECT EASE LANCETS.. 97 | | JOLESSA | 131 |
| hydrocortisone-acetic acid | 110, 111 | INNO SPIRE ELEGANCE .. 97 | | JULUCA | 11, 12 |
| hydromorphone | 87 | INNO SPIRE ESSENCE 97 | | Junel 1.5/30 (21) | 131 |
| hydroxychloroquine ... | 6, 152, 160 | insulin asp prt-insulin aspart | 139, 140, 143 | Junel 1/20 (21) | 131 |
| hydroxyprogesterone presv) | 142 | insulin lispro | 140, 143 | Junel Fe 1.5/30 (28) | 131 |
| hydroxyprogesterone cap(ppres) | 142 | insulin lispro protamin-lispro | 140, 141, 143 | Junel Fe 1/20 (28) | 131 |
| hydroxyurea | 21 | INSULIN SYRINGE | 98 | K | |
| hydroxyzine hcl | 2, 80 | INSULIN SYRINGE MICROFINE | 97 | KADIAN | 87 |
| | | INSULIN SYRINGE ULTRAFINE..... | 98 | KALETRA | 15 |
| | | insulin syringe-needle u-100 | 98 | KALYDECO | 173 |
| | | insulin syringes (disposable) | 98 | Kariva (28)..... | 131 |
| | | INTELENCE | 12 | Kelnor 1/35 (28)..... | 132 |
| | | INTERMEZZO | 80 | ketoconazole | 7, 185 |
| | | Introvale | 131 | KETONE URINE TEST ... 101 | |
| | | INVEGA SUSTENNA | 81 | ketoprofen | 89 |
| | | INVIRASE | 15 | ketorolac..... | 89, 116 |
| | | ipratropium bromide .. 34, 170 | | KEVZARA | 152, 153, 160 |
| | | ipratropium-albuterol .. 35, 39, 170, 181 | | KIMONO CONDOMS(NON- LUBRICATED)..... | 168 |
| | | irbesartan | 47, 48 | KINERET | 153, 161 |
| | | irbesartan- hydrochlorothiazide. | 47, 48, 67, 106 | Klor-Con | 104 |
| | | | | KLOR-CON/25 | 104 |
| | | | | KOMBIGLYZE XR... 129, 135 | |
| | | | | K-PHOS ORIGINAL | 102 |
| | | | | KPN | 196 |
| | | | | KYPROLIS | 22 |
| | | | | L | |
| | | | | I norgest/e.estradiol-e.estrad | |
| | | | | | 132 |

labetalol 36, 38, 46, 51, 52, 59
 lactulose 102
 lamivudine 13
 lamivudine-zidovudine 13
 lamotrigine 74, 75, 77
 lancets 98
 LANCETS,THIN 98
 LANCETS,ULTRA THIN ... 98
 lansoprazole 124
 lanthanum 103, 146
 lapatinib 22
 Larin 24 Fe 132
 LASTACAFT 108
 latanoprost 117
 LC PLUS 98
 ledipasvir-sofosbuvir 8, 9
 leflunomide 153, 161
 Lessina 132
 letrozole 22, 128
 leucovorin calcium 146
 LEUKERAN 22
 LEUKINE 41
 leuprolide 22, 136
 levalbuterol hcl 39, 181
 levalbuterol tartrate ... 39, 181
 levetiracetam 75
 levetiracetam in nacl (iso-os) 75
 levobunolol 110
 levocarnitine 167
 levocarnitine (with sugar) 167
 levocetirizine 3, 179
 levofloxacin 7, 18
 levonorgestrel-ethinyl estrad 132
 levothyroxine 145
 LEXIVA 15
 LICE KILLING 189
 LICE KILLING (PERMETHRIN) 189
 lidocaine 185
 lidocaine hcl 116
 Lidocaine Viscous 116
 lidocaine-prilocaine 185
 linezolid 17
 LINZESS 122
 liothyronine 145
 lisinopril 49, 50
 lisinopril-hydrochlorothiazide 49, 50, 67, 106

LITE TOUCH LANCETS ... 98
 lithium carbonate 77
 lithium citrate 77
 LO LOESTRIN FE 132
 LOKELMA 103
 lopinavir-ritonavir 15
 loratadine 3, 179
 LORATADINE-D .. 3, 33, 170, 179
 loratadine-pseudoephedrine 3, 33, 170, 179
 lorazepam 82, 83
 Lorazepam Intensol 82, 83
 Loryna (28) 132
 losartan 47, 48
 losartan-hydrochlorothiazide 47, 48, 67, 106
 LOTRONEX 118
 lovastatin 63
 loxapine succinate 79
 lubiprostone 119
 LUBRICANT DRY EYE RELIEF 113
 LUBRICANT EYE 113
 LUBRICANT EYE (CMC-GLYCER)(PF) 113
 LUBRICANT EYE (PROPYL GLYCOL) 113
 LUBRICANT EYE DROPS 113
 LUBRICANT EYE(DEXTRAN70-HYPM) 113
 LUBRICANT GEL 113
 LUBRICATING DROPS .. 113
 LUBRICATING RELIEF... 113
 LUPKYNIS 166
 LUPRON DEPOT 23, 137
 LUPRON DEPOT (3 MONTH) 22, 137
 LUPRON DEPOT (4 MONTH) 22, 137
 LUPRON DEPOT (6 MONTH) 23, 137
 LUPRON DEPOT-PED 23, 137
 LUPRON DEPOT-PED (3 MONTH) 23, 137
 Lutera (28) 132
 LYSODREN 23

M
 magnesium oxide 117
 MAKENA (PF) 142
 malathion 189
 MATULANE 23
 Matzim La.. 53, 54, 56, 60, 69
 MAVYRET 9
 MAXIDEX 110
 MAYZENT 161
 MAYZENT STARTER PACK 161
 meclizine 2, 118
 MEDROL 127
 medroxyprogesterone 142
 mefloquine 6
 megestrol 23, 142
 melatonin 167
 meloxicam 89
 melphalan 24
 melphalan hcl 23
 memantine 84
 MENACTRA (PF) 31
 Menest 136
 MENQUADFI (PF) 31
 MENVEO A-C-Y-W-135-DIP (PF) 31
 MEPRON 6
 mercaptopurine 24, 166
 mesalamine 118
 mesalamine with cleansing wipe 118
 MESNEX 168
 metaproterenol 39, 181
 metformin 130
 methadone 87
 methazolamide 110
 methenamine mandelate... 19
 methimazole 129
 methocarbamol 36
 methotrexate sodium 24, 153, 161, 166
 methotrexate sodium (pf) .24, 153, 161, 166
 methyldopa 33, 57
 methyldopa-hydrochlorothiazide. 33, 57, 67, 106
 methylergonovine 169
 methylphenidate hcl ... 90, 91
 methylprednisolone 127

metipranolol 110
 metoclopramide hcl 123
 metolazone 68, 107
 metoprolol succinate .. 39, 51,
 52, 59
 metoprolol tartrate 40, 51, 52,
 59
 metronidazole 4, 6, 185
 mexiletine 58
 Mibelas 24 Fe 132
 miconazole nitrate 185
 MICONAZOLE-3 185
 MICROLET LANCET 98
 midodrine 33
 MIGERGOT 37, 79
 MILLIPRED 127
 minocycline 19
 minoxidil 62
 mirtazapine 76
 misoprostol 123
 M-M-R II (PF) 31
 modafinil 93
MODERNA COVID-19
 VACCINE (EUA) 31
 mometasone ... 110, 177, 187
MONOJECT INSULIN
 SYRINGE 98
 montelukast 176
 morphine 87
 morphine concentrate 87
MOTEGRITY 123
MOVANTIK 122
 moxifloxacin 7, 18, 109
MOZOBIL 42
MULPLETA 42
MULTAQ 59
MULTI-VIT WITH
 FLUORIDE-IRON . 44, 149,
 196
MULTI-VITAMIN WITH
 FLUORIDE .. 149, 196, 197
 mupirocin 185
MY WAY 132
 mycophenolate mofetil 166
MYFORTIC 166
MYLERAN 24
MYNATAL . 44, 104, 197, 199
MYNATAL-Z.... 44, 104, 197,
 199
 Myorisan 193

MYRBETRIQ 196
N
 nabumetone 89
 nadolol 36, 51, 52, 59
 naloxone 88, 146
 naltrexone 88, 145
NAMENDA XR 84
 naproxen 89, 147
 naratriptan 92
NARCAN 88, 146
NATAZIA 132
NATURE-THROID 145
 Necon 0.5/35 (28) 132
NECON 7/7/7 (28) 132
 neomycin 4
 neomycin-bacitracin-poly-hc
 109, 111
 neomycin-bacitracin-
 polymyxin 109
 neomycin-polymyxin b-
 dexameth 109, 111
 neomycin-polymyxin-
 gramicidin 109
 neomycin-polymyxin-hc... 109
NEPHRO-VITE RX.. 199, 201
NEVANAC 116
 nevirapine 12
NEXAVAR 24
NEXLETOL 50
NEXLIZET 51, 58
 niacin 51
 nicardipine. 54, 60, 61, 63, 69
NICODERM CQ 35
 nicotine 35
 nicotine (polacrilex) 35
NICOTROL 35
NICOTROL NS 35
 nifedipine.. 54, 55, 60, 61, 63,
 69, 70
NILANDRON 24
 Nitro-Bid 64
 nitrofurantoin 19
 nitrofurantoin macrocrystal 19
 nitrofurantoin monohyd/m-
 cryst 19
 nitroglycerin 65
NIVESTYM 42
 noreth-ethinyl estradiol-iron
 133

norethindrone (contraceptive)
 133
 norethindrone acetate 142
 norethindrone-e.estriadiol-iron
 133
 norgestimate-ethinyl estradiol
 133
Nortrel 0.5/35 (28) 133
NORTREL 1/35 (21)..... 133
Nortrel 7/7/7 (28) 133
 nortriptyline 93
NORVIR 15
NP THYROID 145
NPLATE 42
NUCALA 176
NUEDEXTA 84, 172
NURTEC ODT 84
 nystatin 18, 189
 nystatin-triamcinolone 189
O
O-CAL FA.. 44, 104, 197, 199
OCELLA 133
ODEFSEY 12, 14
OFEV 171
 ofloxacin 18, 109
OGESTREL (28) 133
 olanzapine 78, 81
 olmesartan 47, 48
 olmesartan-amlodipin-
 hcitiazid 47, 48, 55, 61, 62,
 67, 106
 olmesartan-
 hydrochlorothiazide. 47, 48,
 67, 106
 olopatadine 108
 omega 3-dha-epa-fish oil... 51
 omega-3 acid ethyl esters . 51
 omeprazole 124
 ondansetron 117
 ondansetron hcl 117
ONETOUCH DELICA
 LANCETS 98
ONETOUCH ULTRASOFT
 LANCETS 98
ONGLYZA 135
OPSUMIT 70, 182
ORAP 79
ORENCIA 153, 154, 162
ORENCIA (WITH MALTOSE)
 153, 161

ORENCIA CLICKJECT .. 153,
 161
 ORENITRAM 70, 182
 ORIAHNN 128, 136, 142
 ORILISSA 129
 ORKAMBI 172, 173
 oseltamivir 16
 OTEZLA 154, 162, 193
 OTEZLA STARTER 154, 162,
 194
 OTREXUP (PF) 24, 154, 162,
 166
 OXBRYTA 40
 oxcarbazepine 75
 oxybutynin chloride 195
 oxycodone 87
 oxycodone-acetaminophen
 73, 88
 oxycodone-aspirin 88, 91
 OZEMPIC 138
P
 palonosetron 118
 pamidronate 148
 PANOXYL 188
 pantoprazole 124
 paroxetine hcl 92
 PASER 7
 PAXIL 93
 PEAK AIR PEAK FLOW
 METER 98
 peg 3350-electrolytes 119
 penicillamine 125, 154
 penicillin v potassium 16
 PENNSAID 89, 189
 PENTASA 119
 pentoxifylline 43
 permethrin 189
 perphenazine 89
 perphenazine-amitriptyline 90,
 93
 PERSONAL BEST FULL
 RANGE 99
 PFIZER COVID-19 VACCINE
 (EUA) 31
 Phenadoz 1, 80
 phenazopyridine 185
 phenelzine 86
 phenobarbital 82
 phentermine 72
 phenylephrine hcl 117

Phentyek 58, 86
 phenytoin sodium 58, 86
 physostigmine salicylate... 37,
 146
 phytonadione (vitamin k1)
 146, 201
 PIFELTRO 12
 pilocarpine hcl 116
 pimecrolimus 166, 194
 pindolol 36, 51, 52, 59, 63
 PIN-X 5
 pioglitazone 145
 piroxicam 89
 PLEGRIDY 162, 163
 PNEUMOVAX-23 31
 POCKET PEAK FLOW
 METER 99
 podofilox 194
 Polycin 109
 polymyxin b sulf-trimethoprim
 109
 Portia 28 133
 potassium chloride 104
 potassium citrate 102
 POTIGA 75
 PRADAXA 40
 PRALUENT PEN 65
 pramipexole 86
 prasugrel 46
 pravastatin 63
 prazosin 36, 46
 PRECISION XTRA
 MONITOR 99
 PRECISION XTRA TEST 101
 PRED MILD 111
 prednisolone 127
 prednisolone acetate 111
 prednisolone sodium
 phosphate 111, 127
 prednisone 127
 PREDNISONE INTENSOL
 127
 pregabalin 73, 75, 85
 PREMARIN 136
 PREMPHASE 136
 PREMPRO 136
 PRENATABS FA 44, 104,
 197, 199
 PRENATABS RX 44, 105,
 197, 199

PRENATAL 19 .. 44, 197, 199
 PRENATAL LOW IRON ... 45,
 105, 197, 199
 PRENATAL
 MULTIVITAMINS .. 45, 197,
 200
 PRENATAL PLUS 45, 105,
 197, 200
 PRENATAL VITAMIN PLUS
 LOW IRON ... 45, 105, 197,
 200
 PRENATAL VITAMIN WITH
 MINERALS ... 45, 105, 197,
 200
 PRENATAL-U 198
 pretomanid 7
 PREVNAR 13 (PF) 31
 Prevpac 5, 17, 124
 PREZCOBIX 15, 167
 PREZISTA 15
 PRIFTIN 7, 18
 primaquine 6
 primidone 82
 PRIMSOL 19
 probenecid 107, 147
 probenecid-colchicine.... 107,
 147
 prochlorperazine maleate . 90,
 118
 PROCRIT 42
 Proctofoam Hc 185, 187
 Proctozene-Hc 187
 PRODIGY TWIST TOP
 LANCET 99
 progesterone micronized. 142
 PROLENSA 116
 PROLIA 148
 PROMACTA 42
 promethazine 1, 80, 174
 Promethazine Vc... 1, 33, 174
 Promethazine Vc-Codeine . 1,
 33, 88, 172, 175
 promethazine-codeine..... 88,
 172, 175
 promethazine-dm 2, 172, 175
 promethazine-phenyleph-
 codeine 2, 34, 88, 172, 175
 Promethegan 2, 80
 PRONEB ULTRA II 99
 propafenone 58

propantheline 35
 proparacaine 116
 propranolol 36, 52, 53, 59, 63,
 64, 79
 propranolol-
 hydrochlorothiazid .. 36, 52,
 53, 59, 67, 106
 propylthiouracil 129
 PULMO-AIDE
 COMPRESSOR..... 99
 PULMOZYME 107, 177
 PURALUBE 113
 PURE AND GENTLE EYE
 113
 pyrazinamide 7
 pyridostigmine bromide 37
Q
 QELBREE 85
 QSYMIA 73
 Quasense 133
 quetiapine 78, 81
 quinapril 49, 50
 quinapril-hydrochlorothiazide
 49, 50, 67, 106
 quinidine sulfate 6, 58
 QVAR REDIHALER 127, 178
R
 RABAVERT (PF)..... 31
 rabeprazole 124
 Rajani 133
 raloxifene 135, 148
 ramelteon 80
 ramipril 49, 50
 ranolazine 57
 RAPAMUNE 166
 RASUVO (PF).. 25, 154, 163,
 166
 REBIF (WITH ALBUMIN) 163
 REBIF REBIDOSE 163
 REBIF TITRATION PACK163
 Reclipsen (28) 133
 RECOMBIVAX HB (PF) ... 32
 REFRESH CELLUVISC .. 113
 REFRESH CLASSIC (PF)
 114
 REFRESH CONTACTS .. 114
 REFRESH LACRI-LUBE. 114
 REFRESH OPTIVE 114
 REFRESH OPTIVE
 ADVANCED..... 114

REFRESH OPTIVE
 ADVANCED (PF)..... 114
 REFRESH OPTIVE
 SENSITIVE (PF)..... 114
 REGONOL 37
 RELENZA DISKHALER 16
 RELISTOR 122
 RENFLEXIS ... 122, 154, 163,
 194
 repaglinide..... 141
 REPATHA PUSHTRONEX 65
 REPATHA SURECLICK.... 65
 REPATHA SYRINGE 65
 DESCRIPTOR..... 12
 RESTASIS 111
 RESTASIS MULTIDOSE. 111
 RETACRIT 43
 RETAINE HPMC (PF) 114
 RETAINE PM 114
 RETROVIR..... 14
 REUSABLE NEBULIZER KIT
 99
 REVLIMID 25, 163, 164
 REYATAZ..... 15
 REYVOW 92
 ribavirin..... 17
 RIDAURA 124, 154, 164
 rifabutin 7, 18
 RIFAMATE 7, 18
 rifampin 7, 18
 RIFATER 7, 18
 RISPERDAL CONSTA 78, 81
 risperidone 78, 81
 ritonavir 15
 rivastigmine 38
 rivastigmine tartrate..... 37
 rizatriptan 92
 ropinirole 86
 rosuvastatin..... 63
 rufinamide 75
 RUKOBIA..... 10
 RYBELSUS 138
S
 SABRIL 75
 SAFETY SEAL LANCETS. 99
 SAFETY-LET LANCETS ... 99
 salsalate 91
 SAMI THE SEAL 99
 SANDIMMUNE 155, 164, 167
 SANTYL 194

SAVELLA 91
 SCALPICIN ANTI-ITCH... 188
 SEGLUROMET 130, 144
 selegiline hcl..... 86
 selenium sulfide..... 188
 SELZENTRY 10
 SE-NATAL 19 CHEWABLE
 45, 198, 200
 SEREVENT DISKUS. 39, 181
 sertraline 93
 sevelamer carbonate..... 103,
 146
 sevelamer hcl 103, 146
 SHINGRIX (PF)..... 32
 sildenafil (pulm.hypertension)
 65, 66, 182
 silver sulfadiazine 188
 SIMPONI. 122, 123, 155, 164
 SIMPONI ARIA 122, 155, 164
 simvastatin 63
 sirolimus 167
 SIRTURO 7
 SLEEP AID (DOXYLAMINE)
 1, 80, 175
 SMOOTHLAX 119
 sodium chloride . 99, 103, 105
SODIUM POLYSTYRENE
 (SORB FREE).... 103, 146
 sodium polystyrene sulfonate
 103, 146
 sofosbuvir-velpatasvir... 9, 10
 SOFT TOUCH LANCETS . 99
 solifenacin 195
 SOLTAMOX 25, 135
 SOOTHE HYDRATION ... 114
 SOOTHE LUBRICANT ... 114
 sorbitol..... 119
 sotalol..... 36, 52, 53, 59, 64
 Sotalol Af... 36, 52, 53, 59, 64
 SOVALDI 9
 spinosad 190
 SPIRIVA RESPIMAT. 35, 171
 spironolactone 64, 66, 104
 spironolacton-
 hydrochlorothiaz64, 66, 67,
 104, 106
 SPORANOX 7
 SPRAVATO 76
 Sprintec (28)..... 133
 SPRYCEL 25

| | |
|--------------------------------|------------------------|
| SSKI | 6, 129, 146, 174 |
| stavudine | 14 |
| STEGLATRO | 144 |
| STELARA | 155, 164, 194 |
| STERILE LUBRICANT | 114 |
| STIOLTO RESPIMAT | 35, 39, 171, 181 |
| STRIBILD | 11, 14 |
| sucralfate | 124 |
| sulfacetamide sodium | 109 |
| sulfacetamide sodium (acne) | 188 |
| sulfacetamide sodium-sulfur | 188 |
| sulfacetamide-prednisolone | 109 |
| sulfamethoxazole- | |
| trimethoprim | 18 |
| sulfasalazine | 18, 119, 155, 164 |
| sulindac | 89 |
| sumatriptan | 92 |
| sumatriptan succinate | 92 |
| SUNRISE COMPRESSOR-NEBULIZER | 99 |
| SUPRAX | 4 |
| SUTENT | 25, 26 |
| SYMDEKO | 172, 174 |
| SYMJEPI | 33, 170 |
| SYMLINPEN 120 | 128 |
| SYMLINPEN 60 | 128 |
| SYMPROIC | 123 |
| SYMTUZA | 14, 15, 17, 168 |
| SYNAREL | 137 |
| SYNTROID | 145 |
| SYSTANE (PF) | 114 |
| SYSTANE (PROPYLENE GLYCOL) | 115 |
| SYSTANE BALANCE | 115 |
| SYSTANE GEL | 115 |
| SYSTANE LIQUID GEL | 115 |
| SYSTANE NIGHTTIME | 115 |
| T | |
| TABLOID | 26 |
| tacrolimus | 167, 194 |
| tadalafil (pulm. hypertension) | 66, 182 |
| TALTZ AUTOINJECTOR | 194 |
| TALTZ SYRINGE | 194 |
| Tamiflu | 16 |
| tamoxifen | 26, 135 |
| tamsulosin | 38 |
| TARGETIN | 26, 195 |
| TASIGNA | 26 |
| TDVAX | 28 |
| TEARS NATURALE FORTE | 115 |
| TECHLITE LANCETS | 99 |
| TEKTURNA HCT | 66, 68, 106 |
| telmisartan | 47, 48 |
| telmisartanamlodipine | 47, 48, 55, 61, 62, 70 |
| telmisartan- | |
| hydrochlorothiazid | 47, 49, 68, 106 |
| temazepam | 83 |
| temozolomide | 26 |
| TENVAC (PF) | 28 |
| tenofovir disoproxil fumarate | 14 |
| terazosin | 36, 46, 64 |
| terbinafine hcl | 4, 184 |
| terbutaline | 39, 181 |
| terconazole | 185 |
| teriparatide | 141, 147 |
| testosterone | 128 |
| testosterone cypionate | 128 |
| testosterone enanthate | 128 |
| tetracaine hcl | 116 |
| tetracycline | 19 |
| THALOMID | 165 |
| THEO-24 | 62, 102, 184, 196 |
| THEOCHRON | 62, 102, 184, 196 |
| theophylline | 62, 102, 184, 196 |
| THERATEARS | 115 |
| THINPRO INSULIN SYRINGE | 99 |
| thioridazine | 90 |
| thiothixene | 93 |
| tiagabine | 75 |
| timolol maleate | 110 |
| TIVICAY | 11 |
| TIVICAY PD | 11 |
| tizanidine | 36 |
| TOBI PODHALER | 4 |
| TOBRADEX | 109, 111 |
| tobramycin | 109 |
| tobramycin in 0.225 % nacl | 4 |
| tobramycin with nebulizer | 5 |
| TODAY CONTRACEPTIVE SPONGE | 168 |
| tolazamide | 145 |
| tolcapone | 84 |
| tolterodine | 195 |
| topiramate | 75 |
| toremifene | 27, 135 |
| torsemide | 64 |
| TOVIAZ | 195 |
| TRACLEER | 70, 182 |
| TRADJENTA | 135 |
| tramadol | 88 |
| trandolapril | 49, 50 |
| tranexamic acid | 43 |
| travoprost | 117 |
| trazodone | 93 |
| TRECATOR | 7 |
| TRELEGY ELLIPTA | 171, 178, 181 |
| treprostinil sodium | 70, 183 |
| tretinoin | 186 |
| tretinoin (antineoplastic) | 27 |
| TREXALL | 155, 165, 167 |
| triamicinolone acetonide | 111, 177, 188 |
| triamterene- | |
| hydrochlorothiazid | 66, 68, 104, 107 |
| triazolam | 83 |
| TRICARE | 45, 198, 200 |
| trientine | 125 |
| trifluoperazine | 90 |
| trifluridine | 110 |
| trihexyphenidyl | 35, 74 |
| TRIJARDY XR. | 130, 135, 144 |
| TRIKAFTA | 173, 174 |
| Tri-Legest Fe | 133 |
| Tri-Lo-Sprintec | 134 |
| trimethoprim | 19 |
| TRINATE | 45, 105, 198, 200 |
| Tri-Sprintec (28) | 134 |
| TRIUMEQ | 11, 14 |
| TRI-VI-SOL | 198, 201 |
| TRI-VIT WITH FLUORIDE AND IRON | 45, 149, 198 |
| TRI-VITAMIN WITH FLUORIDE | 149, 198, 199, 201 |
| TROGARZO | 10 |
| tropicamide | 116 |

trospium 195
 TRUEPLUS INSULIN 99
 TRULANCE 123
 TRULICITY 138
 TRUMENBA 32
 TRUST NATAL DHA 45, 105,
 198, 200
 TRUSTEX NON-LUB
 CONDOMS 168
 TRUSTEX-RIA NON-LUB
 CONDOMS 168
 TWINRIX (PF) 32
 TYMLOS 141, 147
 TYVASO 70, 183
 TYVASO REFILL KIT 70, 183
 TYVASO STARTER KIT .. 70,
 183

U

UBRELVY 84
 UCERIS 127
 UDENEYCA 43
 ULESFIA 189, 190
 ULTICARE 99
 ULTILET CLASSIC
 LANCETS 100
 ULTILET LANCETS 100
 ULTRA CMFT INS SYR
 (HALF UNIT)..... 100
 ULTRA COMFORT INSULIN
 SYRINGE 100
 ULTRA FRESH PM 115
 ULTRA THIN LANCETS . 100
 UPTRAVI 71, 183
 urea 188
 ursodiol 119

V

VAGINAL CONTRACEPTIVE
 FILM 169
 VAGINAL CONTRACEPTIVE
 FOAM 169
 valacyclovir 17
 valganciclovir 17
 valproate sodium... 76, 78, 79
 valproic acid 76, 78, 79
 valproic acid (as sodium salt)
 76, 78, 79
 valsartan 47, 49
 valsartan-hydrochlorothiazide
 47, 49, 68, 107
 vancomycin 8

VANDAZOLE 185
 VAQTA (PF) 32
 VASCEPA 51
 VCF CONTRACEPTIVE GEL
 169
 Velvet Triphasic Regimen
 (28) 134
 VELPHORO 103
 VELTASSA 104
 VEMLIDY 17
 venlafaxine 91
 VENTAVIS 71, 183
 verapamil.. 53, 54, 55, 56, 57,
 60, 71
 VERQUVO 71
 VIBERZI 123
 VICTOZA 2-PAK 138
 VICTOZA 3-PAK 138
 VIDEX 2 GRAM PEDIATRIC
 14
 vigabatrin 76
 VIMPAT 76
 VINATE II 198
 VINATE M 45, 198, 200
 VINATE ONE ... 45, 105, 198,
 200
 VIOS AEROSOL DELIVERY
 SYSTEM 100
 VIRACEPT 15
 VIREAD 14
 VISINE TIRED EYE RELIEF
 115
 VITAMIN B-1 200
 VITAMIN B-6 200
 VITAMIN D3 201
 VIVOTIF 32
 voriconazole 7, 8
 VORTEX HOLDING
 CHAMBER 100
 VORTEX HOLDING
 CHAMBER CHILD 100
 VORTEX HOLDING
 CHAMBER TODDLER. 100
 VORTEX VHC FROG MASK-
 CHILD 100
 VORTEX VHC LADYBUG
 MASK-TODDLR 101
 VOTRIENT 27
 VYVANSE 72

W

WAL-FEX D 24 HOUR . 3, 33,
 170, 180
 WAL-ITIN 3, 180
 WAL-PHED ... 2, 33, 170, 175
 warfarin 40
 WIDE-SEAL DIAPHRAGM
 60 169
 WIDE-SEAL DIAPHRAGM
 65 169
 WIDE-SEAL DIAPHRAGM
 70 169
 WIDE-SEAL DIAPHRAGM
 75 169
 WIDE-SEAL DIAPHRAGM
 80 169
 WIDE-SEAL DIAPHRAGM
 85 169
 WIDE-SEAL DIAPHRAGM
 90 169
 WIDE-SEAL DIAPHRAGM
 95 169
 WING TIP TUBING 101
 Wixela Inhub 39, 127, 178,
 181

X

XALKORI 27
 XARELTO 40
 XARELTO DVT-PE TREAT
 3D START 40
 XELJANZ 155, 156, 165
 XELJANZ XR 156, 165
 XENICAL 123
 XEOMIN 40, 168
 XGEVA 148
 XIFAXAN 18
 XIGDUO XR 130, 144
 XIIDRA 111
 XOLAIR 179
 XULANE 134

Z

zaleplon 80
 ZARXIO 43
 Zenatane 195
 ZENPEP 120
 ZEPATIER 9, 10
 zidovudine 14
 ziprasidone hcl 78, 81
 zoledronic acid 148

| | | | | | |
|--------------------------------|-----|------------------|-----|------------------|--------|
| zoledronic acid-mannitol-water | 148 | ZOLPIMIST | 80 | Zovia 1/50E (28) | 134 |
| ZOLINZA | 27 | zonisamide | 76 | ZUBSOLV | 88 |
| zolmitriptan | 92 | ZORTRESS | 167 | ZUPLENZ | 118 |
| zolpidem | 80 | ZOSTAVAX (PF) | 32 | ZYPREXA RELPREVV | 78, 81 |
| | | Zovia 1/35E (28) | 134 | | |